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Chapter 1
General introduction
1.1 The problem
It is estimated that annually more than one million patients need treatment for skeletal
problems worldwide.1 These problems occur in the field of plastic and reconstructive
surgery, orthopaedic surgery, craniofacial surgery and dental implantology and include the
treatment of bone defects created during tumor surgery or caused by trauma, the recon-
struction of congenital skeletal abnormalities, the promotion of fracture healing, spinal
arthrodesis and joint and tooth replacement. Treatment does not always result in a solution
of the problem because of inadequate local bone conditions and impaired bone healing.2
Complicated fractures may fail to heal, resulting in so-called delayed unions or non-unions.3,4
The treatment of bone tumors or congenital syndromes are frequently associated with a
large bone defect, which requires the grafting of a large amount of autogenic or allogenic
bone.
Autografting, the transplantation of bone from one site to another site in the same
individual, is the current golden clinical standard. An advantage of autografts is that they
are osteogenic. However, the use of autografts is associated with significant morbidity at the
site of harvest, i.e. the donorsite. For instance, harvesting bone from the iliac crest has been
reported to result in 6-20% of the patients developing minor complications, such as pain,
hypersensitivity, anesthesia, superficial infection, seroma and haematoma, and 3-8%
developing major complications, such as herniation, meralgia paresthetica or pelvic in-
stability.5-7 In addition, autografting requires a second surgical procedure, which adds
operating time. The use of autogenous bone can also be hampered by a lack of the avail-
ability of sufficient bone tissue.
Allografting is the transplantation of bone from a donor to a recipient of the same
species. Allografts are less osteogenic, more immunogenic and show a greater rate of
resorption.6 In addition, disease transmission (e.g. HIV) from donor to recipient is possible
and has been reported.8-11 Xenografting is the transplantation of bone between species.
Xenografts are also prone to immune rejection and are generally not considered an option
for clinical use.6 Some of the problems encountered with auto- and allografts can be omitted
by using synthetic materials. Materials that have been used are ceramics –for example,
calcium phosphates and glass ceramics– and polymers –for example, polymethylene metha-
crylate (PMMA). The advantages of these materials are non-immunogenicity and avail-
ability. In addition, some are partly or completely biodegradable. Although some of these
materials improve the bone repair process, they do not possess bone-inductive activity.
1.2 Tissue engineering
Tissue engineering is a new interdisciplinary field of research that is formally defined by:
“The application of the principles and methods of engineering and the life sciences toward
the fundamental understanding of structure-function relationships in normal and
pathological mammalian tissues and the development of biological substitutes that restore,
maintain, or improve tissue function.”12,13 and “....tissue engineering applies the principles
of biology and engineering to the development of functional substitutes for damaged
tissue.”1
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Tissue engineering strategies can be used to create organs like the liver, kidney, heart,
pancreas, intestine and skin, and tissues such as adipose tissue, tendon, muscle, nerves,
cartilage and bone.14 Tissue engineering requires the use of three key elements: (1) a ma-
trix –also termed scaffold or carrier material– combined with (2) cells and/or (3) bioactive
molecules (e.g. growth factors). The matrix provides mechanical support and serves as a
substrate upon which the cells attach, proliferate and undergo differentiation. Further, the
matrix can serve as a delivery vehicle for cells or growth factors.
If tissue engineering is applied for the regeneration of bone by creating so-called bone
graft substitutes (BGS), three strategies can be pursued: a matrix-based, a cell-based and
growth factor-based strategy or a combination of growth factors and cells.
In view of this, bone (graft) substitutes can be divided in three classes: (1) osteo-
conductive, (2) directly osteogenic and (3) osteoinductive.15 Additionally, a combination
of (2) and (3) is possible. To date, mainly osteoconductive bone graft substitutes, like
allograft bone and ceramic materials (for example hydroxyapatite or tricalcium phosphate),
have been used clinically.
For directly osteogenic bone graft substitutes, cells from the osteogenic lineage –osteo-
progenitor cells or osteoblast-like cells– are added to a porous scaffold. In post-natal life,
osteoprogenitor cells or Mesenchymal Stem Cells (MSCs) can be derived from bone mar-
row. For osteoinductive bone graft substitutes, osteoinductive growth factors especially
members of the Transforming Growth Factor beta superfamily [Bone Morphogenetic
Proteins (BMPs) or Transforming Growth Factor betas (TGF-βs)], are combined with the
carrier. Upon implantation, cells are recruited by chemotaxis and induced to form bone by
these bioactive molecules.
A combination of osteoinductive and directly osteogenic BGS can be created by simply
combining cells with growth factors or with genetically transfected cells that overexpress
growth factors.16
1.3 Osteoinductive bone graft substitutes
While several growth factors, like Insulin-like Growth Factor (IGF), basic Fibroblast
Growth Factor (bFGF) and Platelet-Derived Growth Factor (PDGF), have been shown to
stimulate bone formation, two members of the Transforming Growth Factor beta super-
family –Bone Morphogenetic Proteins and Transforming Growth Factor betas– have been most
extensively studied. 
1.3.1 Transforming Growth Factor beta superfamily
Bone Morphogenetic Proteins and Transforming Growth Factor betas are members of the
TGF-β superfamily, which is a large family of secreted signalling molecules that are related
to each other by sequence similarities but possess a wide ranging number of biological
functions. The TGF-β superfamily comprises the TGF-βs, BMPs (except BMP-1, which is a
metalloprotease),17,18 Growth and Differentiation Factors (GDFs), inhibins/activins,
11
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Müllerian Inhibiting Substance (MIH), Vg-related genes, nodal-related genes, Drosophila
genes [e.g. Drosophila decapentaplegic (dpp) and 60A] and glial-derived neurotrophic factor
(GDNF)19,20 (Figure 1).
1.3.2 Bone Morphogenetic Protein
In the early 1960s demineralized bone matrix (DBM) was discovered to induce ossification
in intramuscular sites in rabbits.21 The responsible molecule was found to be a protein
called Bone Morphogenetic Protein.22 Morphogenesis is defined as the generation of form,
the process of tissue and organ construction and assembly. A morphogen is a molecule that
initiates the formation of a morphogenetic field by means of a single or complex stimulus to
the genome.23 BMPs function as signalling molecules in embryonal morphogenesis, e.g. limb
development, and are also involved in fracture repair.4,24-29
To date 15 BMPs are known (BMP1–15).30 BMP-2 to -9 are members of the TGF-β
superfamily on the basis of their similar amino acid sequences. Other BMPs have been
identified by low-stringency hybridization and consensus polymerase chain reaction.19,20,31
Based upon sequence similarities, three separate subgroups of BMPs exist within the BMP
family: (1) BMP-3 by itself, (2) BMP-5, -6, -7 [Osteogenic Protein-1 (OP-1)] and -8 (OP-2)
and (3) BMP-2 and BMP-4.31 BMP-2, BMP-4, BMP-5, BMP-6 and BMP-7 have been shown
to be osteoinductive in vivo, while BMP-13 and -14 have been shown to induce tendon and
ligament in ectopic implantation.30,31
BMP is a low-molecular-weight glycoprotein with a primary structure 40–50% similar
to that of TGF-β.23 BMPs are synthesized as larger precursor molecules consisting of a
signal peptide, a prodomain and a carboxy-terminal region of 100–125 amino acids. This
carboxy-terminal region contains a pattern of seven highly conserved cysteine residues.
When the carboxy-terminal region is cleaved from the precursor, the molecule becomes a
dimer bound by a cysteine-disulfide bridge. In this way, active homodimeric and hetero-
dimeric BMPs are secreted.20 Heteromeric BMPs of BMP-2/7 and BMP-4/7 have been
shown to be more active than homodimeric BMPs, both in vitro and in vivo.32,33
BMPs are present in bone matrix, dentin matrix, osteosarcoma and many other tis-
sues. In cortical bone, BMPs are present in low quantities: 1–2 µg BMP/kg bone.34 BMPs
can be isolated from demineralized bone matrix (DBM) – for example, by guanidine
extraction; these BMPs are termed purified or native BMPs. Following extraction, they are
purified using chromatographic techniques. These BMPs can either be highly purified or
partially purified, depending on the number of chromatographic steps. Highly purified
BMPs possess a higher osteogenic activity than partially purified BMPs and have also been
shown to be more potent than recombinant human BMP-2.35
Since 1988, BMPs have been produced using molecular cloning techniques, the so-
called recombinant BMPs.36 These recombinant BMPs can be produced by transfected cells;
mammalian Chinese hamster ovary cells37 or bacteria like E. coli are two examples.38-40
Recombinant BMPs have been produced from humans and other species (e.g. bovines).
Members of the TGF-β superfamily exert their effect through transmembrane receptor
complexes.19 These receptors are members of a family of serine/threonine kinase receptors
that includes receptors for BMPs, TGF-βs, activins and inhibins. There are two types of
12
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Figure 1. 
Dendrogram of the TGF-β superfamily. 
BMP receptors: Type-I (BMPR-1A or BMPR-1B) and type-II (BMPR-II) receptors. These
BMP receptors have been shown to bind BMP-2, BMP-4 and BMP-7. While individual
receptors show a low affinity for BMPs, binding affinity is high when receptors form a
heterotetramer. To initiate cell signals, both types of receptors are required. Upon the
binding of BMPs, the type-II receptor activates the type-I receptor which initiates an
intracellular response through the so-called Smad pathway. The type-I receptor primarily
determines the specificity in signalling. Three types of Smads can be distinguished:
receptor-regulated Smads (R-Smads), common Smads (Co-Smads) and the inhibitory smads
(I-Smads).41 Smads play a critical role in transmitting signals to the nucleus. TGF-β and
inhibin type-I receptors activate Smad 2 and 3, while BMP type-I receptors activate Smad 1,
5 and 8. Once phosphorylated, these R-Smads dissociate from the receptor and enter the
nucleus. In the nucleus heteromeric complexes of Smads regulate gene transcription.
1.3.3 Transforming Growth Factor beta
TGF-β was discovered as a product of murine sarcoma virus transformed cells.42 It
was first defined by, and named after, its ability to induce the formation of colonies in
normal rat kidney fibroblasts in anchorage-independent culture. As tumor-derived cells or
induced tumor cells were known to form similar colonies, TGF-β was therefore thought to
“transform” normal cells into neoplastic cells.43 Transforming Growth Factor alpha is an
unrelated peptide that shares a high degree of homology with Epidermal Growth Factor
(EGF).
Active TGF-β is a 25-kDa polypeptide consisting of 112 amino acids. Similar to BMP,
TGF-β consists of two polypeptide chains; these chains can either be identical (homo-
dimers) or different (heterodimers). TGF-β homodimers consist of five subtypes: TGF-β1–5.
There are three main types in mammals: TGF-β1–3, while TGF-β4 and TGF-β5 have been
found in chicken and amphibians, respectively. TGF-β4 in chicken is homologous to mam-
malian TGF-β1. Structural homology between isomers is 64–82%.44 Heteromers TGF-β1.2
and TGF-β2.3 also occur in mammals but in lower amounts.45
TGF-β is present mostly in platelets10 and bone2 from which it has been isolated.
Alternatively, TGF-β can be produced by transfected cells using molecular cloning tech-
niques; for example Chinese Hamster ovary cells.46,47 In many tissues, TGF-β is secreted in
a latent form, which consists of a TGF-β dimer, a precursor and a TGF-β binding protein.
Bone cells also produce a latent form without the binding protein. TGF-β must be
dissociated from the latent complex to become biologically active.48
Almost all cells have surface receptors for TGF-β,49 with osteoblasts bearing the
highest number of TGF-β receptors.50,51 TGF-β receptors are trans-membrane receptors
and members of the serine/threonine kinase receptor family. Three types of TGF-β
receptors can be distinguished: type-I, type-II and betaglycan (previously termed type-III)
receptors. Heteromeric complexes of type-I and -II receptors appear to be a general re-
quirement for signalling in the TGF-β superfamily. Following binding of the TGF-βs to the
receptor complex, signalling occurs through the Smad pathway as described for BMPs.
TGF-β type-I receptors activate Smad 2 and 3, while BMP type-I receptors activate Smad 1,
5 and 8.41,52
14
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1.4 Biological effects of BMP
1.4.1 BMP in vitro
BMPs have been described to have both stimulating and inhibiting effects on cellular differ-
entiation and proliferation of various cell types. Their effects are dependent on cell type,
differentiation stage, dose and exposure time. Different BMPs can also show varying levels
of activity. The cells that respond to BMP include mesenchymal-type cells, cartilage, bone
and muscle cells.
For undifferentiated cells and cells within the osteogenic lineage, BMPs (rhBMP-2 and
rhBMP-7) have been described to enhance proliferation in vitro. This has been shown for
cell lines C3H10T1/2 (murine multipotential mesenchymal cells), ROB-C26 (a potential rat
osteoblast precursor cell line) and fetal rat calvarial cells.53-58 However, with respect to the
latter cells, it has also been reported that proliferation is not increased by rhBMP-2.59 Cell
growth has been reported to be unaffected by rhBMP-2 in W20-17 cells (a bone marrow
stromal cell line) and rat bone marrow stromal cells.55,56,60 In contrast, MC3T3-E1 (mouse
osteoblastic cells) and ROB-C20 (a more differentiated rat osteoblast cell line than ROB-
C26) have been reported to be growth-inhibited by BMPs.57,61
The most striking ability of BMPs is to stimulate the differentiation of undifferentiated
cells towards the chondroblastic and osteoblastic phenotype and to inhibit it towards the
myogenic and adipocytic phenotype. In C3H10T1/2 cells, rhBMP-2 inhibits adipocytic
differentiation and stimulates development of the chondroblastic and osteoblastic pheno-
type.54,62 In addition, when these cells are transfected with the BMP-2 or BMP-4 gene, they
also show ostegenic expression.63,64 In another cell line BMS2 (murine multipotent bone
marrow stromal cells), rhBMP-2, rhBMP-4 and rhBMP-6 inhibit the differentiation of
adipocytes and stimulate the development of the osteoblastic phenotype.65 In ROB-C26 cells
(a cell line capable of differentiating into muscle cells and adipocytes) and myoblastic cells,
rhBMP-2 has been shown to inhibit myogenic differentiation and stimulate development of
the osteoblastic phenotype.57,66 The osteoblastic phenotype was stimulated by BMP-2 in
MC3T3-E1 and W-20-17 cell-lines60,65,67 and in more heterogenous cell cultures like rat and
human bone marrow stromal cell cultures.55,68,69 In fetal rat calvarial osteoblast cell cultures,
BMP-2, -4, -6 and -7 have also been shown to enhance osteogenic expression.53,70-74
The various BMPs have different activities. BMP-6 has been shown to have a higher
activity in rat calvarial osteoblast cultures than BMP-2 and BMP-4,75 while BMP-2 seems to
have a higher activity than BMP-4 and -6 in ST2 and MC3T3 bone marrow stromal cell
lines.76
BMPs exert their effects in vitro in a dose-dependent manner.54,56,57,60,72 In C3H10T1/2
cells, rhBMP-2 at low concentrations (10 ng/ml) stimulates development of the adipocyte
phenotype, while the chondroblastic and osteoblastic phenotype is stimulated at higher
concentrations (100 ng/ml and 1,000 ng/ml).54 Not only the concentration but also the
duration of BMP stimulation affects differentiation. An exposure to 100 ng/ml rhBMP-2, for
as short a period as 1 hour stimulates adipocytic differentiation in C3H10T1/2 cells.54 On the
other hand, Katagiri et al.62 found that 100 ng/ml rhBMP-2 for 3 days stimulated alkaline
phosphatase (AP) expression in C3H10T1/2 cells. In C26 cells (a potential rat osteoblast
precursor cell) also a 3-day exposure to 1,000 ng/ml and a 6-day exposure to doses of 10,
100 and 1,000 ng/ml significantly stimulated AP expression.57 Thies et al. found an effect
in W-20-17 cells, a bone marrow stromal cell line, on AP activity 12 h after rhBMP-2
stimulation.60 In bone marrow stromal cells, a maximum effect was found after 2 weeks of
stimulation with 1,000 ng/ml rhBMP-2, while C3H10T1/2 cells exhibited higher osteo-
genic expression with increasing duration up to 4 weeks.55
Effects of BMPs on osteoblast differentiation can be synergistically enhanced by
glucocorticoids like dexamathasone and triamcinolone.68,77 In view of this, glucocorticoid
co-treatment potentiates BMP effects up to tenfold.77 In addition, BMP-2 is also expressed
by rat bone marrow stromal cells and enhanced by exposure to dexamethasone.78
In very low concentrations (1 ng/ml), rhBMP-2, but not rhBMP-4 and rhBMP-6,
exerts a chemotatic effect on the migration of human stromal osteoblasts, human osteo-
blasts and U2-OS cells.79 In addition, rhBMP-4 and native BMPs in the femto-molar range
have been shown to be chemo-attractive for monocytes.80
1.4.2 BMP in vivo
1.4.2.1 BMP in heterotopic locations
BMPs combined with a suitable carrier material induce new bone in heterotopic implanta-
tion. The rodent ectopic assay model is frequently used to assess osteogenic activity.
Sampath et al.81 studied different substances in a rat subcutaneous assay model. These
substances included BMP, TGF-β, Platelet-Derived Growth Factor (PDGF), Epidermal
Growth Factor (EGF), Fibroblast Growth Factor (FGF), Cartilage-Derived Growth Factor
(CDGF), insulin and growth hormone. Only BMP was shown to be capable of inducing
bone formation in a rat ectopic assay model.81,82 On the other hand, another group report-
ed that in baboons rhTGF-β1 and rhTGF-β2 can induce bone formation in a heterotopic lo-
cation when combined with inactivated DBM (iDBM).83-85 However, it should be stated
that iDBM might still contain trace amounts of other substances, like BMPs.
1.4.2.2 Endochondral ossification
The classical description of BMP- or DBM-induced osteogenesis in heterotopic locations
suggests that BMPs induce enchondral osteogenesis in which cartilage formation precedes
the formation of bone.86 When DBM or BMPs are implanted in an extraskeletal site in
rodents a sequence of events is activated that is quite similar to embryonic bone formation
and fracture healing.87 Initially, the chemotaxis of undifferentiated mesenchymal cells
occurs, following which the cells proliferate (Figure 2). Subsequently, these cells differ-
entiate into chondroblasts and chondrocytes that produce cartilaginous extracellular matrix
including type-II collagen and proteoglycans. The chondrocytes mature and become
hypertrophic, and cartilage begins to mineralize. Following the period of chondrogenesis,
blood vessels appear at the implantation site. Bone-forming cells are then observed, which
produce bone matrix while the calcified cartilage is being removed by osteoclasts. Mineral-
ized bone matrix is observed, which contains osteocalcin. Once bone has been formed,
hemopoietic bone marrow appears within the bone. Eventually, the newly formed bone
undergoes remodelling. In Figure 2, the time sequence of the events as proposed by
16
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Wozney is also depicted. The speed of the bone formation process is dependent upon the
concentration of BMP used.88
1.4.2.3 Influence of vascularization
Caplan et al. also described the ectopic ossification process upon implantation of DBM or
BMPs.89 He hypothesized that in endochondral ossification a sequence of events takes
place similar to embryonic endochondral ossification in which two waves of Mesenchymal
Stem Cells (MSCs) are recruited to the implantation site, and osteogenesis occurs though a
vascular driven process completely independent of the prior presence of cartilagenous
matrix. The formation of cartilage and bone is dependent on two distinct waves of MSCs in
which vascularization plays an important role. Cartilage is thought to be replaced by
marrow and not to be a template on which bone is formed. 
The initial inflammatory response brings in and provides factors that attract MSCs.
MSCs are recruited by BMPs and other factors in the DBM by chemotactic effects. MSCs
subsequently proliferate. These MSCs and the inflammatory response are encysted in a
relatively a-vascular environment by a surrounding cell layer of flattened fibroblasts
(MSCs) designated the “stacked cell layer”; which causes the a-vascular environment. Ca-
pillaries can be observed outside this cell layer. The next phase is a cartilage differentiation
phase in which the MSCs inside the stacked cell layer differentiate towards chondrocytes.
This is followed by cartilage hypertrophy and first bone formation in which chondrocytes
in the core of the implant differentiate into hypertrophic cartilage cells, produce cartilagi-
nous matrix and start to mineralize. Cells on the outside close to the “stacked cell layer”
differentiate into osteoblasts, which produce osteoid. The next phase is the vasculature
invasion stage, which is believed to be initiated by angiogenic factors produced by hyper-
trophic cartilage cells; the result is that vasculature and resorptive cells are brought in. The
outer bony collar is resorbed and vascularization takes place. Caplan hypothesized that in
this phase a new wave of MSCs is attracted. These synthesize osteoid directly on the
surface of the carrier which subsequently becomes mineralized and forms bone while the
calcified cartilage is resorbed. The final phase is the marrowization phase in which it is
thought that MSCs differentiate into marrow stroma. In addition, hemopoietic cells and
osteoclasts can be seen in the newly formed bone.
1.4.2.4 Direct ossification and the role of vascularization
As stated above, BMP-induced bone formation was believed to follow the sequence of
endochondral ossification.86 More recently, direct ossification without pre-existing cartilage
has been reported to occur on implanted BMP carriers: initially on fibrous collagen mem-
brane (FCM) and subsequently on hydroxyapatite.90,91 On the other hand, fibrous glass
membrane (FGM) and insoluble bone matrix (IBM) have been shown to induce an endo-
chondral ossification-like process.92,91
Although the exact mechanism by which vascularization influences the differentiation
between chondroblasts and osteoblasts has not been fully elucidated, a strong connection
exists between vascularization and bone formation. Consequently, vascularization is con-
sidered to be a crucial step in ectopic bone formation.93 For example, anti-angiogenic agents
like TNP-470 have been shown to inhibit rhBMP-2-induced ectopic osteogenesis.94 Some
researchers attribute the effect of vascularization to the supply of osteoblasts.95 Vascular
17
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pericytes, which are undifferentiated cells, have been shown to be able to differ-entiate into
chondrocytes and osteoblasts in vitro and can form cartilage and bone in vivo.96 Other
studies have shown that a low oxygen concentration favors chondrogenesis, while a higher
oxygen concentration supports bone formation.97-100 This is thought to be related to the
higher oxygen and nutrient requirement of osteoblasts.97
It is also well known that carrier geometry influences the bone formation process,101-
103 which is supposed to be related to the influence of carrier geometry on vascularization
and thereby on oxygen supply.101 Consequently, carriers which induce bone formation in-
dependent of cartilage have been hypothesized to provide a higher oxygen supply due to
geometry.90 Direct bone formation was first shown for fibrous collagen membrane (FCM).
90 In addition, comparison of porous particles of hydroxyapatite (PPHAP) and fibrous glass
membrane (FGM) revealed that the latter exhibited chondrogenesis while the former
showed membranous ossification.91 For FGM, rhBMP-2 induced osteogenesis was en-
hanced by the addition of bFGF, while the amount of cartilage decreased. This was
attributed to the stimulating effect of bFGF on vascularization.104 A comparsion between
BMP-induced osteogenesis in hydroxyapatite carriers with different shapes –porous
particles (PPHAP), porous block and non-porous particles– in an ectopic assay model revealed
that the first two carriers effectively induced ectopic osteogenesis while the latter did
not.105 The solid particles were hypothesized to prevent vascularization through close
contact between the particles and the absence of an interconnected porosity. A similar
observation was made in a carrier of hydroxyapatite particles having a honey-comb shape.
Here, bone formation occurred between the particles, while cartilage formation occurred in
the small pores which were thought to inhibit vascularization.106 For BMP induced
osteogenesis, the optimal pore size for block-shaped hydroxyapatite carriers has been re-
ported to be between 300 and 400 µm.
Recently, an observation which supports the relationship between neovascularization
and osteogenesis has been made for a scaffold composed of bioglass fibers [composed of
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Figure 2. 
The sequence of events in
the heterotopic ossification
process upon implantation
of DBM or BMPs. 
CaO, P2O5, and SiO2 (CPSA)].107 Bone formation was observed completely around a porous
ball-shaped CPSA implant, whereas scant bone formation was observed in a less porous
bundle-shaped implant. Further research revealed that Vascular Endothelial Growth Factor
(VEGF) receptors (Flt-1 and KDR) were expressed in the porous ball-shaped implant but
not in the bundle-shaped implant. 
In light of the above-mentioned, carriers have been identified that have a vascular
inducing geometry –for example FCM and PPHAP– and a vascular-inhibiting geometry –for
example FGM.106,107
1.4.2.5 Heterotopic implantation
In rodents, implant locations are either subcutaneous, mostly at the back or ventral thorax,
or intra-muscular (for example the thigh muscles, calf muscles or abdominal muscles). In a
comparative study in which osteoinduction by native bovine BMP in different tissues was
observed, it was demonstrated that muscle was the best responding tissue.108 Recent studies
using rhBMP-2 also found that intra-muscular implantation was superior to subcuta-
neous,109 inter-muscular and intra-fatty implantation.110
Only a few reports describe ectopic bone formation in higher animals, i.e. non-human
primates. The first publication of ectopic induction of bone and cartilage is of subcuta-
neously implanted DBM in rhesus monkeys.111 Native and recombinant human BMPs
have also been shown to induce heterotopic bone formation in non-human primates. In the
squirrel monkey, rhBMP-2 with DBM as a carrier has been shown to induce bone when
implanted intramuscularly.112 In baboon, native BMP together with baboon inactivated
DBM or hydroxyapatite induced bone and cartilage in the rectus abdomis muscle.113,114 In
the same animal, OP-1 (rhBMP-7) also induced bone and cartilage formation in an intra-
muscular site.85
1.4.2.6 Concentration
In vivo, BMPs show a dose-response relationship and, generally, higher doses are needed in
higher animals. In the rat ectopic assay model, a concentration study was performed using
rhBMP-2 (50% pure) with rat insoluble bone matrix (IBM or inactivated DBM) as a
carrier.88 Bone and cartilage formation were studied from day 5 to 21. When subcutaneous-
ly implanted in rats, 0.5 to 115 µg BMP induced cartilage formation by day 7 and bone
formation by day 14. Higher doses induced more reproducible bone formation. A dose of
600 ng rhBMP-2 consistently induced the formation of cartilage and bone.88 In addition,
high doses induced bone formation earlier – by day 5; at day 7 the amount of cartilage
formed reached a plateau at doses higher than 6.2–12.0 µg. The amount of bone increased
with increasing dosage. This was confirmed by Volek-Smith et al., who showed a linear
dose-response relationship between 0.2 and 150 µg rhBMP-2 with inactivated rat matrix as
a carrier.115
If BMPs are injected without a carrier material in an ectopical implantation site they
may quickly diffuse without inducing bone formation. At high concentrations, however –
100–200 µg rhBMP-2 – this procedure has been shown to be osteoinductive88 in the rat
ectopic assay model. The presence of a carrier material allows BMPs to be present locally at
a high concentration.
It has been recently demonstrated that in vivo BMP effects can be synergistically
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enhanced by other factors such as TGF-β1,82,85 TGF-β2,116 Prostaglandin E1 (PGE1)117,118
and bFGF.104
A comparison regarding osteoinductive effectiveness between the BMPs is hard to
make because of the great difference in animal models. However, it has been demonstrated
that BMP-5 is less osteoinductive than BMP-7 or BMP-2.34 It has also been reported that
highly purified native BMPs are more effective in heterotopical osteoinduction than recom-
binant human BMPs.35 A comparative study showed that rhBMP-2 was less osteoinductive
than equivalent amounts (50 µg) of native bovine BMP (bBMP) in a rat ectopic assay mod-
el using atelopeptide collagen type-I as a carrier. Calcium content produced by rhBMP-2
was 1/10 of that produced by bBMP. A possible explanation for this difference is that native
BMP is a mixture, which allows the substances present to act synergistically in bone
formation.
1.4.2.7 BMPs in orthotopic locations
BMPs have been shown to be effective in bone healing in a number of locations and animal
models. These include spinal fusion (rabbits, dogs, sheep, goats and non-human primates), long
bone defects (mice, rats, rabbits, dogs, sheep and non-human primates), mandibular and cranial
bone defects (mice, rats, rabbits, dogs, pigs, sheep and goats), fracture healing (rabbits, goats and
dogs) and dental situations, such as periodontal regeneration (rats, cats, dogs and non-human
primates), alveolar ridge augmentation, maxillary sinus floor augmentation (goats and non-
human primates) and osseo-integration of dental implants (dogs and non-human primates).119
1.5 Biological effects of TGF-β
1.5.1 TGF-β in vitro
Although the three mammalian isoforms of TGF-β may have different effects in vivo, they
have similar activities in vitro while showing quantitative differences.44,120,121 The effect of
TGF-β is dependent on cell type, differentiation stage, growth conditions and the presence
of other growth factors.122
Three major biological activities exist for TGF-β:44,120 (1) TGF-β inhibits cell growth in
most cell types, but stimulates cell growth in mesenchymal cell types, including os-teoblasts
and chondroblasts; (2) TGF-β also exerts an immunosuppressive effect that is partly related
to the inhibiting effect on the proliferation of T-and B-lymphocytes; (3) TGF-β stimulates
extracellular matrix deposition (e.g. collagen, fibronectin, glycosaminoglycans and proteo-
glycans).
TGF-β acts on osteoblasts, chondrocytes and cells of the osteoclastic lineage as well as
on other cells.123-125 With respect to bone cells, both stimulating and inhibiting effects have
been described for cellular differentiation and proliferation. In vitro osteoblasts synthesize
and respond to TGF-β.50 Not fully differentiated cells within the osteoblast lineage are
sensitive to the mitogenic effect of TGF-β.123,124 For example, TGF-β has been found to
stimulate proliferation in fetal bovine bone cells.50 This stimulating effect on proliferation
has been shown to be biphasic: low concentrations stimulate proliferation and high concen-
20
General introduction
trations inhibit it.50,126,127 In more differentiated cell cultures, TGF-β stimulates the syn-
thesis of type-I collagen and suppresses alkaline phosphatase activity.123 This has been
shown for osteoblast-enriched cultures from fetal rat calvaria and MC3T3-E1 cells.126,128
The concentration of TGF-β that stimulated collagen synthesis was higher (15 ng/ml) than
those which stimulated proliferation (0.15–15 ng/ml).126 Both effects have recently been
reported for human bone marrow stromal cells: TGF-β2 increased collagen synthesis and
proliferation while it decreased alkaline phosphatase activity.69
TGF-β inhibits the formation of osteoclast-like cells in vitro and decreases bone resorp-
tion in bone organ cultures.123 In calvaria and long bone cultures, the mineral resorbing
effect of TGF-β has been reported to be biphasic: low concentrations (0.01–0.2 ng/ml)
stimulate while higher concentrations (1–4 ng/ml) inhibit.129
In addition, TGF-β is a potent chemotactic factor for a number of different cell types,
including fibroblasts130 and osteoblast-like cells (e.g. fetal rat calvarial cells and rat osteo-
sarcoma cells).131 For osteoblast-like cells, concentrations between 5 and 15 pg/ml are the
most chemotactic.
1.5.2 TGF-β in vivo
TGF-β plays a significant role in wound healing132 by enhancing the repair of injured tissue
like skin and bone.120,121 TGF-β1 and TGF-β2 have also been shown to stimulate osteo-
genesis in orthotopic sites in rats and mice.133,134 However, TGF-β does not induce bone
formation in a rodent ectopic assay model.81,82 Despite this, the group of Ripamonti et al.
did report the induction of heterotopic ossification by TGF-β1 and TGF-β2 in baboons.83-85
In bone defect healing studies, TGF-β1 with different carriers has been shown to be
beneficial in bone defect healing in different animals and at various locations: cranial
defects (rats, rabbits and baboons), mandibular defects (rats and dogs), radial (rabbits) and
tibial defects (sheep).135-145 TGF-β1 has also been shown to enhance the osseointegration of
metal implants in the humerus and femoral chondyle (dogs).146-148
For bone induction in vivo, a dose-responsive effect exists for TGF-β1 within a certain
range; there is, however, an optimum dose. Therefore, higher doses do not necessarily
generate more bone formation. For example, Beck et al. found that 2 µg of TGF-β1 applied
in a 3% methyl cellulose gel was able to regenerate a critical size defect in a rabbit skull
within 28 days;136,137 the 0.1- and 0.4-µg doses showed less bone formation. On the other
hand, in the same model they found no difference between an 1-µg and 5-µg rhTGF-β1
dose. Also in a rabbit critical size cranial defect model,141 a 40-µg dose was found to be
superior to a 0.4- and 4-µg dose with a DBM carrier. Using the same model, Zellin et al.
found that 5 or 10 µg rhTGF-β1 with porous CaCO3 particles (Coral) was able to close a
critical size cranial defect by 28 days.145 In a rat mandibular defect model, dose-dependent
bone bridging with concentrations ranging from 0.5 µg to 20 µg, has been described to be
independent of the carrier used (methyl cellulose gel, porous CaCO3 particles or poly
(lactide-co-glycolide) beads).145 However, when very low doses of 10 ng and 25 ng in a cal-
cium phosphate cement were implanted into rat cranial defects, only minimal bone forma-
tion was observed. The low dose stimulated the resorption of the bone cement, which
might be explained by the stimulation of osteoclastic activity.149
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1.6 Directly osteogenic bone graft substitutes
1.6.1 Mesenchymal stem cells
1.6.1.1 The mesengenic process
In embryogenesis the mesoderm differentiates into bone, cartilage, muscle, dermis and
other (connective) tissues.150 The genesis of mesodermal tissues is termed the mesengenic
process.151 Pluripotential progenitor cells are thought to exist that have the ability to differ-
entiate into different mesenchymal tissues. These cells, designated osteogenic (stromal) or
mesenchymal stem cells (MSCs),152-154 are hypothesized to enter separate multi-stepped
lineages that will eventually give rise to different tissues: bone, cartilage, tendon/ligament,
muscle, marrow and other connective tissues (Figure 3A).
In post-natal life, the process of tissue repair is thought to be analogous to the mes-
engenic process in embryological development. In tissue repair, mesenchyal stem cells are
first recruited by chemotaxis and then proliferate and commit to a pathway under the
influence of bioactive molecules. Thereafter, the cells progress through a lineage in which
they proliferate and eventually differentiate with matrix production. Finally, the cells
undergo a maturation stage.151
1.6.1.2 The osteoblast lineage
One definition of a stem cell is “a cell that in the adult organism can maintain its own
numbers in spite of physiological or artificial removal of cells from the population”.155 The
differentiation stages of the osteoblast lineage have been designed analogous to the
hematopoietic lineage. Based upon histological and morphological studies, osteoblastic cells
have been categorized in a presumed linear sequence progressing from osteoprogenitor to
pre-osteoblasts, osteoblasts and then lining cells or osteocytes (Figure 3B). At least two
distinctive populations of osteoprogenitor cells exist: one type determined to differentiate
into the mature osteoblastic phenotype [in medium with FCS, Na-β-Glycerophosphate
(β-GP) and ascorbic acid] and the other type that only differentiates in the presence of in-
ductive factors (dexamethasone (dex) and BMPs). The process of progression from pro-
genitor cells to osteoblasts was initially subdivided in three developmental time stages: (1)
proliferation, (2) extracellular matrix development and (3) mineralization with characteris-
tic changes in gene expression.156 Osteoblast-associated genes show time-dependent
expression when progenitors differentiate.157 Recent analysis of cell- and tissue-specific
macromolecules, including bone matrix molecules (e.g. type-I collagen, osteocalcin, osteo-
pontin, bone sialoprotein) and multiple other markers156,157 led to the further categoriza-
tion of osteoblast differentiation into a minimum of seven different stages157,158 (Figure
3B). According to Aubin, these stages include multipotential stem cell, immature osteopro-
genitor, mature osteoprogenitor, pre-osteoblast, mature osteoblast, osteocytes and lining
cells. For the osteoblast lineage, a reciprocal relationship exists between proliferation and
differentiation.159
1.6.1.3. Bone marrow stroma
For tissue engineering purposes, undifferentiated cells can be isolated from fetal tissue and
autologous tissue. Autologous stem cells can be isolated from bone marrow. Although the
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presence of a true stem cell in bone marrow has not been proven, these cells are termed
mesenchymal stem cells.157 Recently, it has been reported that these cells can also be
harvested from adipose tissue.64 The focus here is on bone marrow-derived cells.
In Greek, stroma means “the physical substrate, or something upon which one rests or
lies”.160 In vivo, the bone marrow stroma supports the function and physiology of hema-
topoetic cells. Within the bone marrow space, the stroma includes all cell types between the
marrow blood vessels and the surrounding bone that are not of the hemopoietic lineage.
These cells include marrow adipocytes, stromal fibroblasts [which have also been termed
Westen-Bainton (WB) cells or (adventitial) reticular cells], bone-lining cells and osteoblastic
cells. In post-natal marrow, WB cells are specialized hemopoiesis supporting cells that
express alkaline phosphatase.161,162 These cells are located along the outer wall of the
sinusoids and are considered to be fibroblastic in nature. In post-natal human marrow, WB
cells demonstrate the characteristics of pre-adipocytes,163 which lose their AP activity and
are converted to adipose cells.164 WB cells are multipotential cells in post-natal marrow and
have therefore stem cell characteristics.
1.6.2 Bone marrow stromal cells in vitro
When bone marrow is plated in plastic tissue culture flasks in vitro, non-hematopoietic cells
adhere to the plastic material of the culture flask and can be cultured.153,160,165,166 When
single-cell suspensions are used, colonies are formed, each derived from a single colony-
forming-unit fibroblast (CFU-F).167,168 The cells share some characteristics with fibroblasts
but lack the characteristics of macrophages and endothelial cells. The cells that are grown
from CFU-Fs are termed bone marrow stromal cells (BMSCs).160 Whether these cells are
the same as the earlier described WB cells that occur in vivo is not entirely clear.160 CFU-F
are heterogenous in size and morphology and in their potential for differentiation. Some of
the cells are believed to be multipotential while others are more restricted.157 It is hypo-
thesized that two types of osteoprogenitor cells exist, “inducible” and “determined” osteo-
progenitor cells153 (see figure 3B). When these cells are plated at adequate densities they
proliferate and form monolayers. BMSCs can be isolated by marrow aspiration (e.g. dogs,
goats, sheep and humans), by removal from trabecular bone (e.g. humans) or by removal of
bone marrow from long bones (e.g. rats, mice, rabbits and guinea pigs).15,166,169-172 Bone
marrow cells have been cultured from various species including humans, rodents, dogs,
sheep and goats.166,170,169,172,173
The stromal compartment is heterogeneous in composition and contains undiffer-
entiated cells that can differentiate into several phenotypes in vitro and maintain the ability
to form bone, cartilage, fibrous tissue and hematopoiesis-supporting stroma with adipocytes
in vivo.157,160,174 MSCs represent only a small fraction of the total number of bone marrow
cells: between 0.01 and 0.0001% of the total number of nucleated cells in humans174 or
approximately 1 MSC per 105 adherent stromal cells.64 The number of progenitor cells has
even been shown to decrease with ageing.175-179 In view of this, methods have been
developed to culture-expand and select the osteoprogenitor cell fraction from bone marrow.
15,173,174,180 These methods include density gradient selection of the cell fraction from the
bone marrow, preferential adherance to tissue culture polystyrene and subsequent serial
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passage to expand the cells. In addition, the identification of matrix and soluble markers
and the use of monoclonal antibodies to cell surface antigens [for example STRO-1, SB-10
(antibody recognizing ALCAM) and HOP-26] can be used to select certain immature cell
types.174,181-185 However, no markers are currently available to identify true osteogenic
stem cells.
In addition to proliferation, the differentiation of osteoprogenitor cells can be directed
during culture. In view of this, several factors, like dexamethasone and BMPs, are known to
direct the differentiation of undifferentiated cells into the osteoblast lineage in vitro.62,68,186
The addition of proliferation (bFGF) and differentiation (rhBMP-2) stimulating agents
during culture has been shown to enhance the in vivo osteogenic potential.187,188 Prolonged
culturing on a carrier after cell loading has also been shown to be more effective with re-
spect to final in vivo bone formation,189 especially when the medium is supplemented with
dexamethasone during this period.190,191
The osteogenic potential of cell-loaded scaffolds can further be enhanced by modifying
the conditions during seeding (by optimizing the number of loaded cells)188,192,193 and
conditions during culturing (e.g. static vs. dynamic culturing).194,195
1.6.3 Bone marrow stromal cells in vivo
While fresh marrow can form bone upon implantation in vivo,196,197 the culturing of cells
from bone marrow has several advantages. Due to their high proliferation potential, cells
can be culture-expanded by a billion-fold or 30 population doublings.198 This limits the
amount of harvested cells and can increase the number of loaded cells or specimens. In
addition, it has been shown that cultured bone marrow-derived MSCs result in earlier bone
formation199-201 and are more effective than fresh total bone marrow.15
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Figure 3A. 
The mesengenic process. 
Bone formation upon the implantation of cell-loaded scaffolds has been shown in
heterotopic (subcutaneous, intramuscular, under the kidney capsule and intra-abdominal)
and orthotopic sites.15,180,196,199,202,203
Heterotopic bone formation in vivo has been studied in closed and open systems. In
closed systems, bone marrow stromal cells are placed into a diffusion chamber. In this
system, there is no direct contact between host and recipient cells. In open systems, bone
marrow stromal cells are implanted with a scaffold material. In this system, direct contact
between host cells and recipient cells is possible, and vascular ingrowth can occur.
In closed systems, dependent on the size of the chamber, bone or bone and cartilage
are formed.200,204-206 In the heterotopic implantation of fresh or cultured bone marrow cells
loaded on a scaffold, bone is formed with bone marrow-like tissue, without significant
amounts of cartilage, and is therefore similar to intra-membranous bone formation. 190,196,
199,193,207,208 However, occasionally minimal amounts of cartilage occur that is thought to
be related to the geometry of the porous scaffold.193,199,207
Heterotopic bone formation by fresh and cultured bone marrow cells from different
animals loaded onto scaffolds has been shown in nude mice, rats, rabbits and canine.160,173
In addition, cultured human cells have been shown effective in ectopic bone formation in
nude mice. Following heterotopic implantation in rodents with fresh or cultured bone
marrow cells, hematopoietic cells originate from the recipient, while bone originates from
the donor. However, when quail marrow cells were implanted in nude mice, bone was of
donor origin for up to 4 weeks, and of recipient origin after 12 weeks.160
In orthotopic implantation, fresh and cultured bone marrow cells from different ani-
mals loaded onto scaffolds have been successful in the regeneration of cranial defects (mice)
and long bone defects in the radius (dogs), femur (rats and dogs) and tibia (sheep).15,160,
169,180,209 In addition, human cells have also been shown to be effective in bone formation
in long bone defects in athymic rats.210
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Figure 3B. 
The osteoblast lineage.
1.6.4 Dynamic culture methods
To overcome the problems associated with static culture methods (e.g. limited diffusion of
nutrients), dynamic methods have recently been developed. These dynamic methods have
been applied to the engineering of bone, cartilage, endothelium, liver and other tissues.
194,195,211-217 The application of dynamic culture methods such as spinner flasks, micro-
carriers, perfusion culture and rotating wall bioreactors has been reviewed recently by
Temenoff et al. with respect to cartilage engineering.218 The methods that have been
applied to the engineering of bone tissue are perfusion flow and rotating wall vessels.
194,195,219,217
In rotating wall vessels, microcarriers are used for anchorage-dependent cells, and a
zero-gravity environment is created in which the forces of gravity are neutralized by
rotation. The use of rotating wall vessels has been shown to sustain osteogenic expression
for rat bone marrow stromal cells and osteoblast-like cells (SaOS cells and ROS17/2.8 cells)
on different microcarriers.217 In addition, it has been shown to enhance osteogenic expres-
sion in vitro for the latter cells (SaOS cells and ROS17/2.8 cells) when compared with static
culture methods.195,219
The same has been proven for perfusion flow –a three-dimensional medium-rotating
configuration system– on the osteogenic expression of rat bone marrow stromal cells
cultured on calcium phosphate samples. The dynamic culture method was found to sustain
a viable cell population, and more bone matrix was formed in the dynamic than in the
static culture environment.194
Although these results hold some promise for the future, the beneficial effect of
rotating wall vessels has been proven for immortalized and osteosarcoma cell lines only; a
rat bone marrow stromal cell culture was used, but no comparison was made between static
and dynamic culturing. For perfusion flow, only preliminary data are available. Never-
theless, this method has been shown to enhance osteogenic expression for bone marrow
stromal cells over static culture. No data are currently available on the in vivo osteogenic
activity of these constructs.
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1.7 Combination of cells and growth factors
1.7.1 Direct combination
The combination of cells and growth factors has been shown to enhance the osteogenic
response. For example, fresh bone marrow combined with rhBMP-2 or TGF-β1 has been
shown to be more effective in bone defect healing in vivo than marrow alone.220-222 In these
studies, the combination of rhBMP-2 and marrow was even more effective than the carrier
with BMP alone.222,220 These results hold some promise for future applications.
1.7.2 Gene therapy
In gene therapy, genetic information is transferred to cells. When the gene is transfected
into the cells, the targeted cells produce the encoded protein. In this way, both short- and
long-term expression are possible. Gene therapy can either be systemic or regional. The
vector can be introduced directly into a certain location in vivo, or specific cells can be har-
vested, which are then transfected ex vivo. This latter approach offers a better control over
which cells receive the vector. The vector that is used can either be viral [e.g. retro-viruses,
adeno-virsuses, cytomegalo viruses (CMV), herpes simplex viruses and adeno-associated
viruses] or non-viral (e.g. liposomes or DNA ligand complexes).223 While the non-viral
vectors are easier to produce, raise less safety concern and are less immunogenic, they are
also less effective.
Various types of cells that have been ex vivo transfected have been proven to be
osteinductive in vivo. For example, ex vivo transfected cells with the BMP-2 gene induce
ectopic bone formation in vivo. In mice or rats, these cells include bone marrow stromal
cells, muscle derived cells, articular chondrocytes, fibroblasts and W-20-17 cells.224,225 Bone
marrow stromal cells, transfected with the BMP-2 gene, combined with a DBM carrier
were effective in the healing of femoral defects in rats.226 In addition, fibroblasts transfected
with the BMP-7 gene, combined with gelatin sponges, could induce ectopic bone formation
and regenerate calvarial defects in rats.227
Alternatively, BMP genes can be introduced in vivo. An adenoviral vector containing
the BMP-2 gene induced ectopic bone formation after injection in mice.228 A CMV vector
containing the BMP-2 gene induced ectopic bone formation when injected in rats,229 while,
an adenoviral vector containg the BMP-2 gene promoted spinal fusion in rats.230 A CMV
vector containing the BMP-7 gene, mixed with a collagen carrier, induced ectopic bone
formation when implanted in mice.231
DNA plasmids encoding for BMP-4 together with a collagen carrier have been shown
to regenerate femoral defects in rats.232 Moreover, an adenovirus with BMP-2 or TGF-β
genes could heal a rabbit femoral defect, although BMP-2 was more effective than TGF-β.233
These observations hold some promise for the future though the fate of transfected
cells and the safety of viral vectors need further investigation.
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1.8 Carrier materials
1.8.1 Carrier materials for BMP
Numerous carrier materials in combination with native BMPs from different species or
recombinant human BMPs have been used in heterotopic and orthotopic implantation
119,234 (Table 1). These carrier materials include both organic and inorganic materials.
Organic materials can be divided into biological materials and synthetic materials. The
former include demineralized bone matrix (DBM), inactivated DBM [iDBM or insoluble
bone matrix (IBM)], non-collagenous proteins, collagen (type-I and type-IV, absorbable
collagen sponge, collagen membrane, gel and others), fibrin and AAA (Autolyzed Antigen -
extracted Allogenic) bone. Synthetic organic carriers consist mainly of the poly(α-hydroxyl
acids) such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA) or poly(lactic-co-glycolic
acid) (PLGA).235 Inorganic carriers that have been used include calcium phosphate (CaP)
ceramics –like hydroxyapatite (HA) and tricalcium phosphate (TCP) or HA/TCP composites,
coral and natural bone mineral–, bioglass and metals, for example titanium. In addition,
composite carriers have been created that are a combination of different materials, ex-
amples of these are poly(glycolic acid) with poly-ethylene glycol and hydroxyapatite with
collagen.
A large number of prerequisites have been postulated for the ideal scaffold material
with regard to biocompatibility and biodegradability, absence of allergic reactions and
disease transmission, gross architectural qualities, osteoconductivity, chemotaxis, delivery/
control of osteoinductive protein, angiogenesis and vascularization and administrative is-
sues.236 The carriers that are mainly used are CaP ceramics, poly(α-hydroxyl acids) and
collagen.237 However, it has to be emphasized that none of the currently used carrier ma-
terials meet all of the properties postulated. Some of the materials –synthetic polymers for
example– can elicit an undesirable inflammatory response or foreign body reaction. These
reactions are associated with a reduced osteoinductive response.238,239 Other drawbacks
include the lack of structural support and good mechanical characteristics.240,241
1.8.2 BMP release
Few reports exist on the release of BMPs from carrier materials. The release of different
BMPs from frequently used carriers, including collagen, synthetic and natural ceramics,
DBM and PGA, was studied in the rat ectopic assay model by the Genetics Institute.242,243
The release of rhBMP-2 was found to occur in two phases – an initial phase, characterized
by a rapid release in the first hours, and a secondary phase, characterized by a slower more
gradual release. Collagen was found to retain the highest fraction of BMPs during the initial
period (70%), gradually releasing BMP over the next 2 weeks. The other materials retained
30-50% of their load in this initial period. Synthetic hydroxyapatite particles seemed to
retain the lowest amount during the initial phase (10%). In general, mineral and mineral-
based carriers (except synthetic hydroxyapatite) retained a high fraction of the BMPs in the
secondary phase, which reflects a high affinity for BMPs. The release rate of BMP shown
by DBM was similar to collagen, though the latter retained higher amounts.
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Table 1.
Table showing the carrier/scaffold materials that have been described for BMP, TGF-β and osteogenic
cells.
Osteogenic cellsTGF-βBMP
∗ ∗
Carriers / scaffolds
Calcium phosphate ceramics:
Hydroxapatite (HA) (synthetic and coral-derived)
∗ ∗ ∗Tricalcium phosphate (TCP)
∗ ∗Hydroxyapatite / tricalcium phosphate (HA/TCP)
∗ ∗Calcium sulphate paste
∗ ∗ ∗Coral (calcium carbonate)
∗Natural bone mineral
∗Bioglass
∗Apatite-wollastonite containing glass ceramic
∗Alumina ceramic (with or without a CaP coating)
∗ ∗Titanium
Other ceramics:
Others:
Metals:
1  Inorganic materials
2  Organic materials
Ceramic materials:
A. Biological materials
∗ ∗Tinium alloy (Ti-6Al-4V) (with a CaP coating)
∗ ∗ ∗Demineralized bone matrix / inactivated demineralized bone matrix
∗ ∗Collagen
∗Non-collagenous protein (NCP)
∗Fibrin
∗Lyophilized cartilage
∗Autolyzed Antigen - extracted Allogenic (AAA) bone
∗Inactivated dentin matrix
In addition to carrier properties, the release of BMPs is influenced by intrinsic protein
properties like solubility.243 BMP-carrier affinity has been found to vary for different re-
combinant human BMPs (rhBMP-2, chemically modified rhBMP-2, rhBMP-4 and rhBMP-
6). RhBMP-2 and rhBMP-6 showed the highest affinity for the carriers, while rhBMP-4
showed a lower affinity, and the chemically modified rhBMP-2 even less. Further, a higher
retention of BMP within the implant was positively correlated with a higher osteo-
inductive response.
1.8.3 Carrier materials for TGF-β
The literature available on in vivo bone induction by TGF-βs is substantially less than for
BMPs. TGF-β has been shown to be beneficial in bone defect healing –cranial defects,
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Table 1. continued
Table showing the carrier/scaffold materials that have been described for BMP, TGF-β and osteogenic
cells.
Osteogenic cellsTGF-βBMPCarriers / scaffolds
Polymers:
Poly(α-hydroxyl acids):
∗Poly(lactic acid) (PLA)
∗Poly(glycolic acid) (PGA)
∗ ∗ ∗Poly(lactic-co-glycolic acid) (PLGA)
∗Poly(lactic acid) -polyethylene glycol
∗Hydrogels
∗Methyl cellulose gel
∗PLGA / DBM
2  Organic materials
3  Composites
B. Synthetic materials
∗PLGA / polyethylene glycol
∗PLGA / gelatin sponge
∗TCP / collagen
∗ ∗HA / collagen
∗ ∗HA / TCP / Collagen (e.g. Collagraft)
∗Coral / Collagen
mandibular defects and long bone defects–, and in the osseointegration of implants (see
earlier).
The carrier materials include organic and inorganic materials (Table 1). Organic
materials comprise DBM140-142 or inactivated DBM (iDBM)143,244 and methyl cellulose
gel.245,246 A polymer that has been investigated is poly(lactic-co-glycolic acid) (PLPG).247 In
addition, a composite of PLPG and DBM144 has been studied. Inorganic materials used
include calcium phosphate ceramics, for example tricalcium phosphate granules,221,248
coral249 and calcium phosphate cement.250 Calcium sulphate paste has also been used.144
While most of these formulations have been shown to be effective in bone defect
healing when combined with various doses of TGF-β1, negative results have also been
reported. For example, despite relatively high TGF-β1 doses, Gombotz et al. only found an
inflammatory response with the PLPG/DBM carrier in critical size defects in rat calvaria
with little bone formation.251 This reaction might be attributable to the PLPG but also to
the xenogenic DBM. Although a TGF-β1-loaded iDBM carrier could regenerate a critical
size defect in sheep tibia,139 this carier was not able to close critical sized defects in baboons
but only stimulated bone formation at the edges.143 Blom et al.250 only found limited bone
formation when calcium phosphate cement was used with a very low concentration of
rhTGF-β1. Similarly, in a dog radial defect model a 10-ng dose combined with a PLPG car-
rier did not show any response.252
In osteointegration studies, rhTGF-β1 stimulated bone ingrowth up to threefold in
hydroxyapatite/tricalcium phosphate (HA/TCP)-coated titanium-fiber-metal-coated tita-
nium alloy rods.148 In a similar manner, rhTGF-β1 has been shown to enhance mechanical
fixation and bone ongrowth for TCP-coated solid titanium alloy implants.146,147
1.8.4 Carrier materials for osteogenic cells
The carriers that have been used for osteogenic cells are mainly ceramic materials (Table
1). These materials are either coral-derived or synthetic hydroxyapatite (HA), tricalcium-
phosphate (TCP), composites of HA and TCP (60/40 and 65/35), coral and alumina
ceramic. Other materials that have occasionally been studied are biological materials like
collagen and demineralized bone matrix, porous titanium felt and polymers, like PLGA. In
addition, composites such as HA and collagen have been investigated.160,253
1.9 Clinical research
The clinical use of BMPs has been described in orthopedic and oral-maxillo-craniofacial
applications. In the first investigations carried out, native BMP was used in a non-
controlled manner. Johnson et al. treated segmental defects of the tibia and resistant non-
unions of the tibia, femur and humerus.254-260 In these studies, native human BMP
(hBMP) with non-collagenous protein (NCP) was used. This BMP was either suspended in
gelatin capsules, in a strip of poly(lactic-co-glycolic acid) or absorbed to autogenic or allo-
genic autolyzed antigen-extracted bone. The concentration of BMP used in these studies
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was 50–100 mg per implant. In segmental defects, the healing periods varied between 4 and
9 months; in non-unions, healing varied between 3 and 7 months. In most patients success-
ful healing could be obtained without an immunological response or any other adverse
effects. Although many patients were treated with human BMP/NCP, no control group was
included and, as a result, no final conclusions could be drawn as to whether BMP was
effective in this treatment.
Sailer et al.261 used native bovine BMP (bBMP) for the treatment of craniofacial
defects including maxillofacial reconstructions, pseudarthroses (mandible and maxilla),
cranial reconstructions (contour augmentation) and compromised situations in implant-
ology. In the majority of cases, BMP was combined with bone matrix granules at a bBMP
concentration of 1 mg purified BMP/cm3; in other cases bBMP was combined with
lyophilized cartilage or bone. In this way, 482 patients were treated in which 381 cranio-
maxillofacial operations were performed (Le Fort osteotomies, saggital splitting of the skull,
mandibular reconstruction, genioplasty etc.), and 725 implants were placed. Sailer also
concluded that no adverse reactions were observed towards bBMP and found bBMP to be
effective in these cases. However, the patient groups were not homogeneous and no con-
trols were included.
More recently, pilot studies have been published in which rhBMP-2 and rhBMP-7
(OP-1) have been used clinically in orthopaedic and dental and cranio-maxillofacial appli-
cations.30,262-267
Maxillary sinus floor augmentation has been performed with absorbable collagen
sponge together with rhBMP-2 (1.77–3.40 mg) in 12 patients. The average height increase
of the maxillary sinus floor was 8.51 mm, but this varied between 2.3 and 15.7 mm.262 No
immunological or adverse effects were noted. In another clinical study, absorbable collagen
sponge with rhBMP-2 was unable to stimulate bone formation in alveolar ridge augmen-
tation but it did stimulate bone formation in extraction pockets.263 Maxillary sinus floor
augmentation with OP-1 and a collagen carrier only demonstrated bone formation in one
of the three patients.265
In 12 patients with open tibial fractures, rhBMP-2 (3.4–6.8 mg) with an absorbable
collagen sponge carrier was used.267 Fractures were fixed with an external fixator or
intramedullary (IM) nail. In 9 patients the fracture healed without further surgical inter-
vention. The remaining 3 patients, all treated with external fixator, needed further
treatment. No second intervention was needed in the group treated with IM nail fixation.
In a feasibility study, the same authors found a 40% second intervention rate for current
treatment methods. In addition, no adverse effects occurred, but 2 patients showed a transi-
ent occurrence of antibodies against rhBMP-2 at 2 weeks.
Two controlled studies have been performed with rhBMP-7. In 30 patients with non-
union tibial fractures, 14 patients were treated with rhBMP-7 and a type-I collagen carrier,
and a control group of 16 patients were treated with autogenous iliac crest bone. After 9
months, healing of non-unions could be confirmed radiographically in 27 patients; 1 auto-
graft and 2 rhBMP-7-treated non-unions failed to heal. In addition, 2 patients were not
fully weight-bearing. Of the remaining patients, 18 patients were pain-free, while the others
had mild to moderate pain upon weight-bearing.
Another controlled study by Geesink et al.264 demonstrated that 2.5 mg rhBMP-7 with
a collagen type-I carrier could regenerate a 15-mm tibial defect in patients undergoing a
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tibial osteotomy. RhBMP-7 significantly stimulated bone defect healing compared to
collagen alone. However, with DBM, 6/6 patients demonstrated healing, while in 5/6 pa-
tients healing was observed with rhBMP-7. No adverse reaction from or immunological
reaction towards the rhBMP-7 was observed; however, only in the OP-1 group had 3 pa-
tients pain 1 year post-operative, which could be related to excessive bone formation.
No clinical data are available for TGF-β in bone defect healing. However, when sys-
temically administered in patients with progressive multiple sclerosis, TGF-β2 has been
shown to result in a reversible decline in renal function.268
Conolly et al. developed a method in which a percutaneous injection of autologous
marrow aspirate was effective in 80% of the cases in stimulating bone healing, including
delayed unions and fracture non-unions, arthrodeses and bone defects.269,270
Limited clinical studies are available in which marrow stromal cells have been ex vivo
expanded for clinical use. In a non-controlled study, cultured human bone marrow stromal
cells have been loaded into DBM and transplanted into non-unions, pseudarthrosis and
bone defects. A 2-year follow-up in 15 patients revealed that healing occurred in all pa-
tients.271 In another study, allogenic lyophilyzed bone fragments combined with either
fresh autogenous marrow (30 patients) or cultured autogenous bone marrow stromal cells
with autogenous marrow (10 patients) were evaluated for the healing of mandibular defects
(cyst excision or correction of mandibular deformation). While both strategies were able to
regenerate the defect, the cultured bone marrow stromal cells with autogenous marrow
resulted in faster bone healing.201
Taken together, these studies show that BMPs and osteogenic cells can be used to
stimulate bone healing.160 Nevertheless, the response shows inter-individual differences.
1.10 Titanium and calcium phosphate coatings
1.10.1 Titanium
In addition to polymers and ceramics, metals like titanium can also be used to create BGS.
Porous and non-porous titanium implants with varying geometrical properties have been
investigated. In a preliminary study, a titanium fiber mesh (similar to the one we propose)
with a thickness of 2 mm, a fiber diameter of 50 µm and a pore range of 100- 600 µm has
been used as a scaffold for osteogenic cells. When loaded with fresh autogenous bone mar-
row cells, this fiber mesh could generate bone formation in heterotopic implantation.272
Another porous sintered titanium fiber metal implant loaded with syngeneic marrow cells
has been found to generate bone formation in a rat femoral defect model. However, this
titanium implant was less effective in healing the defect than a hydroxy-apatite/tricalcium
phosphate ceramic.273 Other titanium wire metals or fiber meshes have also been shown to
allow bone ingrowth274,275 which is enhanced by TGF-β1.148
Porous and non-porous titanium implants have also been studied as carriers for Bone
Morphogenetic Proteins both in heterotopic and orthotopic locations. Cylindrical porous
titanium implants loaded with rhBMP-2 induced heterotopic bone formation.276 The same
was found for non-porous titanium alloy substates loaded with native BMP277 in which the
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application of a titanium or hydroxyapatite coating increased the amount of newly formed
bone.278 In an orthotopic location, rhBMP-7 was observed to enhance osseointegration of
non-porous titanium implants.279
1.10.2 Calcium phosphate coatings
Titanium fiber mesh can be provided with a calcium phosphate (Ca-P)-coating. It is
generally supposed that Ca-P coatings enhance the bone formation process. Calcium phos-
phate coatings can be applied using various methods such as plasma spraying, high velocity
oxygen-fuel spraying, electrophoretic deposition, sol-gel deposition, hot isostatic pressing,
frit enamelling, ion-assisted deposition, pulsed laser deposition, electrochemical deposition,
biomimetic deposition and sputter coating.280 We propose the use of a sputter coating since
the coating is very thin and suitable for coating substrates with difficult geometrical shapes.
Sputter coating is a process in which the atoms or molecules of a material are ejected by
bombardment of high-energy ions. The freed particles deposit on a substrate placed in the
vacuum chamber. Several sputter techniques exist: diode sputtering, direct current or ion-
beam, and radio-frequent (RF) sputtering. We use a magnetically enhanced variant of the
diode sputtering – the so-called RF magnetron sputter technique, which is suitable for
sputtering metals, alloys and ceramics as well as other materials.
The use of such a thin RF magnetron-sputtered ceramic coating on metal implants has
already been proven to enhance osteogenic expression in vitro and osteoconduction in
vivo.281-283 A thicker plasma spray coating has been shown to enhance bone formation in
fresh marrow cell-loaded alumina ceramic,284 but it has not been proven that it stimulates
BMP-induced bone formation.276,278,279
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1.11 Objective and hypothesis
Because of the associated disadvantages of currently used carrier materials in the creation
of BGSs, titanium fiber mesh might be a potential scaffold material for loaded applications.
This titanium mesh has excellent mechanical properties in terms of stiffness and elasticity.
Further, it is biocompatible both for soft tissue and bone, and easy to handle during surgery.
Although titanium is not degradable, for a large number of reconstructive procedures, this
is no drawback. An additional advantage is that the titanium fiber mesh can be provided
with a calcium phosphate coating.
On the basis of available literature, we hypothesize that a Ca-P ceramic coating will
also have a beneficial effect on the effectiveness of a titanium scaffold in the creation of
BGS.235 Therefore, the objective of this thesis was to examine the use of a titanium fiber
mesh scaffold with or without a thin calcium phosphate coating in the creation of BGS.
In order to evaluate the feasibility of a titanium fiber mesh scaffold in the creation of
BGS the following questions have to be answered:
1. What is the osteogenic expression in porous titanium fiber mesh loaded with rat bone
marrow cells in vitro, and how is it influenced by cell seeding density and rhBMP-2
concentration?
2. What is the efficacy of a titanium fiber mesh loaded with cultured osteogenic cells on
bone formation in an ectopic location, and what is the additional influence of the ap-
plication of a thin Ca-P coating?
3. What is the effect of the cell seeding method in combination with prolonged in situ
culturing on bone formation in titanium fiber mesh scaffolds in an ectopic location?
4. Can titanium fiber mesh loaded with Bone Morphogenetic Proteins (BMPs) induce
bone formation in an ectopic location, and can the osteoinductive effect of recombinant
human BMP synergistically be enhanced by native bovine BMPs?
5. What is the nature of the bone induction process in various BMP-loaded carrier ma-
terials?
6. What is the bone formation-supporting efficacy of titanium fiber mesh as-received,
provided with a thin calcium phosphate coating, or loaded with rhTGF-β1 in an ortho-
topic site?
7. What is the efficacy of porous PPF provided with rhTGF-β1 on bone induction in an
orthotopic site, and what is the effect of a fibronectin coating on the bone response to
porous PPF?
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Influence of rhBMP-2 on rat bone marrow
stromal cells cultured on titanium fiber mesh
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Tissue Eng. 2001; 7:373.
2.1 Introduction
Bone Graft Substitutes (BGSs) can be fabricated using a porous carrier material together
with osteogenic cells or osteoinductive factors like Bone Morphogenetic Proteins (BMPs).
One disadvantage of most of the currently used carrier materials is that they are not very
strong and can easily transform. Another candidate carrier material for the creation of BGS
is sintered titanium (Ti) fiber mesh material. Ti-mesh loaded with BMPs has been shown
to adequately induce ectopic bone formation in vivo.1-3 We also know that a porous scaffold
material loaded with bone marrow stromal cells can generate ectopic bone formation. If this
technique is also to be applied for Ti-fiber mesh, we first have to demonstrate that bone
marrow stromal cells will show osteogenic expression in Ti-fiber mesh. An additional fac-
tor is that the level of in vitro and in vivo osteogenic expression in a porous scaffold material
is dependent on the number of loaded osteogenic cells and culture conditions.4-6
Some investigators have attempted to improve culture conditions (for other cell types)
by optimizing nutrient supply using dynamic culture methods, i.e. perfusion culture, spin-
ner flasks and rotating wall bioreactors.7 Others have experimented with various growth
factors, for example, bFGF to promote cell growth and rhBMP-2 to stimulate cell differen-
tiation.8
The objective of the study reported here was to investigate: (1) the osteogenic expres-
sion in porous titanium mesh loaded with rat bone marrow cells in vitro; (2) the influence
of cell seeding density on the osteogenic expression in porous titanium mesh in vitro and
(3) the rhBMP-2 concentration dependency of the osteogenic expression in titanium mesh
in vitro. 
2.2 Materials and methods
2.2.1 Substrates
Porous Ti-fiber mesh (Bekaert, Zwevegem, Belgium) with a volumetric porosity of 86%
and a fiber diameter of 50 µm was used as-received. The average pore size of Ti-fiber mesh
is approximately 250 µm. Discs were fabricated from 0.8-mm-thick titanium fiber mesh
sheets to a diameter of 6 mm and a weight of approximately 15 mg. Larger discs were used
for DNA measurements: 10 mm in diameter and a weight of approximately 40 mg. 
2.2.2 Bone Morphogenetic Protein
The BMP used in the present study was recombinant human BMP-2 (rhBMP-2). RhBMP-2
was produced by Chinese hamster ovary (CHO) cells9 and was a kind gift from Genetics
Institute, Cambridge, Mass., USA. RhBMP-2 was used in various concentrations: 10 ng/ml,
100 ng/ml and 1,000 ng/ml. Controls without BMP were used as well. In appropriate sam-
ples, BMP was present in the media from day 0 up to day 7 postseeding. During this period
rhBMP-2-containing medium was changed 3 times. Thereafter, medium without BMP was
used.
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2.2.3 Cell isolation and culture
In order to test the effect of the Ti-mesh and rhBMP-2 dose on bone induction, we used a
rat bone marrow stromal (RBM) cell culture technique.10 Briefly, bone marrow cells were
obtained from femora of young male Wistar rats (weight: 120–150 g, age: 40–43 days). The
femurs were excised, epiphyses were cut off and both diaphyses were washed 3 times in α-
Minimal Essential Medium (α-MEM, Gibco BRL, Life Technologies B.V., Breda, The
Netherlands) with gentamycin (10 times culture concentration). The femurs were then
flushed out, using complete medium: α-MEM supplemented with 10% fetal calf serum
(FCS, heat induced at 56°C for 35 min, Gibco), 50 µg/ml freshly prepared ascorbic acid
(Sigma, Chemical Co., St. Louis, Mo., USA), 10 mM Na-β-glycerophosphate (Sigma), 10-8 M
dexamethasone (Sigma) and antibiotics [gentamycin and amphotericine B (Fungizone®)].
Per two femurs 15 ml of this medium was used. The cells were suspended and cultured in
three 80-cm2 tissue culture flasks (Nunc Products, by Gibco) maintained in a humidified
atmosphere of 95% air, 5% CO2 at 37°C.
After 7 days of primary culture, cells were detached using trypsin/EDTA (0.25% w/v
trypsin/0.02% ethylene diamine tetra acetic acid), concentrated by centrifugation at 1,500
rpm for 5 min and resuspended in a known amount of media. A Coulter® counter was used
to count the cells. The cell suspension was diluted to 3.33 x 105 cells/ml [low cell density
(LD)] and 3.33 x 106 cells/ml [high cell density (HD)] in complete media.
The Ti-meshes were placed in 24-well plates. Thirty-microliter aliquots (85-µl aliquots
for the larger substrates for DNA analysis) of the cell suspensions were seeded onto the top
of the meshes, resulting in a seeding density of 3,54 x 104 cells/cm2 (LD) and 3,54 x 105
cells/ cm2 (HD) when normalized to the top surface area of the meshes. In this way a total
of 10,000 and 100,000 cells (28,000 and 280,000 cells for the larger substrates for DNA
analysis) were added to the LD and HD meshes, respectively.
After seeding, the meshes were left undisturbed in an incubator for 3 h to allow for
cellular attachment to the substrates. Thereafter, an additional 1 ml of media was added to
each well. Appropriate meshes received medium with rhBMP-2. The medium was changed
every 2-3 days. 
In this way eight experimental groups were created (Table 1). The cells were kept in
culture for different time periods up to 16 days. Each experiment was performed twofold,
and in each experiment four replicate samples were used (in total, n=8 for each material
and time period).
2.2.4 Scanning electron microscopy, energy dispersive spectroscopy and
X-ray diffraction
The influence of material properties on cell morphology and extra-cellular matrix (ECM)
synthesis of RBM cells was studied using scanning electron microscopy (SEM) and energy
dispersive spectroscopy (EDS). After 8 and 16 days of incubation the substrates were rins-
ed three times with 0.1 M sodium-cacodylate buffer (pH= 7.4, 37°C). Fixation was subse-
quently carried out for 60 min at 4°C in 2% glutaraldehyde in the same buffer. The speci-
mens were then dehydrated in a graded series of ethanol and dried by tetramethylsilane
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and kept dry until SEM evaluation. Just before analysis, the specimens were sputtered with
gold and examined and photographed using a Jeol 6310 SEM at an accelerating voltage of
10-15 kV. 
Additional samples were sputtered with carbon, and EDS (single spot or line) was
performed to identify the elemental composition of the extracellular matrix using the same
Jeol 6310 SEM which was equipped with a energy disperse X-ray detector (Voyager).
Other samples were used for X-ray diffraction (XRD) analysis at 16 days of culture.
Samples were rinsed twice with phosphate buffered saline (PBS) and dehydrated in a
graded series of alcohol. The samples were then dried using tetramethylsilane and kept dry
until XRD was performed. The crystallographic structure of the deposited matrix was
determined using a Philips PW 3710 based diffractometer. The angle of incidence was kept
fixed at 10ºθ . To analyze the reflected beam, we used a collimator, monochromator and
proportional counter. The step was 0.02º 2θ, with a counting time per step of 12 s.
2.2.5 Light microscopy
After 8 and 16 days of culture, specimens for light microscopical analysis were rinsed twice
with PBS and fixed in 4% formaldehyde buffer (pH= 7.4) for 1 h, then rinsed twice with
PBS and once with water and finally stained with Alizarin Red-S for 60 s before dehy-
dration in a graded series of ethanol. These samples were eventually embedded in methyl-
methacrylate. After polimerization thin sections were made using a modified sawing
microtome technique.11 The prepared sections were analyzed under a light microscope
(Leica®). 
2.2.6 DNA analysis
After 4, 8 and 16 days of culture, DNA content was determined in order to obtain indirect
information about cellular proliferation. Incubated specimens were rinsed twice using PBS,
and the cells were lysed using 0.5 ml 1 M NaOH with subsequent sonification for 15 min.
Until the time of analysis, specimens were kept at –20°C. After thawing, samples were
neutralized with 0.5 ml 1 M HCl-PO4 buffer. Fluorescence was read in a fluorometer using
bisbenzimidazole (Hoechst® 33258 reagent).12
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Table 1.
Eight experimental groups were created
Cell seeding density BMP concentration (ng/ml):
LD (Low Density)
HD (High Density) 0 10 100 1,000
0 10 100 1,000
2.2.7 Calcium content
Calcium (Ca) content was assessed after 4, 8 and 16 days of culture to obtain information
about mineralized matrix formation. The samples were rinsed twice with milliQ and kept
at –20°C until calcium assessment. After thawing, 1 ml of acetic acid was added to each
sam-ple and stored overnight under vigorous constant shaking. The calcium content was
deter-mined using the orthocresolphthalein (OCPC) method.13 Optic density was read with
an ELISA reader at a wavelength of 575 nm.
2.3 Results
2.3.1 SEM, EDS and XRD
At low magnification a confluent (multi-) layer of cells was present on top of the meshes.
The surface area covered by this cell layer appeared to increase with increasing cell seeding
density (Figures 1A, 1B) for all time periods. At 8 days, a whitish deposit could be
observed for LD 1,000 and all HD specimens, that covered significant parts of the mesh
surface (Figure 1B). At 16 days this deposit could be observed for all specimens.
At 8 days, examination at high magnification confirmed the presence of cells in the
confluent (multi-) layer on top of the meshes. These cells had spread and exhibited filo-
podia (Figure 1C). Collagen bundles and early signs of calcification, as characterized by the
presence of calcified globular accretions, were seen in LD 1,000 specimens and all HD
specimens (Figure 1C, 1D). EDS confirmed the presence of Ca and P in these calcified
globular accretions.
At 16 days, abundant calcification associated with collagen bundles was observed in all
specimens (Figure 1D). The amount of calcification seemed to increase with increasing
concentration of rhBMP-2 (Figure 1E). The size of the globular accretions increased over
time, and appeared to be cell density-and rhBMP-2 dose-dependent (Figure 1E). This effect
was only seen in the HD specimens.
Further analysis of the samples by XRD revealed that at 16 days the deposited matrix
contained a precipitate of a stable calcium phosphate phase (Figure 2).
2.3.2 Light microscopy
In general, sections showed a red-stained layer on top of the meshes. This layer penetrated
up to approximately 250 µm into the mesh (Figure 3C). Due to the staining technique, cell
morphology itself could not be observed. Although no quantitative analysis was performed,
subjective analysis indicated that the HD specimens appeared to be more densely stained
than LD specimens (Figures 3A, 3B) for both incubation times and showed higher
penetration depth (Figure 3C). Further, the staining density appeared to increase with
culture time (16 days > 8 days) and presence of rhBMP-2 in the culture medium (Figures
3B, 3C).
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Figure 1.
(A) Scanning electron microscopical image at low magnification of a LD 0 sample at 8 days. The surface is only
partially coved by the multilayer of cells (orig. magn. 25x). 
(B) Scanning electron microscopical image at low magnification of a HD 0 sample at 8 days. Note that a larger surface
area is covered by the multilayer of cells than in the LD 0 specimen. A whitish deposit can be observed that covers a part
of the mesh surface (orig. magn. 25x). 
(C) Scanning electron microscopical image at high magnification of a HD 10 sample at 8 days. A bone-like tissue
formation can be observed. A spread osteoblast-like cell is present which exhibits philopodia (orig. magn. 5,000x). 
2.3.3 DNA
The results of the DNA measurements are depicted in Figure 4. ANOVA, and multiple
regression analysis were used to analyze the data from the DNA measurements. The data
showed a normal distribution and ANOVA subsequently showed an influence of
experimental run. At 8 days, the DNA level was generally higher in the second run than in
the first run (P< 0.0005, 3-way ANOVA). A significant overall effect of culture time
(P<0.0005, 3-way ANOVA) and cell seeding density (P<0.0005, 3-way ANOVA) was also
present. From 4 to 8 days DNA increased, from 8 to 16 days DNA content decreased to a
level below that at 4 days. In addition, the higher cell seeding density resulted in a higher
DNA content than that found with the lower cell seeding density. In the first run, a 2-way
interaction was noted between culture time and cell seeding density, but such an inter-
action was not observed in the second run. The interaction in the first run includes lower
DNA measurements for the HD specimens at 8 days. In this run, at 4 to 8 days, the DNA
content remained at about the same level in the HD group. On the other hand, in the
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Figure 1.
(D) Scanning electron microscopical image at high magnification of a HD 0 specimen at 8 days. Globular accretions
together with collagen bundles can be observed (orig. magn. 1,500x). 
(E) Scanning electron microscopical image at high magnification of a HD 0 specimen at 16 days. Abundant
calcification can be seen together with collagen bundles. The globular accretions become larger (orig. magn. 1,500x). 
(F) Scanning electron microscopical image at high magnification of a HD 1,000 specimen at 16 days. The globular
accretions become larger (orig. magn. 1,500x). 
Figure 2. 
X-ray diffraction pattern of
HD specimens at 16 days
treated with different
concentrations of rhBMP-2.
For all rhBMP-2
concentrations, the X-ray
diffraction pattern clearly
shows the presence of a
precipitate of a stable calcium
phosphate phase in the
deposited matrix.
second run an increase in DNA content was found from 4 to 8 days for the HD group. No
significant effect was noted with respect to BMP concentration on DNA measurements (3-
way ANOVA, multiple regression analysis). 
2.3.4 Calcium content
The results of the calcium measurement are shown in Figure 5. ANOVA and multiple
regression analysis were used to analyze the data from the calcium measurements. The data
showed a lognormal distribution and ANOVA subsequently showed an influence of
experimental run. Levels of calcification were generally higher in the second experimental
run. No calcification was seen at 4 days. Multiple regression analysis revealed a significant
overall effect of cell seeding density at 8 days (run 1: P<0.001, run 2: P<0.00005) and 16
days (run 1: P<0.0005, run 2: P<0.005). In general, HD specimens showed a higher
calcium content than LD specimens. Multiple regression analysis revealed that significant
rhBMP-2 concentration effects were found for the HD specimens at 8 days [run 1: 1,000
ng/ml (P<0.00005); run 2: 10 ng/ml (P<0.005), 100 ng/ml (P<0.0005) en 1,000 ng/ml
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Figure 3. 
(A) Light microscopical
image of a LD 0 specimen at
16 days. A red-stained layer
with mineralization is present
on top of the mesh
(orig. magn. 10x). 
(B) Light microscopical
image of a HD 0 specimen at
16 days. The layer on top of
the mesh is more densely
stained than in the LD
specimen (orig. magn. 10x). 
(C) Light microscopical
image of a HD 100 specimen
at 16 days stained with
alizarin red-S. A layer with
mineralization is present in
the upper part of the mesh,
which penetrates up to
approximately 250 µm into
the mesh (orig. magn. 10x).
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Figure 4. 
This graph shows the results
of the DNA measurements for
both experimental runs (mean
and standard deviation [SD]). 
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Figure 5. 
This graph shows the results
of the calcium measurements
for both experimental runs
(mean and SD). ANOVA and
Multiple regression analysis
were used to analyze the
calcium content data. The
influence of rhBMP-2
concentration was evaluated
using multiple regression
analysis and significant
differences are shown. In this
evaluation, the effects of
different concentrations of
rhBMP-2 (10 ng/ml, 100 ng/ml
and 1,000 ng/ml) were
compared to the control
(0 ng/ml) for the same culture
period, cell seeding density
and experimental run. 
(P<0.00005)] and at 16 days [run 1: 1,000 ng/ml (P<0.005); run 2: 100 ng/ml (P<0.01)
en 1,000 ng/ml (P<0.001)]. In addition, in the first run a significant concentration effect
was found for the LD specimens [100 ng/ml (P< 0.05) and 1,000 ng/ml(P<0.005)] at 16
days. Specimens treated with 100 ng/ml and 1,000 ng/ml showed the highest calcification.
2.4 Discussion and conclusion
Our findings show that cells attach and grow well in Ti-fiber mesh. The Ti-fiber mesh
supports differentiation of the bone marrow stromal cells as demonstrated by the presence
of calcified globular accretions and collagen bundles. The calcium measurements suggest
that increasing cell seeding density and high rhBMP-2 concentrations (100 and 1,000
ng/ml) stimulate calcification, while the DNA measurements indicate that increasing cell
seeding density increases the number of loaded cells and that rhBMP-2 does not influence
proliferation.
In contrast to our earlier studies using rat bone marrow stromal cells cultured on solid
Ti-discs, in the present study we found that titanium clearly supports the formation of a
mineralized matrix.14 This finding might be explained by the difference in total number of
cells seeded and number of cells seeded per surface area. In this study, we applied 10,000 or
100,000 cells per Ti-mesh disc (diameter: 6 mm), whereas in the former study only 10,000
cells were applied on larger solid Ti-discs (diameter: 12 mm). Another factor that might
explain these observations is the difference in the geometry of the substrates. 
Our light microscopical results demonstrated only limited cellular penetration into the
fiber mesh material. This has also been observed for other carrier materials, such as poly-
(DL-lactic-co-glycolic acid) (PLGA)4,5 and collagen.15 In the PLGA studies, cells penetrated
up to 240 µm. In the collagen study, cell density was higher in the upper region of the
substrate at 21 days, while at 56 days a two-layer structure existed: osteocytes with mineral-
ization in the upper region, and osteoblasts with less mineralization in the lower region.
Unfortunately, the Alizarin red-S staining used in our experiment is specific for mineral-
ization. Therefore, no cellular morphology could be observed in our mesh material. 
Although penetration depth was not quantified because no clear migration front was
seen, increasing the cell seeding density seemed to enhance penetration. This finding does
not corroborate with other studies. For example, Ishaug et al.4 found that cell seeding
density did in fact influence penetration depth; higher cell seeding densities (22.1 x 105
cells/cm2) negatively influenced penetration depth. Nevertheless, we have to emphasize
that the low cell seeding density (6.83 x 105 cells/cm2) as used in that study is about twice
as high as our high cell seeding density. 
We assume that the phenomenon of limited cellular penetration is due to a diffusion
effect: lower oxygen tension and nutrient supply in the lower regions of the carrier material
inhibit cell growth. This effect will be enhanced when very high cell seeding densities4 are
used. A mechanical obstructive effect due to pore size is not very likely for scaffolds with
pore sizes ranging from 150 µm to 710 µm.4,5 The pore size we used has already been
shown adequate for both blood vessel and bone ingrowth in various ectopic assay models in
vivo.1,2,3,16
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Our DNA measurements revealed that cellular proliferation increased from 4 to 8 days
for all specimens. From 8 to 16 days DNA decreased for all specimens. This decrease in
proliferation was accompanied by a simultaneous increase in calcium content. Three
explanations can be given for this increase in differentiation and decrease in proliferation:
(1) the inverse relationship that exists between proliferation and differentiation;17 (2)
because of the mineralization the nutrient status deteriorates and causes a decrease in the
number of cells; (3) because of the increase in calcification at 16 days and the high affinity
of DNA for calcium, total DNA could not be retrieved. At this moment no final answer can
be given as to which of these three explanations is true. We observed that an increase in
rhBMP-2 concentration does not affect cellular proliferation. This corroborates with earlier
findings of Puleo et al.18 in which rhBMP-2 did not affect cell growth for rat bone marrow
stromal cells but stimulated cell growth in C3H10T1/2 cells .
With respect to mineralized matrix formation, BMP treatment had an increasing
effect. In addition, matrix deposition occurred at earlier time periods. The results of the
present study indicate that rhBMP-2 stimulates the differentiation of RBM cells cultured on
Ti-fiber mesh in a dose-dependent manner. The 1,000 ng/ml concentration stimulated
mineralization in both runs at both 8 days and 16 days, for high density specimens. For
high density specimens, the 100 ng/ml rhBMP-2 concentration was also able to stimulate
differentiation at 8 and 16 days, but only in the second run. The 10 ng/ml rhBMP-2 did not
stimulate mineralization in a reproducible manner. Consequently, the highest concen-
tration (1,000 ng /ml) appears to be the most stimulative on differentiation. For titanium, a
rhBMP-2 concentration of 40 ng/ml has been reported to stimulate differentiation of the
mouse osteoprogenitor cell line 2T9.19,20 The dose response effect we found, corroborates
with a study in which rat bone marrow stromal cells were cultured with rhBMP-2 loaded
PLGA microspheres as scaffold material.18 This dose response effect of BMPs does not
occur only with primary cell cultures like bone marrow stromal cells and calvarial cell
cultures,21 it has also been reported for bone cell lines.22,23 In addition, not only the con-
centration but also duration of rhBMP-2 stimulation affects differentiation. Puleo et al.24
found that a 1-week exposure of 1,000 ng/ml rhBMP-2 was able to stimulate matrix mi-
neralization of rat bone marrow stromal cells. An exposure time of 2 weeks further
enhanced differentiation. Exposure times longer than two weeks did not further enhance
osteoblast differentiation. For this reason we decided to supplement our medium only from
day 0 till day 7 with rhBMP-2. We also know that rhBMP-2 and glucocorticoids, like
dexamathasone and triamcinolone, act synergistically on osteoblast differentiation.25,26 In
view of this Boden et al.26 reported that glucocorticoid co-treatment potentiates BMP effects
up to tenfold. 
The rat bone marrow stromal cell culture we used is a primary cell culture. The
different experimental runs showed different cellular behavior, although overall trends
were the same, the level of DNA and calcium differed between the runs. Under the
influence of growth and systemic factors, bone marrow stromal cells can differentiate into
either adipocytes, chondroblasts, fibroblasts, myoblasts, osteoblasts or reticular cells.27
However, rat bone marrow stromal cell cultures are inhomogeneous cell cultures.
Consequently, not only uncommitted pluripotent but also predetermined cells are present.
24 This causes a certain unpredictability of results between separate cultures. It also
emphasizes the problems with primary cell cultures. In view of this, we assume that
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different numbers of undifferentiated pluripotent cells were present in both runs because
the number of loaded cells and culture conditions were the same for both experimental
runs. To prevent these problems cell lines can be used which represent more homogenous
cultures. An example of a mesenchymal progenitor cell line is the mouse embryonic
fibroblast line C3H10T1/2. These cells are uncommitted and can be induced to differen-
tiate into myoblasts, adipocytes, chondroblasts and osteoblasts depending on the differ-
entiation promoting agent used.28,29,30,31,32 A serious disadvantage is that C3H10T1/2 cells
need the continuous presence of a differentiation-stimulating agent for their osteoblastic
phenotype to be maintained.24
Based upon our observations we conclude that: (1) titanium fiber mesh indeed sus-
tains excellent osteogenic expression in vitro; (2) increasing the cell seeding density has a
positive effect on osteogenic expression in Ti-mesh in vitro; (3) in high density specimens,
rhBMP-2 concentrations of 100 and 1,000 ng/ml stimulate extracellular matrix calcification
in a dose-responsive manner.
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Bone formation in calcium-phosphate-coated
titanium mesh
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3.1 Introduction
At the present time, the clinical standard in the treatment of bone defects is still the use of
autologous bone tissue. Nevertheless, due to both availability and patient-associated
problems, alternative treatment techniques are under development. The rationale of these
new strategies is the construction of a so-called bone graft substitute (BGS) consisting of a
porous material to which bone growth-promoting factors or bone-forming cells are added. It
is this latter technique that especially appears to have great potential in terms of both cost
and human ectopical effectiveness. 
In post-natal life, precursors of osteogenic cells, the so-called osteoprogenitor cells or
mesenchymal stem cells (MSCs), are present in bone marrow. Osteoprogenitor cells
represent only a small fraction of the total number of bone marrow cells, in humans this
has reported to be 0.01-0.0001%.1 Whilst some authors have shown decreased progenitor
cells with ageing,2-6 others have not.7 In view of this, methods have been developed to
culture-expand and select the osteoprogenitor cell fraction from bone marrow.8-10 Pre-
liminary studies of Bruder et al. demonstrated that BGSs with culture-expanded bone
marrow-derived MSCs are more effective in bone formation in segmental defects than
BGSs loaded with fresh syngeneic marrow.8 On the other hand, not only the proliferation
but also the differentiation of osteoprogenitor cells can be directed. Several factors have
been shown to direct differentiation of marrow-derived MSCs into the osteoblast lineage in
vitro: dexamethasone11,12 BMPs,12,13 1,25-dihydroxyvitamin D3,14 retinoic acid13 and
fluoride.15
In addition to osteogenic potential, a BGS requires the use of a suitable carrier or
scaffold material. Applied carrier materials include ceramics (e.g. hydroxyapatite and/or
tricalcium phosphate), and polymers (e.g. poly(α-hydroxyl acids): poly(lactic acid), poly
(glycolic acid) or co-polymers). The disadvantage of most of these scaffold materials is that
they are not very strong and can easily transform.16 Another candidate scaffold material for
loaded applications is titanium (Ti) fiber mesh.17 This titanium mesh has excellent mecha-
nical properties in terms of stiffness and elasticity.17 Further, it is bone-compatible and easy
to handle during surgery. Although titanium is not degradable, for a large number of recon-
structive procedures, this is no drawback. An additional advantage is that the titanium
fiber mesh can be provided with a very thin calcium phosphate (Ca-P)-coating. It is gener-
ally assumed that calcium phospate coatings enhance the bone formation process.18
The current study is part of a series of experiments in which we explore the efficacy of
titanium fiber mesh as scaffold material in the creation of BGSs. The objective of the
present study was to investigate whether: (1) titanium mesh loaded with cultured osteo-
genic cells can generate bone formation in an ectopic location, and (2) the application of a
thin Ca-P coating will have an additional effect on bone formation.
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3.2 Materials and methods
3.2.1 Scaffold materials
Sintered porous Ti-fiber mesh (Bekaert N.V., Zwevegem, Belgium) with a volumetric
porosity of 86%, density of 600 g/m2 and fiber diameter of 50 µm was used as scaffold
material. The average pore size of the mesh was about 250 µm. The prepared implants were
disc shaped with a diameter of 6 mm, thickness of 0.8 mm, and weight of about 15 mg. All
implants were ultrasonically cleaned with 70% ethanol for 15 min. The mesh was applied
as-received (Ti) or provided with a thin (1 µm) Ca-P coating (Ti-CaP) on both sides. The
coating procedure was performed using a commercially available RF magnetron sputter
unit (Edwards ESM 100).19 The target material used in the deposition process was a copper
disc provided with a plasma-sprayed hydroxyapatite coating (CAMCERAM®). The process
pressure was 5 x 10-3 mbar and the sputter power was 400 W. The deposition rate of the
films was 100–150 nm/min sputtering. 
After deposition, all coated specimens were subjected to an additional heat treatment
for 2 h at 500°C. X-ray diffraction (XRD) (Figure 1), Fourier Transform Infrared spec-
troscopy (FTIR) and Energy Dispersive Spectroscopical (EDS) analysis showed that this
resulted in the coatings having a crystalline apatite structure with a Ca/P ratio of 1.8–2.0.
Before use, implants were sterilized by autoclaving for 15 min at 121°C. A total of 120 discs
were prepared: 60 Ti and 60 Ti-CaP. 
3.2.2 Cell culture technique
The rat bone marrow (RBM) cell culture technique was used as described by Maniato-
poulos.20 Rat bone marrow (RBM) cells were obtained from femora of 5 six-week-old
syngeneic Fisher 344 male rats (100–120 g). Epiphyses were cut off, and both diaphyses
were flushed out using complete medium consisting of α-Minimal Essential Medium (α-
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Figure 1.
X-ray diffraction pattern of a
crystalline sputter coating
deposited on titanium fiber mesh
(heat treatment for 2 h at 500ºC)
(Ti = titanium substrate).
MEM, Gibco BRL, Life Technologies B.V., Breda, the Netherlands) supplemented with
10% fetal calf serum (FCS, heat induced at 56°C for 35 min., Gibco), 50 µg/ml freshly
prepared ascorbic acid (Sigma, Chemical Co., St. Louis, Mo., USA), 10 mM Na-β-glycero-
phosphate (Sigma), 10-8 M dexamethasone (Sigma), and gentamycin. Per two femurs, 15 ml
of this medium was used. Finally, cells were suspended and cultured in complete medium
in three 80-cm2 tissue culture flasks (Nunc. Products, Gibco). Cultures were incubated in a
humidified atmosphere of 95% air, 5% CO2 at 37°C. After seven days of primary culture,
cells were detached using trypsin/ EDTA (0.25% w/v trypsin/ 0.02% ethylene diamine
tetra acetic acid (EDTA)).
3.2.3 Bone graft substitute preparation
The cells were concentrated by centrifugation at 1,500 rpm for 5 min and resuspended in a
known amount of media. Cells were counted by a Coulter counter and diluted to 5.0 x 106
cells/ml in serum-free α-MEM. A total of 120 meshes, 60 Ti and 60 Ti-CaP, were placed in
24-well plates. Half of these meshes were loaded with cells and the other half were used as
controls. Before loading, all materials were treated with RF glow-discharge (Harrick PDC-
3XG, Argon, 0.15 Torr, for 5 min) to enhance wettability. Subsequently, under a sterile
laminar flow, 20 µl aliquots of the cell suspensions were seeded onto the top of appropriate
meshes, resulting in a seeding density of 3.54 x 105 cells/cm2. After that, the 24-well plates
were exposed to a vacuum (5 x 104 N/m2 Vacuum) for 10 min. Subsequently, the meshes
were left in an incubator at 37°C for 20 min, at which time the meshes were turned and
the other side was loaded in a similar manner. The meshes were then placed in an in-
cubator for an additional 1.5 h to enable the cells to attach. In this way, both sides of the
mesh material were loaded, resulting in a total seeding density of 200,000 RBM cells per
mesh. Finally, 1 ml of serum free medium was added to each well. All non-loaded control
meshes were treated in a similar manner using serum free medium without cells. After
incubation all implants were transported in serum free medium to the animal facility. 
3.2.4 Experimental design and surgical procedure
For implantation, 30 four-week-old syngeneic Fisher 344 male rats (50-60 g) were used.
Surgery was performed under general inhalation anesthesia with a combination of
halothane, nitrous oxide and oxygen. The RBM-loaded and non-loaded control meshes
were subcutaneously implanted into the back of the animals. To insert the implants, the
animals were immobilized and placed in a ventral position. The back of the animals was
shaved, washed and disinfected with povidone-iodine. To insert the subcutaneous implants,
we made four small longitudinal incisions on both sides of the vertebral column. Lateral to
the incisions, a subcutaneous pocket was created using blunt dissection. After placement of
the implants, the skin was closed using staples (Agraven®).
Each animal received one subcutaneous implant of each type. To localize the implants
a latin square design was used to assure complete statistical randomization. A total of 120
implants were placed: 30 Ca-P-coated Ti-implants loaded with RBM cells (Ti-CaP-RBM);
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30 Ca-P-coated Ti-implants without RBM cells (Ti-CaP); 30 non-coated Ti-implants loaded
with RBM cells (Ti-RBM); 30 non-coated Ti-implants without RBM cells (Ti). The sam-
ples without cells served as controls. Implantation periods were 2, 4 and 8 weeks. At the
end of each implantation period, 10 rats were sacrificed (n=10 for each material and time
period). Further, six out of the ten rats in the 8-week group received sequential triple
fluorochrome labeling. The fluorochrome labels tetracline (yellow), alizarin-complexone
(red), and calceine (green) were administered at 2, 4 and 6 weeks post-operatively,
respectively. These labels were injected intramuscularly except for alizarin-complexone,
which was given subcutaneously. The treatment dose was 25 mg/kg body weight for each
label. In this study, national guidelines for the care and use of laboratory animals were
respected.
3.2.5 Histological preparation and evaluation
At the end of the experiment, euthanasia was performed using an overdose of ether
anesthesia. Following euthanasia, the implants with their surrounding tissue were retrieved
and prepared for histological evaluation. The specimens were then fixed in 4% phosphate-
buffered formaldehyde solution (pH=7.4), dehydrated in a graded series of ethanol and
embedded in methylmethacrylate. Following polymerization, at least three 10-µm-thick
sections were prepared per implant using a modified sawing microtome technique.21 Before
sections were made, the specimens were etched with hydrochloric ethanol for 15 s, stained
with methylene blue for 1 min and stained with basic fuchsin for 30 s. Finally, sections
were investigated with a light microscope. 
Besides thin sections, two additional 30-µm-thick sections were prepared from the 24
samples of the six animals that received fluorochromes, these sections were not stained.
They were evaluated with a fluorescence microscope equipped with an excitation filter of
470-490 nm.
The light and fluorescent microscopical assessment consisted of a complete morpho-
logical description of the tissue response to the different implants. In addition, quantitative
information was obtained on the amount of bone formation into the various mesh im-
plants, i.e.:(1) the number of specimens which showed bone formation; (2) largest
horizontal and vertical diameter of the observed bone formation.
3.3 Results
During the experiment, all rats remained in good health and did not show any wound
complications. At the end of the experiment, all implants could be retrieved. At retrieval,
the implants were surrounded by a thin reaction-free fibrous capsule. There was no in-
dication that the thickness of the capsule varied between the various implantation periods
and implantation types. No bone formation could be observed macroscopically.
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Table 1.
Scheme showing the number of implants in which bone formation could be observed at different explan-
tation periods (n=10 for each implant and time period). In addition, results are shown of the statistical
evaluation (two-tailed Fisher’s exact test), comparing Ti-CaP-RBM and Ti-RBM groups at various im-
plantation periods.
3.3.1 Light microscopical evaluation
Evaluation of the prepared sections revealed no big differences in overall tissue response
with respect to the various implantation periods and fiber mesh materials. All implants
were surrounded by a thin fibrous tissue capsule about four to six cell layers thick. The
capsule became more dense over time, but the thickness in cell layers remained the same.
The capsule was free of inflammatory cells and contained fibrocytes, collagen and blood
vessels. Inside the implants, the mesh porosity was filled with fibrous tissue and capillaries.
Some implants also showed fatty tissue ingrowth. Hardly any inflammatory cells could be
seen (Figure 2).
Further analysis revealed that for all implantation periods none of the Ca-P-coated and
non-coated control meshes supported bone formation (Table 1). On the other hand, the
RBM-loaded specimens showed osteogenic capacity: 5 Ti-CaP-RBM and 2 Ti-RBM samples
showed bone formation at 2 weeks post-implantation. At 4 weeks, this increased to 6 Ti-
CaP-RBM and 3 Ti-RBM specimens. Finally, at 8 weeks, in the Ti-RBM meshes bone
formation decreased to zero. On the other hand, in 6 Ti-CaP-RBM specimens bone was still
present at 8 weeks (Table 1).
Statistical analysis, using the Fisher’s exact test, revealed that there was significantly
more bone formation in the Ti-CaP-RBM group than in the Ti-RBM group only at 8 weeks
(two-tailed Fisher’s exact test, p = 0.01084) (Table 1).
Bone formation was generally characterized by the presence of randomly distrib-uted
single or multiple spheres in the pores of the Ti-mesh in close contact to the Ti-fibers
without an intervening fibrous tissue layer (Figure 3). No preference for the inner or outer
mesh area was observed. Quantitative measurements showed that the horizontal diameter
of these spheres varied from about 50 µm to 700 µm. Morphologically, the appearance of
these spheres was characterized by the presence of osteocyte-like cells embedded in a
mineralized matrix. The amount of bone was found to be small. In addition, the morpho-
logical examination revealed that in none of the sections either cartilage or bone marrow
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Implant:
Ti-CaP-RBM 5 (n=10) 6 (n=10) 6 (n=10)
Ti-Ca P 0 (n=10) 0 (n=10) 0 (n=10)
Ti-RBM 2 (n=10) 3 (n=10) 0 (n=10)
Ti
* Fisher’s exact test (two-tailed)
NS = non-significant
P-value*: 0.34985 (NS) 0.36985 (NS) 0.01084 (P<0.05)
0 (n=10) 0 (n=10) 0 (n=10)
2 weeks 4 weeks 8 weeks
Implantation period:
formation was observed. Finally, in only one Ti-CaP-RBM and one Ti-RBM implant was
bone formation more pronounced at 4 weeks. In these specimens, bone penetrated almost
through the total thickness and extended to about half of the diameter of the mesh material
(Figure 4A and Figure 4B).
3.3.2 Fluorescence microscopical evaluation
Fluorescence microscopical evaluation of the labeled 8-week sections confirmed that
mineralized tissue was present in four Ti-CaP-RBM samples. No fluorescence staining
could be observed in Ti-RBM or control implants. The accumulation of the fluorescent
labels demonstrated that the bone was indeed deposited in spherical foci. The multiple
labeling procedure also revealed that the bone formation started from the center of a pore
and proceeded in a centrifugal manner (Figure 5).
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Figure 2.
Undecalcified section of a
control mesh without bone
formation 2 weeks
after implantation.
The implant is surrounded by
a thin fibrous tissue capsule.
No inflammatory cells are
observable. Inside the implant,
the mesh porosity is filled with
fibrous tissue with capillaries
(orig. magn. 20x).
Figure 3.
Undecalcified section of a
calcium phosphate-coated
mesh loaded with RBM cells
(Ti-CaP-RBM) 8 weeks after
implantation. Bone formation
is characterized by the
presence of randomly
distributed multiple spheres
in the porosity of the Ti-mesh.
Osteocyte-like cells are
present, embedded in a
mineralized matrix
(orig. magn. 20x).
3.4 Discussion and conclusion
The results of this study show that the biocompatibility of titanium mesh is excellent as
demonstrated by the thin capsule thickness and absence of inflammatory cells in both
loaded and non-loaded meshes. These findings corroborate those of our earlier studies in
which the soft tissue reaction to a similar titanium mesh was investigated in rabbits22 and
goats.23 However, in contrast with the latter experiments, the present study did not indicate
any variation in the thickness of the capsule with respect to the length of the implantation
period (Figure 2). Apparently, this lack of variation is due to the rapid wound healing
response in this small animal model and once again emphasizes that the results of the
present study cannot be freely extrapolated to the human situation. 
The RBM-loaded meshes showed only a very limited amount of bone formation.
Consequently, histomorphometrical measurements to quantify the area occupied by bone
in relation to the total mesh volume, were not useful. In addition, the number of “positive”
implants as well as the amount of bone formation were significantly lower compared with
other studies.8-10,24 We assume that this difference in bone formation is due to our culture
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Figure 4.
(A) Undecalcified section
of a non-coated mesh loaded
with RBM cells (Ti-RBM)
4 weeks after implantation.
Bone formation penetrates
through half of the total
thickness of the mesh and
about half of the diameter
of the mesh
(orig. magn. 10x).
(B) Undecalcified section
of a Ca-P-coated mesh loaded
with RBM cells (Ti-CaP-RBM)
4 weeks after implantation.
In this section bone formation
also penetrates through half
of the total thickness of the
mesh and about half of the
diameter of the mesh
(orig. magn. 20x).
and loading technique. For example, culture techniques that have been used in previous
studies were based on the expansion of undifferentiated cells before their differentiation
was directed into the osteogenic lineage. Consequently, the addition of dexamethasone to
the culture medium has been shown to be a very relevant parameter in osteogenic expres-
sion and differentiation. However, dexamethasone does inhibit the proliferation of mesen-
chymal stem cells. In the current study, dexamethasone was already present in the primary
culture medium during expansion, in most other studies, mesenchymal stem cells are pre-
cultured in the absence of dexamethasone. Occasionally, in addition to dexametha-sone,
other proliferation and differentiation simulating growth factors, like bFGF and rhBMP-2,
have been supplemented to the medium during culture expansion of MSCs.25 Therefore,
the timing of our addition of dexamethasone can be questioned. Perhaps, a later moment is
more appropriate. Additional research will have to be conducted to answer this question.
The same is true for the addition of other factors used to influence the loading efficiency.
For example, the presence of Fetal Bovine Serum (FBS) or Fetal Calf Serum (FCS) in the
cell suspension during loading has been shown to increase the loading efficiency more than
2 times.26 We omitted the use of FCS to avoid an adverse immunological reaction. Fibronec-
tin has also been demonstrated to enhance the loading efficiency of bone cells in porous
scaffolds.27
In contrast with other studies, we also preferred not to continue culturing after
seeding the cells into the scaffolds. Nevertheless, prolonged culturing after loading has been
shown to be more effective with respect to final bone formation, especially when the
medium is supplemented with dexamethasone during this period. This method can be
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Figure 5.
Fluorescent light micrograph
of a calcium phosphate coated
mesh loaded with RBM cells
(Ti-CaP-RBM) 8 weeks after
implantation. In the center
of the bone sphere the
tetracycline label (T) can be
observed. Followed more
excentrically by the alizarin
complexone label (A) and
the calcein label (C).
The accumulation sequence
of the various labels
demonstrates that the newly
formed bone was deposited in
a centrifugal manner starting
from the center of a pore
(orig.magn. 20x).
considered as in situ cell expansion. Our choice is based on the fact that the current study is
part of a series of experiments, in which we intend to examine the final potential of our
scaffold material in a step-like manner.
The most frequently used loading techniques are the suspension and droplet methods.
In suspension methods, scaffolds are incubated in a cell suspension with a known number
of cells for a predetermined time.8-10 An advantage of this technique is that the entire
surface of the mesh is surrounded by a highly concentrated cell suspension, thereby allow-
ing for attachment. After that, these scaffolds can either be submitted to further culturing
or immediately implanted. Before implantation, the total number of cells attached to such a
construct has been reported to be increased up to 15 million cells per milliliter carrier
volume.9 In the droplet methods, droplets of cell suspension with equal volumes and
known numbers of cells are placed on top of the scaffold. After a certain incubation period
a sufficient amount of medium is added and the scaffolds can either be incubated for
prolonged culturing or implanted directly. One advantage of the droplet method is that the
number of loaded cells can be standardized. Also, the total number of cells required for
loading is less. In the present study, we applied about 9 million cells per milliliter carrier.
The final number of cells per surface area, was 3.54 x 105/cm2. In contrast, Mikos et al.28
used a similar loading technique, with a seeding density of 6.83 x 105/cm2. In this study,
significantly more bone formation occurred. Therefore, we cannot exclude that the number
of cells we applied per mesh was below a certain required critical threshold.
Loading techniques often include the use of a mild vacuum for a short period of time
in order to remove air from the porous scaffolds to enhance the contact between the
scaffold material and cell suspension. To our knowledge no detrimental effect of the use of
mild vacuum on bone formation has been published to date. For example, the loading
technique used by Bruder et al. involves the application of a vacuum9 in 3 bursts of 5
seconds each.8,10 Still adequate bone formation was found. In our study we exposed the
specimens only to a mild vacuum of 5 x 104 N/m2 (500 mbar) for a very short time period. 
The fluorescent labeling study revealed that the newly formed bone was deposited in a
centrifugal manner. This finding agrees with another study in which a comparable tita-
nium scaffold material was used.24 However, bone formation and consequent fluoro-
chrome labeling only occurred in the Ca-P-coated mesh implants. For so-called bioactive im-
plant materials or implants provided with a bioactive surface coating, bonding osteogenesis
has been described.24,29 We know that the thin RF magnetron sputter coating did not
penetrate completely throughout the mesh, despite the fact that we coated the mesh on
both sides. As a result, the inside of the mesh still consists of the original titanium surface.
This explains the absence of bonding osteogenesis.
On the other hand, the applied coating was evidently able to further enhance bone
formation, as in the non-coated specimens less bone was formed and bone formation was
even completely absent at 8 weeks. A similar effect on osteogenesis has been described for
thick plasma-sprayed hydroxyapatite (HA) coatings.18 This effect is supposed to be due to
the high affinity of calcium phosphate ceramics to bone-growth-stimulating proteins, like
Bone Morphogenetic Proteins (BMPs). In addition to plasma-sprayed HA coatings, a
similar increased adsorption and efficacy of BMP has also been shown recently for thin
Ca-P coatings.30
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On the basis of our observations we conclude that the combination of Ti-mesh with
RBM cells can indeed generate bone formation. Nevertheless, the occurrence as well as the
amount of new bone is very limited, using the procedures described in this study. Further,
we confirm our earlier observations that a thin Ca-P coating can have an additional positive
effect on the bone-generating properties of a scaffold material.
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Chapter 4
Bone formation in Ca-P-coated and
non-coated titanium fiber mesh
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4.1 Introduction
Mesenchymal stem cells (MSCs) can be used for the functional repair or regeneration of
large bone defects. In this approach a three-dimensional (3-D) scaffold material is used to
deliver the cells to the bone defect site. The final success of this tissue-engineered strategy is
determined by the number of responsive MSCs loaded in the scaffold as well as by the
material characteristics of the delivery vehicle. 
MSCs, or osteoprogenitor cells, which are precursors of osteogenic cells, are present in
bone marrow, where they represent only a small fraction of the total number of bone
marrow cells.1 The number of progenitor cells has even been shown to decrease with
ageing.2-6 In view of this, methods have been developed to culture-expand and select the
osteoprogenitor cell fraction from bone marrow.7-9 In addition, it has been shown that
cultured bone marrow-derived MSCs are more effective in bone formation than fresh
marrow.7,10-12
It is important to note that besides proliferation also the differentiation of osteopro-
genitor cells can be directed during culture. In view of this, several factors, like dexametha-
sone and Bone Morphogenetic Proteins (BMPs), are known to direct the differentiation of
these cells into the osteoblast lineage in vitro.13-15 The addition of proliferation (basic Fibro-
blast Growth Factor, bFGF) and differentiation [recombinant human (rh)BMP-2] stimulat-
ing agents during culture has been shown to enhance the in vivo osteogenic potential.16,17
The osteogenic potential of cell-loaded scaffolds can further be increased by modifying the
conditions during seeding (by optimizing the number of loaded cells),17-20 and culturing for
example, static versus dynamic culturing.21-23
Tissue engineering of bone requires the use of a suitable carrier or scaffold material.
The currently applied 3-D scaffold materials include ceramics, polymers and collagen. The
disadvantage of most of these scaffold materials is that they are not very strong and can
easily transform.24 Consequently, we have suggested previously the use of porous sintered
titanium (Ti) fiber mesh as a scaffold for MSCs.25 This titanium mesh has excellent mecha-
nical properties26 and has been proven to be bone-compatible and is easy to handle during
surgery. Although titanium is not degradable, this is no drawback for a large number of re-
constructive procedures. An additional advantage is that the titanium fiber mesh can be
provided with a very thin calcium phosphate (Ca-P) coating which has been described to
have a positive effect on bone formation.25,27 Conversely, we found the occurrence as well
as the amount of bone formation to be very limited when osteogenic cells were seeded in
Ti-fiber mesh scaffolds.25 We assumed this latter result to be related to the culture and cell-
loading technique, which involved the use of a droplet-loading technique without prolonged
culturing in vitro. In view of this it should be noted that prolonged culturing after loading
has been shown to be more effective with respect to final bone formation,28 especially
when the medium is supplemented with dexamethasone during this period.29,30
The objective of the present study was to investigate the effect of a suspension-loading
method versus a droplet-loading method in combination with prolonged in situ culturing on
bone formation in titanium fiber (Ti) mesh scaffolds in a rat ectopic assay model.
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4.2 Materials and methods
4.2.1 Scaffold materials
Sintered porous Ti-fiber mesh (Bekaert N.V., Zwevegem, Belgium) with a volumetric
porosity of 86%, a density of 600 g/m2 and a fiber diameter of 50 µm was used as scaffold
material. The average pore size of the mesh was about 250 µm. Ti-fiber mesh discs were
punched out of a Ti-fiber mesh sheet. As a result of the fabrication process, the meshes had
an easily discernable top and bottom. The prepared implants were disc-shaped with a
diameter of 6 mm, a thickness of 0.8 mm, and a weight of about 15 mg. 
All implants were ultrasonically cleaned with 70% ethanol for 15 min. The mesh was
applied as-received (Ti) or provided with a thin (2 µm) Ca-P coating (Ti-CaP) on both
sides. The coating procedure was performed using a commercially available RF magnetron
sputter unit (Edwards ESM 100).31 The target material used in the deposition process was
a copper disc provided with a plasma-sprayed hydroxylapatite coating (CAMCERAM®).
The process pressure was 5 x 10-3 mbar, and the sputter power was 400 W. The deposition
rate of the films was 100–150 nm/min sputtering. 
After deposition, all coated specimens were subjected to an additional heat treatment
for 2 h at 500°C. X-ray diffraction (XRD), Fourier Transform Infrared spectroscopy
(FTIR) and Energy Dispersive Spectroscopical (EDS) analysis showed that this resulted in
coatings having a crystalline apatite structure with a Ca/P ratio of 1.8–2.0.25 Before use, the
implants were sterilized by autoclaving for 15 min at 121°C. A total of 156 discs were pre-
pared: 78 Ti and 78 Ti-CaP.
4.2.2 Cell culture technique
The rat bone marrow (RBM) cell culture technique was used as described by Maniato-
poulos.32 RBM-cells were obtained from femora of 16 six-week-old syngeneic Fisher 344
male rats (110–130 g). Epiphyses were cut off, and both diaphyses were flushed out using
complete medium consisting of α-Minimal Essential Medium (α-MEM, Gibco BRL, Life
Technologies B.V., Breda, the Netherlands) supplemented with 10% fetal calf serum (FCS,
heat induced at 56°C for 35 min., Gibco), 50 mg/ml freshly prepared ascorbic acid (Sigma,
Chemical Co., St. Louis, Mo., USA), 10 mM Na-β-glycerophosphate (Sigma), 10-8 M dex-
amethasone (Sigma), and gentamycin. A 15-ml aliquot of this medium was used per two
femurs. The cells were then suspended and cultured in complete medium in three 80-cm2
tissue culture flasks (Nunc. Products, Gibco) in a humidified atmosphere of 95% air, 5%
CO2 at 37°C. After 8 days of primary culture, the cells were detached using trypsin/EDTA
[0.25% (w/v) trypsin/0.02% ethylene diamine tetra-acetic acid].
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4.2.3 Scaffold preparation
After detachment, the cells were concentrated by centrifugation at 1,500 rpm for 5 min,
resuspended in a known amount of medium and counted using a Coulter® counter. The
cell suspension was diluted to 5 x 106 cells/ml in complete medium. Thereafter, the cells
were seeded onto the carrier materials.
Cells were seeded on top of the scaffold materials using either a droplet (D) or a sus-
pension (S) loading method. For the droplet method, appropriate meshes were placed, top-
side up, in a 24-well plate and loaded by placing 40-µl-aliquots of the cell suspension
(200,000 cells/mesh) on top of the meshes. The meshes were exposed to a mild vacuum (5
x 104 N/m2) for 10 min and then placed in an incubator (95% air, 5% CO2, at 37°C) for 2
h. With the suspension method, appropriate meshes were loaded by placing them in the cell
suspension (5 x 106 cells/ml) in an Eppendorf® tube (6 meshes/0.8 ml cell suspension). Af-
ter a brief exposure to a mild vacuum applied with a 50-ml syringe, the tubes with the cell
suspension and meshes were placed in an incubator for 2 h (95% air, 5% CO2 at 37°C).
The tubes were shaken manually every 30 min. After 2 h the meshes were removed from
the tubes with the suspension and also placed in 24-well plates.
Following the incubation period, all specimens were placed in 24-well plates and 1 ml
of complete medium was added to each well. The medium was changed every 2–3 days. All
constructs were cultured for 8 days in a humidified atmosphere of 95% air, 5% CO2 at
37°C prior to implantation. After that, the medium was replaced by serum-free medium,
and all of the scaffolds were transported to the animal facility.
4.2.4 Experimental design and surgical procedure
For implantation, thirty-nine 4-week-old syngeneic Fisher 344 male rats (50–60 g) were
used. Surgery was performed under general inhalation anesthesia with a combination of
halothane, nitrous oxide and oxygen. The RBM-loaded meshes were subcutaneously
implanted into the back of the animals. To insert the implants, we immobilized the animals
in a ventral position. The back of the animals was shaved, washed, and disinfected with
povidone-iodine. To insert the subcutaneous implants, we made four small longitudinal in-
cisions on both sides of the vertebral column. Lateral to the incisions, a subcutaneous pocket
was created using blunt dissection. Implants were inserted with their top side towards the
skin. After placement of the implants, the skin was closed using staples (Agraven®).
Each animal received one subcutaneous implant of each type. A statistical random-
ization scheme was used to localize the implants. A total of 156 implants were placed: (1)
39 droplet-loaded Ca-P-coated Ti implants, (Ti-CaP-RBM-D); (2) 39 suspension-loaded Ca-
P-coated Ti implants (Ti-CaP-RBM-S); (3) 39 droplet-loaded non-coated Ti implants, (Ti-
RBM-D); and (4) 39 suspension-loaded non-coated Ti implants, (Ti-RBM-S). Implantation
periods were 2, 4, and 8 weeks. At the end of each implantation period, 13 rats were eu-
thanized.
Four rats in the 8-week group received sequential triple fluorochrome labeling. The
fluorochrome labels tetracycline (yellow), alizarin-complexone (red), and calceine (green)
were administered at 2, 4, and 6 weeks post-operatively, respectively. These labels were
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injected intramuscularly except for alizarin-complexone, which was given subcutaneously.
The treatment dose was 25 mg/kg body weight for each label.
In this study, national guidelines for the care and use of laboratory animals were
respected.
4.2.5 Implant retrieval and evaluation
At the end of the experiment, euthanasia was performed using carbon dioxide. Following
euthanasia, the implants with their surrounding tissue were retrieved and prepared for
histological (n=7 for each material and time period) and calcium content analysis (n=6
for each material and time period).
4.2.6 Histology
The histological samples were fixed in 4% phosphate-buffered formaldehyde solution
(pH=7.4), dehydrated in a graded series of ethanol and embedded in methylmethacrylate.
Following polymerization 10-µm-thick sections were prepared per implant using a modified
sawing microtome technique.33 Before sections were made, the specimens were etched with
hydrochloric ethanol for 15 s, stained with methylene blue for 1 min and stained with basic
fuchsin for 30 s. The prepared sections were examined under a light microscope (Leica®).
In addition to the thin sections described above, two additional 30-µm-thick sections
were prepared from the samples of the four animals that received fluorochromes. These
sections were not stained but evaluated with a fluorescence microscope equipped with an
excitation filter of 470–490 nm. 
The light and fluorescent microscopical assessment consisted of a complete morpho-
logical description of the tissue response to the different implants. In addition, quantitative
information was obtained on the amount of bone formation into the various mesh implants
i.e., the number of specimens which showed bone formation.
4.2.7 Calcium content measurement
The specimens for the calcium content analysis were lyophilized and kept at –80°C until
the time of measurement. After thawing, 1 ml of acetic acid was added to each sample and
stored overnight under constant shaking. The calcium content was determined using the
orthocresolphthalein (OCPC) method34 with an ELISA reader set at a wavelength of 575
nm.
77
Bone formation in Ca-P-coated and non-coated titanium fiber mesh
Fisher’s exact test (two-tailed)
(* = P<0.005, • = P<0.05, º = P<0.05)
4.2.8 Statistical evaluation
A Fisher’s exact test was used to analyze the results of the histological analysis. A Kruskal-
Wallis non-parametric test was applied to evaluate the results of the calcium content
measurement. Differences between droplet-loaded and suspension-loaded specimens were
tested within Ca-P-coated (Ti-CaP-RBM-D vs. Ti-CaP-RBM-S) and within non-coated (Ti-
RBM-D vs. Ti-RBM-S) specimens at each time period. Differences between Ca-P-coated
and non-coated specimens were tested within droplet-loaded (Ti-CaP-RBM-D vs. Ti-RBM-
D) and suspension-loaded (Ti-CaP-RBM-S vs. Ti-RBM-S) specimens at each time period.
4.3 Results
During the experiment, all of the rats remained in good health and did not show any
wound complications. At the end of the experiment, all of the implants could be retrieved.
At retrieval, the implants were surrounded by a thin reaction-free fibrous capsule. No bone
formation could be observed macroscopically.
4.3.1 Light microscopical evaluation
Evaluation of the prepared sections revealed no major differences in overall tissue response
with respect to the various implantation periods and fiber mesh materials. All of the im-
plants were surrounded by a thin fibrous tissue capsule. Hardly any inflammatory cells
could be seen in Ca-P-coated specimens, while some multinucleated cells were present in
the non-coated specimens.
Further analysis revealed that in five of the Ti-CaP-RBM-D implants bone-like tissue
was present at 2 weeks; this number had increased to six implants at 4 weeks. By 8 weeks
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Implant:
Table 1.
The number of specimens which showing bone formation (n=7 for each implant and time period) and
the results of the two-tailed Fisher’s exact test.
Ti-CaP-RBM-D 5 (n=7) • 6 (n=7) * 4 (n=7)
Ti-CaP-RBM-S 0 (n=7) • 2 (n=7) 2 (n=7)
Ti-RBM-D 0 (n=7) º 0 (n=7) * 0 (n=7)
Ti-RBM-S 0 (n=7) 0 (n=7) 0 (n=7)
2 weeks 4 weeks 8 weeks
Implantation period:
º
there were four implants showing bone-like tissue. In the Ti-CaP-RBM-S implants bone for-
mation was absent in all of the implants at 2 weeks and was present in only two implants
at 4 and 8 weeks (Table 1).
Bone formation in these Ca-P-coated implants was characterized by the presence of
osteocyte-like cells embedded in a bone-like tissue matrix (Figure 1E). Bone was present
inside the scaffold, although a preference for the upper mesh area was observed. The newly
formed bone was always in close contact with the Ti-fibers without an intervening fibrous
tissue layer. The suspension-loaded Ca-P-coated implants appeared to support less bone
formation than the droplet-loaded Ca-P-coated implants. In none of the sections was
cartilagenous tissue observed.
In droplet-loaded specimens the appearance of the bone-like tissue varied from single
or multiple spheres (Figure 1A, B) to filling a significant part of the mesh porosity (Figure
1C, D). The latter was demonstrated by four of the five positive implants at 2 weeks, by
two of the six at 4 weeks, and by two of the four at 8 weeks. When bone filled a significant
part of the porosity bone marrow-like tissue was observed inside the newly formed bone.
For droplet-loaded implants, the amount of bone per implant seemed to be highest at 2
weeks; it had decreased by 4 weeks and had remained at that level at 8 weeks.
In suspension-loaded specimens only single or multiple spheres were observed in the
mesh material (Figure 1A, B), and in only half of the positive implants was bone present in
all three prepared sections of each specimen. In suspension-loaded implants the amount of
bone formation seemed to be the same at 4 and 8 weeks. 
In none of the Ti-RBM-D and Ti-RBM-S implants was bone-like tissue observed.
However, all of these non-coated implants showed irregular deposits of a basic fuchsin-stained
layer in close association with the titanium fibers (Figure 1F, G, H). Again these deposits
showed a preference for the upper mesh area. The deposited layer lacked a typical bone-like
organization: no osteocyte-like cells embedded in a mineralized tissue matrix were seen
(Figure 1H). On the other hand, multi-nucleated cells were observed in close association with
the deposits at all evaluation periods.
Table 1 provides quantitative information on the number of specimens showing bone
formation. The presence of bone formation was defined as a positive implant. Our statis-
tical analysis, using the Fisher’s exact test (two-tailed), revealed a significant difference
between Ti-CaP-RBM and Ti-RBM implants for Ti-CaP-RBM-D versus Ti-RBM-D at 2
(P<0.05) and 4 (P<0.005) weeks. In addition, at 2 weeks a significant difference was
present between Ti-CaP-RBM-D and Ti-CaP-RBM-S implants (P<0.05) (Table 1).
4.3.2 Fluorescence microscopical evaluation
Fluorescence microscopical evaluation of labeled 8-week sections revealed that in only one
of the evaluated Ti-CaP-RBM-D and in one of the Ti-CaP-RBM-S bone was present. The
newly formed bone was deposited initially at the surface and then grew into the porosity
(Figure 2A, B). In none of the Ti-RBM implants was organized bone formation with clear
ossification fronts observed. In all of the specimens, diffusely stained deposits of tetra-
cycline (and sometimes calcein) were mainly localized in contact with the Ti-fibers (Figure
2C, D).
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Figure 1.
Undecalcified sections of:
(A,B) A calcium phosphate-coated mesh loaded with RBM cells using a suspension method (Ti-CaP-RBM-S) 8 weeks after
implantation. The appearance of spherical-shaped locations of newly formed bone in the porosity of the Ti-mesh was
seen for both suspension- and droplet-loaded CaP-coated specimens. Bone was present inside the fiber mesh, althoug
a preference for the upper mesh area was observed. Osteocyte-like cells are present, embedded in a mineralized matrix
[(A) orig. magn. 10x, (B) orig. magn. 1.6x]. 
(C,D) A calcium phosphate-coated mesh loaded with RBM cells using a droplet method (Ti-CaP-RBM-D) 4 weeks after
implantation. In some of the droplet-loaded CaP-coated specimens bone filled a significant part of the mesh porosity.
In these specimens bone marrow-like tissue can be observed [(C) orig. magn. 10x, (D) orig. magn. 1.4x]. 
(E) A calcium phosphate-coated mesh loaded with RBM cells using a droplet method (Ti-CaP-RBM-D) 4 weeks after
implantation. Bone formation is present in close contact with the titanium fibers (Ti). In both droplet-and suspension-
loaded CaP-coated specimens the morphological appearance of the formed bone was characterized by the presence
of osteocyte-like cells embedded in a mineralized matrix (orig. magn. 20x). 
(F,G) A non-coated mesh loaded with RBM cells using a droplet method (Ti-RBM-D) 4 weeks after implantation.
In all droplet-and suspension-loaded non-coated implants irregular deposits were seen throughout the mesh in close
association with the titanium fibers. These deposits showed a preference for the upper mesh area
[(F) orig. magn. 10x, (G) orig. magn. 1.4x].
4.3.3 Calcium content measurement
The box-whisker plot of Figure 3 shows the results of the calcium content measurement.
Calcification was present in all experimental groups as early as 2 weeks. Nevertheless, a
wide variation in the total amount of calcium existed between the various specimens and
implantation periods.
Statistical evaluation of the data using a Kruskal-Wallis non-parametric test revealed a
significantly lower calcium content in the Ti-CaP-RBM specimens than in Ti-RBM
specimens at 2 and 4 weeks for both Ti-CaP-RBM-D versus Ti-RBM-D (2 weeks: P< 0.01,
4 weeks: P<0.005) and Ti-CaP-RBM-S versus Ti-RBM-S (P< 0.005) specimens, and at 8
weeks for Ti-CaP-RBM-D versus Ti-RBM-D only (P<0.01) (Figure 3). In addition, at 2
weeks the Ti-CaP-RBM-D specimens showed a significantly higher calcium content than
the Ti-CaP-RBM-S specimens (P<0.05). For non-coated specimens no difference was
found with respect to loading method.
4.4 Discussion and conclusion 
In a previous rat ectopic assay25 we evaluated the bone generating properties of Ca-P-coated
and non-coated Ti-mesh implants loaded with RBM cells using a droplet-loading technique
without prolonged culturing in vitro. Bone-like tissue formed in both the Ca-P-coated and
non-coated specimens, but disappeared in the non-coated specimens by 8 weeks. In the
present study we observed bone-like tissue formation only for Ca-P-coated specimens. No
histomorphometrical analysis was performed, instead calcium content was quantified. For
non-coated specimens we found only irregular calcified deposits that showed none of the
morphological characteristics of bone. The mineralized nature of these deposits was
confirmed by the calcium content measurements. 
We hypothesize that the beneficial effect of a Ca-P coating is due to a positive effect on
cell differentiation.35-37 Consequently, marrow-derived MSCs are directed into the osteo-
blast lineage. This corroborates with previous in vitro studies of our group in which the
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Figure 1. continued
Undecalcified section of: 
(H) A non-coated mesh loaded with RBM cells using a
droplet method (Ti-RBM-D) 4 weeks after implantation.
In both droplet-and suspension-loaded non-coated
specimens the morphological appearance is characterized
by irregular basic fuchsin-stained deposits in close
association with the titanium fibers. The deposited layer
lacked a typical bone-like organization: No osteocyte-like
cells embedded in a mineralized tissue matrix were seen
(orig. magn. 20x). 
Figure 2. 
Fluorescent light micrograph of:
(A) A calcium phosphate-coated mesh loaded with RBM cells using a droplet method (Ti-CaP-RBM-D) 8 weeks after
implantation. Clear ossification fronts can be observed in the newly formed bone. The newly formed bone shows a
preference for the upper mesh area (orig. magn. 5x). 
(B) A calcium phosphate-coated mesh loaded with RBM cells using a droplet method (Ti-CaP-RBM-D) 8 weeks after
implantation. In the center of the spherical-shaped bone, the tetracycline label (T) can be observed, followed more
excentrically by the alizarin complexone label (A) and the calcein label (C). The accumulation sequence of the various
labels demonstrates that the newly formed bone was deposited on the fibers proceeding away from the surface 
(orig. magn. 20x). 
(C) A non-coated mesh loaded with RBM cells using a droplet method (Ti-RBM-D) 8 weeks after implantation.
Fluorochrome stained deposits can be seen throughout the mesh. Suspension-and droplet-loaded implants showed the
same image (orig. magn. 5x).
(D) A non-coated mesh loaded with RBM cells using a droplet method (Ti-RBM-D) 8 weeks after implantation.
No organized bone formation with clear ossification fronts was observed. Diffusely stained deposits of tetracycline (T)
[and sometimes calcein (C)] are mainly localized in close contact with the titanium fibers (orig. magn. 10x). 
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application of a Ca-P coating on solid titanium discs has been shown to delay the prolifera-
tion of rat bone marrow cells by 8 days, while differentiation was stimulated by 16 days.36,
38 This positive effect of a calcium phosphate coating can be mediated by an increased level
of Ca2+-ions that results from the superficial dissolution of the coating. Osteoblast-like cells
have been shown to possess calcium receptors on their surface.39 It is also known that
Ca2+-ions can stimulate cells within the osteogenic lineage to express BMP-2 and BMP-4
mRNA, to produce collagen type I and to proliferate.40,41 An additional effect of a calcium
phosphate coating can be achieved due to the high affinity of calcium phosphate ceramics
to bone-growth-stimulating proteins, such as BMPs.42,43 This last suggestion has recently
been confirmed for thin Ca-P coatings.27
We observed that for all of the implantation periods only a calcified deposit was
present in the 8-day cultured non-coated meshes. Earlier scanning electron- and light-
microscopical observations of non-coated 3D-Ti-scaffolds revealed that after 8 days of
culturing a dense confluent layer of cells with some mineralized matrix is present in the
upper part of the mesh.20 In order to form bone upon implantation, an adequate cell-cell,
cell-matrix, and cell-vascular relationship has to be present.44,45 We suppose that this dense
layer prevents the creation of an adequate cell-vascular relationship. Consequently, the cells
might not be able to survive.
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Figure 3. 
Figure showing a Box-Whisker plot of the results of the calcium content measurements (n=6 for each implant and time
period). The line within the boxes indicates the median. The boxes indicate the 25th to 75th percentile of the data. The
error bars indicate the 5th and 95th percentile. Significant differences of the Kruskal-Wallis non-parametric test are also
shown.
Nevertheless, calcium measurements revealed an increase in calcium content in these
non-coated specimens after implantation (Figure 3). This calcification occurred without
any morphological evidence of bone formation. This phenomenon has also been described
for non-cell loaded solid titanium discs provided with an amorphous calcium-phosphate
coating. In that study, a CO3-AP precipitate was formed on the discs after implantation in
rabbits.46 The formation of such a biological apatite on implant surfaces is probably in-
fluenced by dissolution/precipitation-mediated events.47,48 The partial dissolution of the
calcium phosphate surface causes an increase in the levels of local calcium and phosphate
ions, thereby increasing the degree of saturation in the micro-environment. This will
facilitate the precipitation of a stable calcium phosphate phase which incorporates other
ions (carbonate, magnesium etc. ) and organic macromolecules from the biological fluids.49,
50 In a similar way, the dissolution of the initial in vitro calcification within our Ti-RBM
specimens might have initiated a dissolution/precipitation process that resulted in in-
creased mineral deposition. This was confirmed by the fluorescent labeling results. For the
non-coated specimens no clear ossification fronts were observed.
The bone formation in our study showed a high inter-implant variability, as illustrated
by both the histological and calcium content analyses. The histological analysis demon-
strated that not all implants formed bone and that the amount of bone formed varied
between implants. Calcium content in the Ti-CaP-RBM meshes was also variable. Some
implants revealed high amounts of calcium (up to 1,000 µg per implant), while others
showed values not higher than the measured calcium content for the Ca-P coating alone. In
the Ca-P-coated meshes a small amount of calcium was present in the Ca-P coating [132
(+/- 11) µg, not shown in Figure 1]. We did not subtract the calcium content from the in
vivo calcium content data since the coating might dissolve in vivo.
In light of the above, attention must be given to the fact that apparently optimal
culture techniques are scaffold-dependent. Further, our findings emphasize that the use of
single bone marker parameters, like calcium content, does not provide sufficient infor-
mation on the amount and quality of tissue-engineered bone. This underscores the impor-
tant role of morphological analysis and the assessment of in vivo osteogenic activity.
In the histological sections, cartilagenous tissue never was observed. Intramembra-
nous bone formation, without the presence of cartilage, has also been reported for ceramic
scaffolds loaded with fresh and cultured bone marrow stromal cells.29,51,52 Still, in order to
fully characterize the bone formation process, shorter implantation periods have to be
investigated.
The biochemical and histological analysis of our specimens revealed that the use of
two different cell-seeding methods did not affect the final amount of bone formation.
Although histological and calcium content measurements showed that at 2 weeks a
significant effect was seen with the droplet method, this effect had disappeared by 4 and 8
weeks. With the droplet method, scaffolds are incubated with a cell suspension droplet
placed on their upper surface. With the suspension method, scaffolds are in contact with
the cell suspension on all sides during incubation. Thereby increasing the potential surface
area for attachment. Since our implants are very thin (only 800 µm), this possible advan-
tage of the suspension method may disappear. The initial positive effect of the droplet
method can be explained since in our experimental setup with the droplet method the
number of loaded cells can be better standardized.
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The findings of the fluorescent labeling study showed that in Ca-P-coated meshes bone
had been deposited on the titanium fibers, growing away from the surface of the scaffold.
This is in concordance with bioactive implant materials or implants provided with a
bioactive surface coating, where bonding osteogenesis has been described.29,51,53-56 In a
previous study, we did not observe bonding osteogenesis, but bone formation started in the
porosity of the mesh and proceeded towards the titanium surface.25 We know that the
deposited thin RF magnetron sputter coating is present on the outer titanium fibers but
does not reach the surface of the inner titanium fibers, despite the fact that we coat the
mesh on both sides. As a result, the inside of the mesh still consists of the original titanium
surface. In the present study, we found that bone formation showed a preference for the
upper mesh area, with the occurence of bonding osteogenesis. In the previous study, bone
was present inside the mesh without a preference for the upper mesh area, which could
explain the absence of bonding osteogenesis. 
We conclude that the combination of Ti-mesh with RBM cells can indeed generate
ectopic bone formation after prolonged in situ culturing. Prolonged culuring in vitro has
different effects for Ti and Ti-CaP implants. In Ti-CaP implants bone-like tissue was
present, while in Ti-implants only abundant mineralization was present without a bone-
like tissue organization. No effect of the loading method, droplet versus suspension, was
observed on the final amount of bone. Finally, our results confirm that a thin Ca-P coating
can have an additional effect on the bone generating properties of a scaffold material. 
85
Bone formation in Ca-P-coated and non-coated titanium fiber mesh
References
1. Haynesworth SE, Reuben D, Caplan AI. Cell-based tissue engineering therapies: the influence of whole body
physiology. Adv Drug Delivery Rev 1998; 33:3. 
2. Bergman RJ, Gazit D, Kahn AJ, Gruber H, McDougall S, Hahn TJ. Age-related changes in osteogenic stem cells in
mice. J Bone Miner Res 1996; 11:568. 
3. Egrise D, Martin D, Vienne A, Neve P, Schoutens A. The number of fibroblastic colonies formed from bone
marrow is decreased and the in vitro proliferation rate of trabecular bone cells increased in aged rats. 
Bone 1992; 13:355. 
4. Kahn A, Gibbons R, Perkins S, Gazit D. Age-related bone loss. A hypothesis and initial assessment in mice. 
Clin Orthop 1995; 313:69. 
5. Liang CT, Barnes J, Seedor JG, Quartuccio HA, Bolander M, Jeffrey JJ, Rodan GA. Impaired bone activity in aged
rats: alterations at the cellular and molecular levels. Bone 1992; 13:435. 
6. Quarto R, Thomas D, Liang CT. Bone progenitor cell deficits and the age-associated decline in bone repair
capacity. Calcif Tissue Int 1995; 56:123. 
7. Kadiyala S, Neelam J, Bruder SP. Culture-expanded, bone marrow-derived mesenchymal stem cells can regenerate
a critical-sized segmental bone defect. Tissue Eng 1997; 3:173. 
8. Kadiyala S, Young RG, Thiede MA, Bruder SP. Culture expanded canine mesenchymal stem cells possess
osteochondrogenic potential in vivo and in vitro. Cell Transplant 1997; 6:125. 
9. Bruder SP, Kraus KH, Goldberg VM, Kadiyala S. The effect of implants loaded with autologous mesenchymal stem
cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 1998; 80:985. 
10. Goshima J, Goldberg, VM, Caplan AI. Osteogenic potential of culture-expanded rat marrow cells as assayed in vivo
with porous calcium phosphate ceramic. Biomaterials 1991; 12:253. 
11. Gundle R, Joyner CJ, Triffitt JT. Human bone tissue formation in diffusion chamber culture in vivo by bone-derived
cells and marrow stromal fibroblastic cells. Bone 1995; 16:597. 
12. Krzymanski G, Wiktor-Jedrzejczak W. Autologous bone marrow-derived stromal fibroblastoid cells grown in vitro
for the treatment of defects of mandibular bones. Transplant Proc 1996; 28:3528. 
13. Leboy PS, Beresford JN, Devlin C, Owen ME. Dexamethasone induction of osteoblast mRNAs in rat marrow
stromal cell cultures. J Cell Physiol 1991; 146:370. 
14. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I. Induction of rapid osteoblast differentiation in rat bone
marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol 1994; 161:218. 
15. Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, Wang EA, Tanaka H, Omura S, Suda T. The non-
osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by
recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 1990; 172:295. 
16. Hanada K, Dennis JE, Caplan AI. Stimulatory effects of basic fibroblast growth factor and bone morphogenetic
protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. 
J Bone Miner Res 1997; 12:1606. 
17. Mendes SC, Van den Brink I, de Bruijn JD, van Blitterswijk CA. In vivo bone formation by human bone marrow
cells: Effect of osteogenic culture supplements and cell densities. J Mater Sci Mater in Med 1998; 9:855. 
18. Holy CE, Shoichet MS, Davies JE. Engineering three-dimensional bone tissue in vitro using biodegradable
scaffolds: investigating initial cell-seeding density and culture period. J Biomed Mater Res 2000; 51:376. 
19. Dennis JE, Caplan AI. Porous ceramic vehicles for rat-marrow-derived (Rattus norvegicus) osteogenic cell delivery:
effects of pre-treatment with fibronectin or laminin. J Oral Implantol. 1993; 19:106. 
20. Vehof JWM, de Ruijter JE, Spauwen PHM, Jansen JA. Influence of rhBMP-2 on rat bone marrow stromal cells
cultured on titanium fiber mesh. Tissue Eng 2001; 7:373. 
21. Baksh D, Davies, JE. Three dimensional fluid flow enhances bone matrix elaboration in vitro. In: Transactions of
the Sixth World Biomaterials Congress, Kamuela, Hawaii, USA, May 15-20, 2000, 438. 
22. Granet C, Laroche N, Vico L, Alexandre C, Lafage-Proust MH. Rotating-wall vessels, promising bioreactors for
osteoblastic cell culture: comparison with other 3D conditions. Med Biol Eng Comput 1998; 36:513. 
23. Botchwey, EA, Pollack, SR, Levine, EM, Laurentin, CT. Bone tissue engineering in a rotating bioreactor using a
microcarrier matrix system. J Biomed Mater Res 2001; 55:242. 
24. Zhang R, Ma PX. Poly(α-hydroxyl acids)/hydroxyapatite porous composites for bone-tissue engineering. 
I. Preparation and morphology. J Biomed Mater Res 1999; 44:446. 
25. Vehof, JWM, Spauwen, PHM, Jansen, JA. Bone formation in calcium-phosphate-coated titanium mesh. 
Biomaterials 2000; 21:2003. 
86
Bone formation in Ca-P-coated and non-coated titanium fiber mesh
26. Jansen JA, von Recum AF, van der Waerden JP, de Groot K. Soft tissue response to different types of sintered
metal fibre-web materials. Biomaterials 1992; 13:959. 
27. Vehof JWM, Mahmood J, Takita H, van ‘t Hof MA, Kuboki Y, Spauwen PHM, Jansen JA. Ectopic bone formation
in titanium mesh loaded with Bone Morphogenetic Protein and coated with calcium phosphate. 
Plast Reconstr Surg 2001; 108:434. 
28. Mizuno M, Shindo M, Kobayashi D, Tsuruga E, Amemiya A, Kuboki Y. Osteogenesis by bone marrow stromal cells
maintained on type I collagen matrix gels in vivo. Bone 1997; 20:101. 
29. Yoshikawa T, Ohgushi H., Tamai S. Immediate bone forming capability of prefabricated osteogenic
hydroxyapatite. J Biomed Mater Res 1996; 32:481. 
30. Yoshikawa T, Ohgushi H, Nakajima H, Yamada E, Ichijima K, Tamai S, and Ohta T. In vivo osteogenic durability
of cultured bone in porous ceramics: a novel method for autogenous bone graft substitution. 
Transplantation 2000; 15:1284. 
31. Jansen JA, Wolke JG, Swann S, Van der Waerden JP, de Groot K. Application of magnetron sputtering for
producing ceramic coatings on implant materials. Clin Oral Implants Res 1993; 4:28. 
32. Maniatopoulos C, Sodek J, Melcher AH. Bone formation in vitro by stromal cells obtained from bone marrow of
young adult rats. Cell Tissue Res 1988; 254:317. 
33. van der Lubbe HB, Klein CP, de Groot K. A simple method for preparing thin (10 microM) histological sections of
undecalcified plastic embedded bone with implants. Stain Technol 1988; 63:171. 
34. Connerty HV, Briggs AR. Determination of serum calcium by means of orthocresolphthalein complexone. 
Am J Clin Pathol 1966; 45:290. 
35. Kim KJ, Itoh T, Kotake S. Effects of recombinant human bone morphogenetic protein-2 on human bone marrow
cells cultured with various biomaterials. J Biomed Mater Res 1997; 35:279. 
36. Hulshoff JE, van Dijk K, van der Waerden JP, Wolke JG, Kalk W, Jansen JA. Evaluation of plasma-spray and
magnetron-sputter Ca-P-coated implants: an in vivo experiment using rabbits. J Biomed Mater Res 1996; 31:329. 
37. Nishio K, Neo M, Akiyama H, Nishiguchi S, Kim HM, Kokubo T, Nakamura T. The effect of alkali- and heat-treated
titanium and apatite-formed titanium on osteoblastic differentiation of bone marrow cells. 
J Biomed Mater Res 2000; 52:652. 
38. ter Brugge PJ, Wolke JGC, Jansen JA. Effect of calcium phosphate coating crystallinity and implant surface
roughness on differentiation of rat bone marrow cells. Submitted: J Biomed Mater Res. 
39. Leis H J, Zach D, Huber E, Ziermann L, Gleispach H, Windischhofer W. Extracellular Ca2+ sensing by the osteoblast
like cell line, MC3T3-E1. Cell Calcium 1994; 15:447. 
40. Ariji H, Nakade O, Koyama H, Takada J, Kaku T. Effects of extacellular calcium on the proliferation and
differentiation and gene expressions of Bone Morphogenetic Proteins -2 and -4 in human gingiva derived
fibroblasts. Jpn J Oral Biol 2000; 42:49. 
41. Nakade O, Takahashi K, Takuma T, Aoki T, Kaku T. Effect of extracellular calcium on the gene expression of bone
morphogenetic protein-2 and -4 of normal human bone cells. J Bone Miner Metab 2001; 19:13. 
42. Uludag H, D’Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted
with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 1999; 46:193. 
43. Uludag, H, D’Augusta D, Golden J, Li J, Timony G, Riedel R, Wozney JM. Implantation of recombinant human
Bone Morphogenetic Proteins with biomaterial carriers: A correlation between protein pharmacokinetics and
osteoinduction in the rat ectopic model. J Biomed Mater Res 2000; 50:227. 
44. Caplan AI, Bruder SP. Cell and molecular engineering of bone regeneration. In: Lanza LP, Langer R, Chick WL,
Editors. Principles of Tissue Engineering, New York, Academic Press, 1997, 603. 
45. Lee YM, Seol YJ, Lim YT, Kim S, Han SB, Rhyu IC, Baek SH, Heo SJ, Choi JY, Klokkevold PR, and Chung C P. Tissue-
engineered growth of bone by marrow cell transplantation using porous calcium metaphosphate matrices. 
J Biomed Mater Res 2001; 54:216. 
46. Wolke JG, de Groot K, Jansen JA. In vivo dissolution behavior of various RF magnetron sputtered Ca-P coatings. 
J Biomed Mater Res 1998; 39:524. 
47. Daculsi G, LeGeros RZ, Nery E, Lynch K, Kerebel B. Transformation of biphasic calcium phosphate ceramics in vivo:
ultrastructural and physicochemical characterization. J Biomed Mater Res 1989; 23:883. 
48. Ducheyne P, Cuckler JM. Bioactive ceramic prosthetic coatings. Clin Orthop 1992; 276:102. 
49. Kokubo T, Ito S, Huang ZT, Hayashi T, Sakka S, Kitsugi T, Yamamuro T. Ca,P-rich layer formed on high-strength
bioactive glass-ceramic A-W. J Biomed Mater Res 1990; 24:331. 
50. LeGeros RZ, Orly I, Gregoire M, Daculsi G. Substrate surface dissolution and interfacial biological mineralization. 
In: Davies JE, editor. The Bone-Biomaterial Interface, Toronto, University of Toronto, 1991, 76. 
51. Ohgushi H, Goldberg VM, Caplan AI. Heterotopic osteogenesis in porous ceramics induced by marrow cells. 
J Orthop Res 1989; 7:568. 
52. Goshima J, Goldberg VM, Caplan AI. Osteogenic potential of culture-expanded rat marrow cells as assayed in vivo
with porous calcium phosphate ceramic. Biomaterials 1991; 12:253. 
87
Bone formation in Ca-P-coated and non-coated titanium fiber mesh
53. Ohgushi H, Okumura M. Osteogenic capacity of rat and human marrow cells in porous ceramics. Experiments in
athymic (nude) mice. Acta Orthop Scand 1990; 61:431. 
54. Takaoka T, Okumura M, Ohgushi H, Inoue K, Takakura Y, Tamai S. Histological and biochemical evaluation of
osteogenic response in porous hydroxyapatite coated alumina ceramics. Biomaterials 1996; 17:1499. 
55. Okumura M, Ohgushi H, Tamai S. Bonding osteogenesis in coralline hydroxyapatite combined with bone marrow
cells. Biomaterials 1991; 12:411. 
56. Okumura M, Ohgushi H, Takakura Y, van Blitterswijk, CA, Koerten HK. Analysis of primary bone formation in
porous alumina: a fluorescence and scanning electron microscopic study of marrow cell induced osteogenesis. 
Biomed Mater Eng 1992; 2:191. 
88
Bone formation in Ca-P-coated and non-coated titanium fiber mesh
89
Engineered Bone. Matrices, cells and bioactive molecules
Chapter 5
Ectopic bone formation in titanium mesh
loaded with Bone Morphogenetic Protein
and coated with calcium phosphate
J.W.M. Vehof, J. Mahmood, H. Takita, M.A. van ‘t Hof,
Y. Kuboki, P.H.M. Spauwen and J.A. Jansen. 
Plast. Reconstr. Surg. 2001; 108:434.
5.1 Introduction
Bone defects are a significant clinical problem. These defects can be caused by trauma,
oncological surgery, or congenital malformations. The clinical standard in the treatment of
bone defects is still the use of autologous bone tissue. Unfortunately, in the case of large
defects, the use of autografts is hampered by a lack of the availability of sufficient bone
tissue. An alternative is the use of so-called bone graft substitutes (BGSs). These substitutes
can be fabricated using a porous scaffold or carrier material together with osteogenic cells
or osteoinductive factors like Bone Morphogenetic Proteins (BMPs). These BMPs can be
isolated and purified from bone of humans or other species (native BMPs). They can also
be produced by transfected cells using recombinant DNA techniques, [recombinant (hu-
man) BMPs]. 
Scaffold materials currently used in the creation of osteoinductive BGS are polymers
or co-polymers [poly(α-hydroxyl) acids; for example, poly-lactic acid, poly-glycolic acid, and
poly(lactic-co-glycolic acid)], calcium phosphate ceramics (e.g., hydroxyapatite and trical-
cium phosphate) and collagen. A disadvantage of these materials is that they are not very
strong and can easily transform.1,2 Another candidate carrier material for the creation of
BGSs for use in load-bearing situations is sintered titanium (Ti) fiber mesh. Titanium is
currently being applied in surgical practice because of its excellent mechanical charac-
teristics in terms of stiffness and elasticity, bone compatibility and ease of use during
surgery. On the other hand, it is not degradable. However, this latter property is no draw-
back for a significant number of reconstructive purposes. An additional advantage of a
titanium scaffold material is that functional bone properties can further be enhanced by the
deposition of a thin calcium phosphate (Ca-P) coating. In view of this, we know that cal-
cium phosphates have a high affinity for BMPs.3,4 which allows easier binding. 
Recently, it has been demonstrated that BMP effects can be synergistically enhanced
by other factors.5-10 On the other hand, synergistic effects between recombinant BMPs and
native BMPs have not yet been investigated. 
Consequently, the objective of the study presented here was to investigate: (1) the
influence of an additional thin Ca-P ceramic coating on the biological activity of a BMP-
loaded Ti-mesh; (2) synergistic effects between native bovine and recombinant human
BMPs. 
5.2 Materials and methods
5.2.1 Implant preparation, carrier material
Sintered porous Ti-fiber mesh (Bekaert N.V., Zwevegem, Belgium) with a volumetric
porosity of 86%, density of 600 g/m2 and fiber diameter of 50 µm was used as scaffold
material. The average pore size of the mesh was approximately 250 µm. The prepared
implants were disc-shaped with a diameter of 6 mm, thickness of 0.8 mm, and weight of
approximately 15 mg. All implants were ultrasonically cleaned with 70% ethanol for 15
min. The mesh was applied as-received (Ti) or provided with a thin (1 µm) Ca-P coating
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(Ti-CaP) on both sides. The coating procedure was performed using a commercially
available RF magnetron sputter unit (Edwards ESM 100).11 Coating treatment and charac-
teristics have been previously reported in detail.12 Before use, implants were sterilized by
autoclaving for 15 min at 121ºC. A total of 224 discs were prepared: 112 Ti and 112 Ti-
CaP.
5.2.2 Implant preparation, Bone Morphogenetic Proteins
The BMPs used in the present study were recombinant human BMP-2 (rhBMP-2) and the
S-300 BMP cocktail. The rhBMP-2 (a generous gift from Yamanouchi Pharmaceutical co.,
Tokyo, Japan) was produced by Chinese hamster ovary (CHO) cells,13 and the S-300 BMP
cocktail was isolated from powdered bovine metatarsal bone. Preparation of this partially
purified BMP was performed using an earlier described method.14-17 The S-300 BMP
cocktail contains all the fractions that possess bone inductive activity in ectopic implan-
tation, but it does not contain a detectable amount of TGF-β1 or TGF-β2.
Before loading with BMPs, all materials were treated with RF glow-discharge (Harrick
PDC-3XG, Argon, 0.15 Torr, for 5 min) to enhance wettability. Ca-P-coated and non-coated
meshes were loaded with both rhBMP-2 and the S-300 BMP cocktail (BMP2/S300) or with
rhBMP-2 (BMP2) alone. The dose of rhBMP-2 and S-300 BMP cocktail that was applied to
the Ti-fiber mesh discs was 8.7 µg and 50 µg (as defined by Kuboki et al.15) in 0.1% TFA
(trifluoroacetic acid), respectively. The BMP solutions were applied to the Ti-fiber mesh
discs prior to implantation, subsequently lyophilized, and then kept at –80°C until im-
plantation.
5.2.3 Experimental design and surgical procedure
Fifty-six 4-week-old Wistar King rats (80 g) were used for implantation. Surgery was
performed following intra-peritoneal injection with 50 mg/ml Nembutal® (10 times diluted,
0.6 ml/100 g body weight). The BMP-loaded Ti-fiber mesh discs were subcutaneously
implanted into the back of the animals.12 Each animal received one subcutaneous implant
of each type. The implants were localized using a Latin square design to assure complete
statistical randomization. 
A total of 224 implants were placed: 56 Ca-P-coated Ti implants loaded with both
rhBMP-2 and S-300 (Ti-CaP-BMP2/S300); 56 Ca-P-coated Ti implants loaded with rhBMP-
2 only (Ti-CaP-BMP2); 56 non-coated Ti implants loaded with both rhBMP-2 and S-300
(Ti-BMP2/S300); 56 non-coated Ti implants loaded with rhBMP-2 only (Ti-BMP2). 
Implantation periods were 5, 10, 20, and 40 days. At the end of each implantation
period 14 rats were euthanized (n=14 for each material and time period). In addition, six
rats out of the 20-day group received sequential double fluorochrome labeling. Fluoro-
chrome labels, i.e. tetracycline (yellow) and calcein (green), were intramuscularly adminis-
tered at 7 and 14 days post-operatively, respectively. The treatment dose was 25 mg/kg
body weight for both labels. After euthanization, the implants with the surrounding tissues
were retrieved and prepared for light-microscopical, biochemical, and genetical evaluation.
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For each material and time period, 6 implants were used for light-microscopical, 6 for
biochemical, and 2 for genetical evaluation.
5.2.4 Light microscopy, subjective and histomorphometry
Implants for histology were fixed in 4% phosphate-buffered formaldehyde solution
(pH=7.4), dehydrated in a graded series of alcohol, and embedded in methylmethacrylate.
After polymerization 10-µm sections were made using a modified microtome technique.18
Light-microscopical sections were stained with basic fuchsin and methylene blue (3
sections per implant). These sections were evaluated with a light microscope (Leica®). 
Slightly thicker sections (30 µm) were made for fluorochrome labeling analysis (2
sections per implant). These sections were left unstained and examined with a fluorescence
micoscope (Leica®) equipped with an excitation filter of 470–490 nm.
Light- and fluorescence-microscopical analysis consisted of a full morphological
description of the tissue response to the different implants. Further, a semi-quantitative
histological grading scale was used to rate the tissue response (Table 1).
In addition, image analysis was performed on all sections of the 20-and 40-day samples
to evaluate the location of newly formed bone. For this purpose a Leica® Qwin-image
analysis system was used. Briefly, the circumferences of both the fiber mesh and bone were
marked in an interactive manner. Then, the largest horizontal and vertical diameter of the
fiber mesh and newly formed bone were calculated. The value of the difference between
the largest vertical diameter of the mesh and the bone was used as a measure of bone
outgrowth. 
5.2.5 Calcium content and alkaline phosphatase activity
After retrieval, implants were lyophilized and kept at –80°C. Calcium content was assessed
using the ortho-cresolphthalein (OCPC) method (n=6 for each material and time period).19
Alkaline phosphatase (AP) activity was measured using a commercially available alkaline
phosphatase kit (Iatron Laboratories, Tokyo, Japan) based upon the Kind and King phenol-
phosphate method (n=6 for each material and time period).20
5.2.6 Osteocalcin expression
Osteocalcin expression was assessed using a reverse transcriptase polymerase chain reac-
tion method (RT-PCR). Total RNA was isolated and extracted from the implant using
Isogen®. A total cDNA library was formed using a commercially available reverse tran-
scriptase (Takara®, Tokyo, Japan). The resulting reverse transcriptase product was then
amplified by PCR with Takara Taq (Takara®, Tokyo, Japan) using primers specific for
osteocalcin and GADPH, a housekeeping gene. The products were analyzed by electro-
phoresis on 2% agarose containing ethidium bromide (50 µg/100 ml in TAE buffer) and
then photographed under UV light excitation.
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5.2.7 Statistical methods
A paired t-test was applied to evaluate the CaP-coating and S-300 effects. The CaP-coating
effect may be calculated within each rat as the difference between the mean of both CaP-
coated implants (Ti-CaP-BMP2/S300 and Ti-CaP-BMP) and non-coated implants (Ti-
BMP2/S300 and Ti-BMP2). In the same manner the S-300 effect was calculated as the
difference between the mean of both S-300-loaded implants (Ti-CaP-BMP2/S300 and Ti-
BMP2/S300) and non-S-300-loaded implants (Ti-CaP-BMP2 and Ti-BMP2). P-values for
the effects were calculated. In case of skew distributions, logtransformation to normality
was used. 
5.3 Results
During the experiment 2 rats died, probably due to the anesthesia. Hence, 8 implants were
lost for genetical evaluation, and a total of 216 implants were retrieved. The other rats
remained in good health and did not show any wound complications. At explantation, all
implants were surrounded by a thin reaction-free fibrous capsule. From 10 days post-
operative onwards, bone formation could be observed macroscopically. 
5.3.1 Light microscopy, subjective
Light microscopical analysis of the sections revealed that all of the implants showed various
stages of the bone formation process; no “negative” implants were observed. Hardly any in-
flammatory cells were observed in or around all specimens. 
At 5 days, dense undifferentiated mesenchymal cells were observed inside the porosity
of, and outside the implants. Foci of hypertrophic cartilage cells were present at the margin
of, and outside the implant. Only in Ti-CaP-BMP2/S300 and Ti-BMP2/S300 implants the
cartilage had started to mineralize (Figure 1A).
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Table 1.
Table showing the semi-quantitative histological grading scale that was used to rate the tissue response.
Score
0
Response
Fibrous tissue
1 Undifferentiated mesenchymal cells
2 Cartilage formation
3 Cartilage maturation, hypertrophy
4 Cartilage maturation, mineralization
5 Mineralized cartilage, bone formation
6 Bone and fully developed bone marrow-like tissue
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Figure 1.
(A) Undecalcified section of a Ca-P-coated titanum
mesh loaded with rhBMP-2 and the S-300 BMP cocktail
(Ti-CaP-BMP2/S300) 5 days after implantation. Dense
undifferentiated mesenchymal cells are visible inside the
porosity of, and outside the titanium (Ti) implant. Foci
of hypertrophic cartilage cells (HC) are visible outside
the implant. Also in these foci cartilage has started to
mineralize (M) (orig. magn. 40x). 
(B) Undecalcified section of a Ca-P-coated Ti-mesh
loaded with rhBMP-2 and the S-300 BMP cocktail
(Ti-CaP-BMP2/S300) 10 days after implantation.
The implant is surrounded by a periosteum-like fibrous
layer. Bone formation is seen inside and surrounding the
Ti-mesh. Inside the implant cartilage with cartilagenous
matrix are present. In the cartilage, areas with
mineralization are seen. The bone formation process is
more differentiated outside than inside the implant
(orig. magn. 20x).
(C) Undecalcified section of a Ca-P-coated Ti-mesh
loaded with rhBMP-2 and the S-300 BMP cocktail
(Ti-CaP-BMP2/S300) 40 days after implantation.
A periosteum-like layer with active bone formation
surrounds the bone. Bone can be observed surrounding
and inside the implant. The bone has a more dense
lamellar structure. Some areas with bone remodeling
can be observed. Inside the implant there is a large
amount of hemopoietic bone marrow-like tissue
(orig. magn. 20x).
(D) Non-stained undecalcified section of a
Ca-P-coated Ti-mesh loaded with rhBMP-2 and the
S-300 BMP cocktail (Ti-CaP-BMP2/S300) 20 days after
implantation. This section is viewed with a fluorescence
microscope. In Ti-CaP-BMP2/S300, Ti-CaP-BMP2 and
Ti-BMP2/S300 implants the tetracylin (7 days) label is
visible at the margin of and outside the fiber mesh,
while the calcein (13 days) label is visible inside the fiber
mesh (orig. magn. 2.5x).
(E) Non-stained undecalcified section of a non-coated
Ti-mesh loaded with rhBMP-2 (Ti-BMP2) 20 days after
implantation. This section is viewed with a fluorescence
microscope. The tetracylin (7 days) label and the calcein
(13 days) label are both visible inside the fiber mesh at
some distance from the outer margin (orig. magn. 2.5x).
At 10 days, the implants were surrounded by a periosteum-like fibrous layer. Inside
the fiber mesh material, cartilage formation with cartilagenous matrix was observed
(Figure 1B). In these cartilagenous areas mineralization was present. In addition, bone and
bone marrow formation were present. Bone was present in the outer layer. For all implant
types, large multi-nucleated cells were observed in close contact with the calcified cartilage
and bone. 
At 20 days trabecular bone was seen throughout the implants in close contact with the
titanium fibers. Inside the trabecular bone, in the porosity of the mesh, hemopoietic bone
marrow-like tissue was seen. No cartilage was observed in any implant. 
At 40 days, a periosteum-like layer with active bone formation was seen surrounding
the bone (Figure 1C). The bone had a more dense lamellar structure. Some areas with bone
remodeling could be observed. A large amount of hemopoietic bone marrow-like tissue was
observed inside the implants. In Ti-CaP-BMP2 and Ti-BMP2 implants, there was less
hemopoietic bone-marrow-like tissue. 
In all S-300-loaded specimens, bone formation was more pronounced and located in-
side as well as surrounding the Ti-mesh (Figure 2A,C). In BMP2-only-loaded specimens
bone was mainly localized inside the mesh material (Figure 2B,D). In addition, in CaP-
coated specimens (Figure 2A,B) more bone could be observed in than in non-coated
specimens (Figure 2C,D).
5.3.2 Fluorochrome labeling
In the 20-day specimens, fluorochrome labels were clearly visible. In the Ti-CaP-BMP2/
S300, Ti-CaP-BMP2 and Ti-BMP2/S300 specimens the tetracycline label (bone formation
after 7 days) was visible at the margin and outside the fiber mesh (Figure 1D). In the Ti-
BMP2 implants the tetracyclin label was visible only inside the fiber mesh (Figure 1E). In
the Ti-CaP-BMP2/S300, Ti-CaP-BMP2 and Ti-BMP2/S300 specimens, the calcein label
(bone formation after 14 days) was seen inside and in a layer at the outer margin of the
formed bone. In Ti-BMP2 implants the calcein label was located inside the fiber mesh at
some distance form the outer border of the mesh. In all experimental groups bone was
formed in a centrifugal manner starting in the porosity of the mesh.
5.3.3 Light microscopy, tissue rating
Although rating indicated that at 5 days the bone formation process had proceeded further
in the S-300-loaded specimens (cartilage maturation) than in BMP2-only-loaded specimens
(chondrogenesis) (Figure 3), statistical analysis using a paired t-test revealed that no S-300
effect existed (Table 2). In addition, no significant effect was found for the CaP coating
(Table 2). From 10 days onwards, no differences in stage of bone formation were observed
between the different implantation materials. Because all scores were the same at these
time periods, no statistical analysis was necessary. At 10 days, bone and cartilage were seen
together in all sections. At 20 days and 40 days, bone was observed in all implants without
the presence of cartilage. 
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5.3.4 Light microscopy, bone location
The results of the histomorphometrical measurements for bone location are depicted in
Figure 4. In S-300-treated specimens (Figures 4 and 2A,C) the bone grew outside the fiber
mesh, whereas in BMP2 -only specimens bone grew inside the mesh (Figures 4 and 2B,D).
In the Ca-P-coated BMP2-only specimens (Figures 4 and 2B) bone grew just up to the
margin of the mesh and in non-coated BMP2-only specimens bone grew inside the porosity
and did not reach the outer margin (Figures 4 and 2D).
Statistical evaluation using a paired t-test revealed a significant effect of the S-300 BMP
cocktail at 20 days (P<0.005) and 40 days (P<0.01) and of the Ca-P coating at 40 days
(P<0.05). Both the S-300 and the Ca-P coating showed a positive effect on the difference in
bone-titanium diameter (Table 2). The S-300 effect was larger than the Ca-P coating effect.
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Figure 2.
(A) Undecalcified section of
a Ca-P- coated Ti-mesh loaded
with rhBMP-2 and the S-300
BMP cocktail (Ti-CaP-
BMP2/S300) 40 days after
implantation. Bone grows
inside and outside the fiber
mesh (orig. magn. 2.5x).
(B) Undecalcified section of
a Ca-P-coated Ti-mesh loaded
with rhBMP-2 (Ti-CaP-BMP2)
40 days after implantation.
Bone grows just up to the
margin of the titanium fiber
mesh (orig. magn. 2.5x). 
5.3.5 Calcium content
The results of the calcium content measurements are depicted in Figure 5. No statistical
evaluation was performed on the 5-day data because the values approached zero. A paired
t-test was performed to examine the effects of the Ca-P coating and S-300 factor at each
separate time period. At 20 days (P<0.0005) and 40 days (P<0.0005), a positive effect
was found with respect to the Ca-P coating (Table 2). This test also showed that the S-300
fraction had a significant positive effect (P<0.0005) at 20 days (Table 2).
5.3.6 Alkaline phosphatase activity
The results of the alkaline phosphatase activity measurements are depicted in Figure 6.
Alkaline phosphatase data showed a lognormal distribution; therefore logtransformation
was performed. A paired t-test was performed to determine the effects of the Ca-P coating
and the S-300 BMP cocktail at each separate time period. At 5 days (P<0.005), 20 days
(P<0.005) and 40 days (P<0.05) a positive S-300 effect was found (Table 2). In addition,
at 40 days (P<0.05) a positive Ca-P effect was found. The highest S-300 effect was found
at 5 days (Table 2).
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Figure 2. 
(C) Undecalcified section
of a non-coated Ti-mesh
loaded with rhBMP-2 and
the S-300 BMP cocktail
(Ti-BMP2/S300) 40 days after
implantation. Bone grows
inside and outside the fiber
mesh (orig. magn. 2.5x).
(D) Undecalcified section of
a non-coated Ti-mesh loaded
with rhBMP-2 (Ti-BMP2) 40
days after implantation. Bone
grows inside the porosity of
the titanium fiber mesh and
does not reach the outer
margin (orig. magn. 2.5x).
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Table 2.
A paired t-test was used to evaluate the CaP-coating effect and the S-300 effect on the tissue rating,
bone location, calcium content and alkaline phosphatase data, (n=sample size, NS=non-significant
P>0.05).
NS2.143.176NS2.612.6965Tissue rating
Bone location (µm) <0.005–2373566NS–57197520
<0.01–1913836<0.05–242245640
NS1.352.846NS2.132.06610Calcium content
(mg/pellet) <0.00051.93.286<0.00051.583.6620
NS2.633.316<0.00052.113.83640
<0.0054015616NS47748665Alkaline phosphatase
(mIU/pellet) NS4565006NS448508610
<0.0054815206NS489512620
<0.054655156<0.005462518640
Time
(days)
Mean
Coating
Coating versus No Coating S-300 versus No S-300
Mean
S-300
Mean
N0 S-300
Mean
No Coating
n p pn
Figure 3.
Results of the semi-quantitative histomorphometrical analysis for tissue rating showing mean and standard deviation
(SD) for the different implants.
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Figure 4.
Figure showing the results of the histomorphometrical analysis for bone location at 20 and 40 days post-implantation
(mean and SD). The largest horizontal and vertical diameter of the bone and Ti-mesh were calculated. The difference
between the largest vertical diameter of the bone and the Ti-mesh was used as a measure of bone outgrowth.
Figure 5.
Figure showing the results of the calcium content measurement at 5, 10, 20, and 40 days post-implantation (mean and
SD).
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Figure 6.
Figure showing the results of
the alkaline phosphatase
activity measurement at 5, 10,
20, and 40 days post-
implantation (mean and SD).
Figure 7.
Figure showing a
gel-electrophoresis picture
taken under UV light
excitation, showing
time-dependent osteocalcin
expression in
(Ti-CaP-BMP2/S300) implants.
Electrophoresis pictures were
the same for all implantation
groups. 
5.3.7 RT-PCR for osteocalcin
With RT-PCR osteocalcin expression was detectable as early as 5 days for all specimens
(Figure 7). Ten days after implantation osteocalcin expression had increased, as demon-
strated by the much clearer osteocalcin bands. Thereafter, osteocalcin expression remained
at about the same level for all specimens. 
5.4 Discussion and conclusion
Our histological findings confirm that Ti-fiber mesh is highly biocompatible as demonstrat-
ed by the absence of inflammatory cells in all BMP-loaded implants.21,22 Further, as
indicated by the various evaluations, Ti-mesh loaded with BMP can indeed adequately
induce ectopic bone formation. 
Although a comparison with other carriers is hard to make, the onset of osteocalcin
expression at 5 days seems relatively early, since osteocalcin is a late marker for bone
formation. We assume that the early expression of osteocalcin in our study is due to the
high compatibility of the Ti-mesh and the Ca-P-coating. The process of bone formation in
all our BMP-loaded samples occurred with a cartilagenous phase present. Thus, the bone
formation process seems to be similar to “endochondral ossification”. Direct ossification
without pre-existing cartilage has been reported in implanted BMP carriers: it was first
reported for fibrous collagen membrane (FCM) and later for hydroxyapatite.14,15,23,24 On
the other hand, fibrous glass membrane (FGM) and insoluble bone matrix (IBM) have been
shown to induce endochondral ossification.14,25
Vascularization is considered a crucial step in ectopic bone formation. We also know
that the geometry of the carrier influences vascularization and thereby oxygen supply.
Various studies have already shown that a low oxygen concentration favors chondro-
genesis, while a higher oxygen concentration supports bone formation.26-28 Carriers that
induce bone formation without cartilage have been hypothesized to provide a higher
oxygen supply due to geometry.23
A precise explanation for the differences in the nature of the bone formation process
between various carrier materials is difficult to provide because a clear comparison be-
tween the materials is difficult to make due to the variation in material properties. Besides
physicochemical properties, materials differ in surface structure, mechanical characteris-
tics, pore size, pore geometry, and pore density. 
The fluorescent labeling study revealed that the newly formed bone was deposited in a
centrifugal manner, starting in the porosity and growing towards the surface of the carrier.
In a previous study,15 bonding osteogenesis, in which bone formation starts at the surface
area and proceeds away from the surface area, was observed for bioactive materials like
hydroxyapatite. We know that the thin RF magnetron sputter coating did not completely
penetrate throughout the mesh, despite the fact that we coated the mesh on both sides. As a
result, the inside of the mesh always consists of the original titanium surface. This probably
explains the absence of bonding osteogenesis.
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In our current study, we also showed that the additional deposition of a thin calcium
phosphate coating on the Ti-mesh had a stimulatory effect on bone formation. We know
that Ca-P ceramics combined with BMPs enhance the bone formation process.14,15,29 This
effect is supposed to be due to the high affinity of BMP to Ca-Ps.3 In a former chromato-
graphic study, we demonstrated that the affinity of BMP for hydroxyapatite is higher than
for titanium.4 Apparently, a similar phenomenon is involved in our Ca-P-coated Ti-mesh.
Nevertheless, we were the first to report that a thin Ca-P coating has a stimulatory effect on
ectopic bone formation by rhBMP-2.30,31 This paper confirms these earlier findings using
larger experimental numbers, earlier time periods and a combination of all possible factors. 
Finally, we observed a synergistic effect between rhBMP-2 and the S-300 BMP
cocktail. It has been reported that highly purified native bovine and human BMPs are about
10 times more potent in ectopic osteoinduction than recombinant human BMP-2.32,33
However, the osteoinductive capacity of the S-300 BMP cocktail, which is a partially
purified BMP fraction, is about 50 times less than the osteoinductive capacity of rhBMP-2.
An earlier preliminary experiment with Ti-fiber mesh as a carrier reinforces this difference
in osteoinductive activity. In that experiment BMP2/S300-loaded as well as BMP2-and
S300-only-loaded specimens were included. At 4 weeks the S300-only-implants showed
hardly any bone formation, whereas BMP2/S300- and BMP2-only-loaded specimens
revealed a level of osteogenesis comparable to that of the current study. Therefore, in the
present study, the potentiating effect of the S-300 BMP cocktail is not simply an additive
effect but a true synergistic effect. Although potentiating effects in vivo between BMP and
other factors like TGF-β1,5,6 TGF-β2,7 Prostaglandin E1 (PGE1)8,9 and basic Fibroblast
Growth Factor (bFGF)10 have been described, such an effect has never been reported for
various types of BMPs. 
In summary, we conclude that Ti-mesh loaded with BMPs can indeed induce ectopic
bone formation in a rat model during a long time span from 10 to 40 days. Our results
confirm our preliminary observations that an additional Ca-P coating can further improve
the osteoinductive properties of a BMP-loaded Ti mesh. The bone formation process in Ca-
P-coated and non-coated Ti-fiber mesh seems to be similar to “endochondral ossification”.
Evidently, rhBMP-2 and the S-300 BMP cocktail act synergistically in ectopic bone induc-
tion in Ti mesh-based BGSs.
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Chapter 6
Histological characterization
of the early stages of Bone Morphogenetic
Protein-induced osteogenesis
J.W.M. Vehof, H. Takita, Y. Kuboki, P.H.M. Spauwen and J.A. Jansen. 
J. Biomed. Mater. Res., conditionally accepted, 2001.
6.1 Introduction
Bone defects form a significant clinical problem. These defects can be caused by trauma,
oncological surgery, or congenital malformations. The golden clinical standard in the
treatment of bone defects is still the use of autologous bone tissue, but the clinical use of
autografts is hampered by donor-site and availability problems. An alternative is the use of
so-called bone graft substitutes (BGSs). These bone graft substitutes can be divided in three
classes: (1) osteoconductive, (2) directly osteogenic, and (3) osteoinductive.1 The main dis-
advantage of osteoconductive BGS, like allograft bone and ceramic materials (e.g., hydroxy-
apatite or tricalcium phosphate), is that they do not actively stimulate the bone-forming
process. Directly osteogenic and osteoinductive BGS can be fabricated using a porous scaf-
fold (or carrier) material together with osteogenic cells or osteoinductive factors [for exam-
ple Bone Morphogenetic Proteins (BMPs)], respectively. 
Carrier materials currently used in the creation of osteoinductive BGS include poly-
mers, [mainly poly(α-hydroxyl acids)], calcium phosphate ceramics (e.g., hydroxyapatite
and tricalcium phosphate), collagen and others. To date our group has tested more than ten
different carrier materials. A large number of prerequisites have been postulated for the
ideal carrier material,2 but it must be emphasized that none of the materials used meet all
of these demands. For example, a disadvantage of some of these materials is that they are
not very strong and can easily transform.3,4 In view of this, we have suggested the use of
titanium fiber mesh as the carrier material.5,6 An additional advantage of a titanium scaf-
fold material is that bone formation can be significantly enhanced by the deposition of a
thin calcium phosphate (Ca-P) coating.6
For the final safe and reliable clinical application of BMP-induced BGSs, both a
significant amount of and high-quality bone must be formed (in the carrier material) with-
in a reasonable time frame. Consequently, further knowledge about the bone formation
process as induced by BMPs has to be obtained. For example, in early studies, BMP-induced
bone formation was believed to follow the sequence of endochondral ossification.7 More
recently, however, direct ossification without pre-existing cartilage has been reported on
implanted BMP carriers: first for fibrous collagen membrane (FCM) and later for hydroxy-
apatite.8,9 On the other hand, fibrous glass membrane (FGM) and insoluble bone matrix
(IBM) have been shown to induce endochondral ossification.9,10 Also, for BMP-loaded
titanium (Ti) the process of bone formation seems to occur with a cartilagenous phase
present.6 Nevertheless, a definitive conclusion about the bone formation process, in differ-
ent scaffold materials, is difficult to draw since bone and cartilage can be independently
induced.8 For the proper characterization of the bone formation process and the elimina-
tion of possible observational errors, BMP-loaded scaffolds have to be evaluated at short
implantation periods. 
Consequently, the objective of the study presented here was to analyze and compare
the early stages of the bone formation process in various BMP-loaded “bone directing” and
“cartilage directing” carrier materials.11
106
Histological characterization of the early stages of Bone Morphogenetic Protein-induced osteogenesis
6.2 Materials and Methods
6.2.1 Implant preparation, carrier materials
6.2.1.1 Ca-P-coated titanium fiber mesh (Ti-CaP)
Sintered porous Ti-fiber mesh (Bekaert N.V., Zwevegem, Belgium) with a volumetric poro-
sity of 86%, density of 600 g/m2, and fiber diameter of 50 µm was used as scaffold material.
The average pore size of the mesh was approximately 250 µm. The prepared implants were
disc-shaped with a diameter of 6 mm, thickness of 0.8 mm, and weight of approximately 15
mg. All implants were ultrasonically cleaned with 70% ethanol for 15 min. The mesh was
applied provided with a thin (1 µm) Ca-P coating (Ti-CaP) on both sides. The coating
procedure was performed using a commercially available RF magnetron sputter unit
(Edwards ESM 100).12
After deposition, all coated specimens were subjected to an additional heat treatment for
2 h at 500ºC. The coatings had a crystalline apatite structure with a Ca/P ratio of 1.8– 2.0.5
Before use, implants were sterilized by autoclaving for 15 min at 121ºC. Before being
loaded with rhBMP-2, the titanium fiber mesh discs were treated with RF glow-discharge
(Harrick PDC-3XG, Argon, 0.15 Torr, for 5 min) to enhance wettability. A total of 12 Ti-
CaP discs were prepared.
6.2.1.2 Insoluble bone matrix (IBM)
Freshly obtained bovine metatarsal bones were processed to obtain bone powders, which
were sieved selectively. After decalcification in diluted HCl at a constant pH of 2.0 at 4ºC
and defatting with methanol and chloroform (volume ratio 1:1) the powders were extracted
four times with 4 M Guanidine HCl, then washed with distilled water and lyophilized. This
method has been described previously.9,13 This preparation is termed insoluble bone matrix
(IBM) and was used as the conventional carrier. The average IBM particle size was 500 µm.
Twelve IBM implants, each weighing 20 mg, were used.
6.2.1.3 Fibrous glass membrane (FGM)
Fibrous glass membrane, 1-mm thick, was constructed from unwoven glass fibers 1 µm in
diameter (Advantec, Tokyo, Japan). The chemical composition has been described pre-
viously.10,14 This FGM was cut into pieces of a uniform size (10 x 5 mm). Twelve FGM
sheets, each weighing 6 mg, were used.
6.2.1.4 Porous particles of hydroxyapatite (PPHAP)
Porous particles of hydroxyapatite were developed jointly by the Department of Biochemis-
try, School of Dentistry, Hokkaido University and Japan Steelworks, Ltd. (Muroran, Japan).
The original product consisted of a block of hydroxyapatite with a porosity of 70% and a
pore size of 150 µm, which was sintered at 1,200ºC for 1h. This product was broken into
granules and sieved to obtain a particle size varying from 300 to 500 µm; these granules
were used as a carrier material. The PPHAP had an interconnected pore structure.9 The
procedure for preparation of the hydroxyapatite and porous particles has been reported
previously in detail.15, 16 Twelve PPHAP implants, each with a weight of 40 mg, were used. 
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6.2.2 Implant preparation, Bone Morphogenetic Proteins
The BMP used in the present study was recombinant human (rh)BMP-2. The rhBMP-2 (a
generous gift from Yamanouchi Co., Tokyo, Japan) was produced by Chinese hamster ovary
(CHO) cells. All materials were loaded with rhBMP-2. A 8.7 µg-dose of rhBMP-2 (diluted
in Phosphate Buffered Saline, PBS) was applied to each implant. The BMP solutions were
applied to the carrier materials prior to implantation. Ti-CaP and FGM implants were
placed in an Eppendorf® tube, and aliquots of rhBMP-2 solution were applied. The IBM
particles and PPHAP were placed in a 1-ml tuberculin syringe of which the tip had been
cut open,17 and aliquots of rhBMP-2 solution were applied. Subsequently, all specimens
were lyophilized and then kept at –80ºC until implantation. 
6.2.3 Experimental design and surgical procedure
Sixteen 4-week-old Wistar King rats were used for implantation. The weight of each rat
was approximately 60-70 g. Surgery was performed following intra-peritoneal injection
with 50 mg/ml Nembutal® (diluted 10 times, 3.6 mg/100 g body weight). The BMP-loaded
carriers were subcutaneously implanted into the back of the animals. To insert the im-
plants, we immobilized the animals in a prone position. The backs of the animals were
shaved and disinfected with 70% ethanol. To insert the subcutaneous implants, we made
three small longitudinal incisions, two on one side and one on the other side of the
vertebral column. Lateral to the incisions, we created a subcutaneous pocket using blunt
dissection. Just before placement of the IBM and PPHAP implants, 30 µl and 40 µl distilled
water was added to each syringe, respectively. After placement of the implants, the skin
was closed using 4-0 nylon sutures. In this way, each animal received three subcutaneous
implants. The implants were localized using a statistical randomization scheme. A total of
48 implants were placed: 12 Ti-CaP, 12 IBM, 12 FGM and 12 PPHAP implants, all loaded
with rhBMP-2. Implantation periods were 3, 5, 7, and 9 days. Four rats were sacrificed at
the end of each implantation period. The retrieved implants were used for light-microscopi-
cal analysis. 
6.2.4 Light microscopy, subjective and tissue rating
For histological preparation, implants were fixed in 4% phosphate-buffered formaldehyde
solution (pH=7.4), dehydrated in a graded series of alcohol, and embedded in methylme-
thacrylate. After polymerization 10-µm sections were made using a modified microtome
technique.18 Light-microscopical sections were stained with basic fuchsin and methylene
blue. At least three sections per implant were made and evaluated with a light microscope
(Leica®). 
Light microscopical analysis consisted of a full morphological description of the tissue
response to the different implants. Further, a semi-quantitative histological grading scale
was used to rate the tissue response (Table 1).
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6.3 Results
All rats survived the experiment in good health and did not show any wound complica-
tions. At the end of the experiment, 48 implants were retrieved. At explantation, all
implants were surrounded by a thin reaction-free fibrous capsule. Macroscopically, bone
formation could be observed only in 9-day IBM implants. In the particulate implants (IBM
and PPHAP) seroma formation was occasionally observed macroscopically.
6.3.1 Light microscopy, subjective
6.3.1.1 Ti-CaP
At 3 days of implantation, the porosity of the CaP-coated titanium mesh was almost devoid
of cells: only some inflammatory cells could be seen mostly outside but also inside the
mesh. This tissue reaction may be associated with the early stage of the wound healing
process. Further, a dense layer of cells was seen surrounding the implant (Figure 1A).
At 5 days, undifferentiated mesenchymal cells occupied the porosity of the mesh. In
addition, foci with cartilage formation and hypertrophic cartilage cells were present, in all
specimens. These foci occurred mainly at the margin of the mesh. No signs of calcification
were observed (Figure 1B), and there were hardly any inflammatory cells present.
At 7 days, cartilage with hypertrophic cartilage cells, had been formed in all implants.
The cartilaginous tissue was found inside and at the margin of the mesh. In two implants
the cartilage had started to mineralize. At the outer margin of one of these implants the
cartilage was already changing to trabecular bone (Figure 1C). Scarcely any inflammatory
cells were observed.
At 9 days, cartilage with a cartilagenous matrix was formed inside the fiber mesh
material. Mineralization was clearly present in these cartilagenous areas. In the outer mesh
areas, the cartilage was changing to trabecular bone. This trabecular bone expressed various
stages of maturity. Further, some multinucleated cells were present in association with the
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Table 1.
Table showing the semi-quantitative histological grading scale that was used to rate the tissue response.
Score
0
Response
Fibrous tissue
1 Undifferentiated mesenchymal cells
2 Cartilage formation
3 Cartilage maturation, hypertrophy
4 Cartilage maturation, mineralization
5 Mineralized cartilage, bone formation
6 Bone and fully developed bone marrow-like tissue
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Figure 1.
Undecalcified sections of:
(A) A Ti-CaP implant 3 days after implantation. The porosity of the CaP-coated titanium mesh is almost devoid of cells.
Only some inflammatory cells can be seen mostly outside but also inside the titanium mesh (Ti) (orig. magn.10x).
(B) A Ti-CaP implant 5 days after implantation. Foci with cartilage formation and hypertrophic cartilage (HC) cells are
present mainly at the margin of the mesh while undifferentiated mesenchymal cells are present inside the titanium
mesh (Ti) (orig. magn. 40x).
(C) A Ti-CaP implant 7 days after implantation. Cartilage, with hypertrophic cartilage cells are found inside and at the
margin of the mesh. The cartilage has started to mineralize. At the outer margin, the mineralized cartilage is already
changing to trabecular bone (orig. magn. 20x).
(D) A Ti-CaP implant 9 days after implantation. In the cartilagenous areas mineralization is clearly present, the
cartilage is changing to trabecular bone which expresses various stages of maturity (orig. magn. 20x).
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Figure 2.
Undecalcified sections of:
(A) An IBM implant 3 days after implantation. The porosity between the particles is almost devoid of cells. Only some
inflammatory cells are seen in between and covering the surface of the IBM particles. The cell-layer which surrounds the
implant seems more dense than in the titanium implants (orig. magn. 5x). 
(B) An IBM implant 5 days after implantation. Foci of hypertrofic cartilage (HC) cells can be observed mainly at the
outside and in between the outer IBM particles. Undifferentiated mesenchymal cells are present between the inner
particles (not shown) (orig. magn. 20x).
(C) An IBM implant 7 days after implantation. A significant amount of cartilage was formed surrounding the implant
and between the particles. In the cartilage many hypertrophic cells can be seen together with mineralization. At the
outside of the IBM implant (top) cartilage was already changed in trabecular bone (orig. magn 10x).
(D) An IBM implant 9 days after implantation. Abundant cartilage and trabecular bone is present. Cartilagenous
matrix with hypertrophic cartilage cells and mineralization mainly occupy the center of the implants. The bone was
observed in the outer implant areas (top) and could be associated with the formation of marrow cavities and bone
marrow-like tissue (orig. magn 10x).
mineralized cartilage. Also, a periosteum-like fibrous layer was formed which surrounded
the titanium mesh. In none of the sections was bone marrow-like tissue observed (Figure
1D).
6.3.1.2 IBM
Three days after implantation, the porosity between the IBM particles was almost devoid of
cells: only some inflammatory cells were seen in between and covering the surface of the
IBM particles. This tissue reaction was very similar to the response to the titanium mesh
implant, although, the cell layer which surrounded the IBM implant appeared to be more
dense (Figure 2A).
At 5 days, undifferentiated mesenchymal cells were present between the IBM par-
ticles, especially in the outer areas. In addition, in two of the three implants, foci of carti-
lage, with hypertrophic cartilage cells could already be observed. These foci were mainly at
the outside and in between the outer particles. Initial mineralization was seen in the
cartilage (Figure 2B).
At 7 days, in all implants a significant amount of cartilage was formed surrounding the
implant and between the particles. Many hypertrophic cells could be observed, and minera-
lization had proceeded. At the outside of the IBM implant cartilage had already changed
into trabecular bone, and a periosteum-like fibrous tissue layer was being formed. Multi-
nucleated cells, in close contact with the mineralized tissue, were occasionally present
(Figure 2C).
At 9 days, abundant cartilage and trabecular bone was present in all implants. The
cartilage was characterized by the presence of hypertrophic cartilage cells and mineraliza-
tion and mainly occupied the center of the implants. Bone was observed in the outer im-
plant areas and could be associated with the formation of marrow cavities and bone mar-
row-like tissue. In addition, cells had grown into the small pores within the IBM particles.
Parts of the IBM stained with basic fuchsin, which indicated mineralization (Figure 2D).
6.3.1.3 FGM
At 3 days, the initial tissue response to FGM was very similar to the response to titanium
implants, including a dense layer of cells which surrounded the implant (Figure 3A). 
Five days after implantation, an inflammatory reaction was still present: evidently,
inside the FGM the number of inflammatory cells had increased. No undifferentiated
mesenchymal cells were seen, and in none of the sections was cartilage or bone present
(Figure 3B).
At 7 days, abundant inflammatory cells (multinucleated cells) were present at the
outer region of the FGM. Spindle-shaped undifferentiated cells were observed inside the
membrane. At the outer surface of all implants, foci of cartilage with hypertrophic cartilage
cells had now formed, which showed some initial mineralization in one implant and initial
bone formation in another (Figure 3C).
After 9 days, spindle-shaped undifferentiated cells were still present. In two implants
foci of cartilage with initial mineralization were located at the outer zone of the FGM
implant. In none of the sections bone formation could be observed (Figure 3D). Multi-
nucleated cells were still present in abundance.
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Figure 3.
Undecalcified sections of:
(A) A FGM implant 3 days after implantation. The initial tissue response to FGM was very similar to other implant
types, including an inflammatory reaction and a dense layer of cells which surrounded the implant (orig. magn. 5x). 
(B) A FGM implant 5 days after implantation. Still an inflammatory reaction was observed. Inside the FGM the
number of inflammatory cells increased compared to 3 days. At the margin multinucleated cells (MNC) can be seen. No
undifferentiated mesenchymal cells are present. In addition, neither cartilage, nor bone are present (orig. magn. 10x).
(C) A FGM implant 7 days after implantation. Abundant inflammatory cells [multi-nucleated cells (MNC)] were
present at the outer region of the FGM. Spindle-shaped undifferentiated cells can be observed inside the membrane.
Now, At the outer surface of the implants, foci of cartilage with hypertrophic cartilage (HC) cells and some initial
mineralization can be observed (orig. magn. 20x). 
(D) A FGM implant 9 days after implantation. Spindle-shaped undifferentiated cells are still present. Foci of cartilage
with initial mineralization are located at the outer zone of the FGM implant. No bone formation can be observed (orig.
magn 10x).
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Figure 4.
Undecalcified sections of: 
(A) A PPHAP implant implant 3 days after implantation. The tissue response for the PPHAP implant is very much
the same as for other implant types. An inflammatory reaction is present and a dense layer of cells which surrounds
the implant. In addition, the HA surface within the pores stains with basic fuchsin which indicates mineralization
(orig. magn. 10x).
(B) A PPHAP implant 5 days after implantation. Inflammatory cells are present inside and between the PPHAP.
Also, multinucleated cells (MNC) can be observed in close contact with the particles. Ingrowth of undifferentiated
mesenchymal cells had occurred between and inside the porous particles. The surface of the hydroxyapatite stains
positive for basic fuchsin, without the presence of osteoblast-like cells or osteocytes. No cartilage or bone is present
(orig. magn 10x). 
(C) A PPHAP implant 7 days after implantation. Calcification without the presence of osteoblast-like cells or
osteocytes is clearly visible at the surface of the hydroxyapatite. The pores show the presence of undifferentiated
mesenchymal cells with which were also present between porous particles. Inside a part of the pores hypertrophic
cartilage cells were observed without mineralization (not shown). Between the particles mineralized cartilage with
transition to trabecular bone can be seen (orig. magn 10x).
(D) A PPHAP implant 9 days after implantation. The presence of calcification at the surface of the hydroxyapatite
particles and the presence of multinucleated cells (MNC) surrounding these particles is still unchanged. Inside the pores
of the particles hypertrophic cartilage (HC) cells together with mineralization can be observed in close association with
the hydroxyapatite surface. Trabecular bone is present between the particles and at the outside of the implants, while
some mineralized cartilage remains between the particles (orig. magn 20x).
6.3.1.4 PPHAP
After 3 days, the tissue response differed only at one point from those to the other implant
materials; i.e., the HA surface within the pores was stained with basic fuchsin (Figure 4A).
Five days after implantation, the number of inflammatory cells had increased inside and
between the PPHAP. Also, multinucleated cells were present in close contact with the
particles. Ingrowth of undifferentiated mesenchymal cells had occurred between and inside
the porous particles. The surface of the hydroxyapatite stained positive for mineralization
(basic fuchsin) without the presence of osteoblast-like cells or osteocytes. No cartilage or
bone could be observed in any specimen (Figure 4B).
At 7 days, calcification without the presence of osteoblast-like cells or osteocytes was
clearly visible at the surface of the hydroxyapatite within the pores. Multinucleated cells
were present in close contact with the porous particles. Hypertrophic cartilage cells were
observed without mineralization inside a portion of the pores; other pores showed the
presence of undifferentiated mesenchymal cells, which were also present between porous
particles. In all specimens, mineralized cartilage with a transition to trabecular bone was
seen between the particles (Figure 4C).
Finally, at 9 days, calcification at the surface of the hydroxyapatite particles and the
presence of multinucleated cells surrounding these particles were still unchanged. Inside
the pores of the particles hypertrophic cartilage cells together with mineralization could be
observed in close association with the hydroxyapatite surface. Further, in all implants trabe-
cular bone was present between the particles and at the outside of the implants, while some
mineralized cartilage remained between the particles (Figure 4D).
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Figure 5.
Results of the semi-quantitative histomorphometrical analysis, showing mean and standard deviation for the different
implants (n=3 for all materials and time periods). In addition, significant statistical differences are depicted (t-test).
6.3.2 Light microscopy, tissue rating
Results of the tissue rating are depicted in figure 5. The results show that at 5 days (hyper-
trophic) cartilage was present in the Ti-CaP and IBM implants. In the PPHAP implants
only undifferentiated mesenchymal cells were found, whereas in the FGM implants no
mesenchymal cells were seen at all. At this time a significant difference in tissue response
existed between the Ti-CaP and PPHAP (P<0.05, t-test), the Ti-CaP and FGM implants
(P<0.01, t-test), and the IBM and FGM implants (P<0.05, t-test). At 7 days, cartilage
mineralization and bone formation had occurred. Although rating appears to indicate that
at 7 days the bone formation process had proceeded further in the IBM and PPHAP speci-
mens (cartilage and bone) than in the Ti-CaP and FGM (cartilage maturation, mineraliza-
tion), the statistical analysis revealed no differences. At 9 days, the Ti-CaP, IBM and
PPHAP rating showed the formation of bone and cartilage; no difference existed between
these materials. The FGM implants had a significantly lower score (cartilage) than Ti-CaP
(P<0.05, t-test), IBM (P<0.05, t-test) and PPHAP (P<0.05, t-test).
6.4 Discussion and conclusion
The biocompatible response of IBM and Ti-CaP as well as the occurrence of inflammatory
cells inside all implants corroborate the results of previous studies.6,9,10,19,20 Also in
agreement with earlier investigations, was our observation that all BMP-carrier combina-
tions initiated an osteoinductive response.6,7,9,10,21,22,23 On the other hand, we observed a
difference in the amount and time-dependent occurrence of cartilage and bone. 
Subjectively, by 9 days the IBM implants yielded the largest amount of bone (IBM >
PPHAP ~ Ti-CaP > FGM). This corresponds with another study in which IBM, FGM
and PPHAP implants were compared.9 This finding is supported by the observation that
collagen, the major constituent of IBM, and calcium phosphates have been proven to have a
high affinity for BMPs, although they show different release profiles.24,25 Unfortunately, no
data are currently available on the exact rhBMP-2 release profile of various carrier ma-
terials. Nevertheless, the affinity of titanium for BMPs has been shown to be lower than
the affinity of calcium phosphates.26 Further, we know that the in vivo osteoinductive
activity is positively correlated with the amount of BMP retained at the implantation site.
24,25 In addition to the release profile, other factors like carrier volume and tissue reaction
might contribute to the differences in the amount of bone formation.27,28
For IBM, PPHAP, and FGM the bone formation process proceeded faster in the
present study than in earlier studies.9,10 We believe that this is due to the concentration and
activity of recombinant BMP-2 used. In previous studies 300 µg (0.5 unit) of a partially
purified BMP fraction (S-300) was used for IBM, PPHAP, and FGM.9 In the present study
and in a previous titanium study, we used 8.7 µg rhBMP-2 which has a higher activity (2 µg
= 1 unit).29 It is well known that higher concentrations of BMP do not only increase the
amount of bone formation but also result in earlier cartilage and bone formation.30
The process of bone formation in all our BMP-loaded samples occurred with the
presence of chondrogenesis. However, the amount and time-dependent occurrence of
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cartilage varied among the carriers, with IBM apparently yielding the largest amount of
cartilage. In addition, in IBM and Ca-P-coated Ti-mesh cartilage formation preceded bone
formation; this was not seen for PPHAP. For IBM, FGM and Ti-CaP the presence of
chondrogenesis agrees with previous studies.6,9,10 On the other hand, for PPHAP the
findings do not correspond with previous studies;9,29 in the latter no cartilage was observed
between 1 and 4 weeks. In addition, the amount of cartilage, as quantified by type II
collagen content (the predominant collagen type present in cartilagenous matrix), has been
reported to be high in IBM and FGM, while PPHAP showed no type II collagen at all (at 3,
5, days and at 1, 2, 3, and 4 weeks).9 Therefore, the present study supports earlier findings
that the bone formation process in IBM and FGM is characterized by an endochondral
ossification-like process. Based upon the morphological analysis, the bone formation
process in Ti-CaP and PPHAP also seems to be characterized by an endochondral ossifica-
tion-like process.
Vascularization is considered to be a crucial step in ectopic bone formation.31 For
example, anti-angiogeneic agents like TNP-470 have been shown to inhibit rhBMP-2-
induced ectopic osteogenesis.32 Some researchers ascribe the effect of vasculari-zation to
the supply of osteoblasts.33 Indeed, vascular pericytes, which are undifferentiated cells,
have been shown to be able to differentiate into chondrocytes and osteoblasts in vitro and
can form cartilage and bone in vivo.34 Other studies have shown that a low oxygen concen-
tration favors chondrogenesis, while a higher oxygen concentration supports bone for-
mation.31,35,36,37 Carrier geometry is known to influence the bone formation process.38,39,40
The geometry of the carrier influences vascularization and thereby oxygen supply. Conse-
quently, carriers which induce bone formation independent of cartilage have been hypo-
thesized to provide a higher oxygen supply due to geometry.8 Recently, a similar obser-
vation has been made for a scaffold composed of bioglass fibers [composed of CaO, P2O5,
and SiO2 (CPSA)].41 Bone formation was observed all around a porous ball-shaped CPSA
implant, whereas scant bone formation was observed in a less porous bundle-shaped
implant. Further research revealed that Vascular Endothelial Growth Factor (VEGF)
receptors (Flt-1 and KDR) were expressed in the porous ball-shaped implants, but not in
the bundle-shaped implant. Again, this finding supports the relationship between neovas-
cularization and osteogenesis. 
Consequently, we hypothesize that the differences in the time-dependent occurrence
and amount of cartilage between the different carrier materials in our study are caused by
differences in vascular-inducing geometry. A greater vascular-inducing geometry leads to
early osteogenesis and the early disappearance of cartilage, while a vascular-inhibiting
geometry leads to a higher amount of cartilage, which remains for a longer time. Therefore,
the terms “bone-directing” and “cartilage-directing” carrier might be appropriate for the
former and the latter, respectively.11,41 In view of this, PPHAP and Ca-P-coated titanium
are bone-directing carriers, while FGM is a cartilage-directing carrier.
It has to be emphasized that, irrespective of the different amounts and different time-
dependent occurrence of cartilage for various carriers, the final product of BMP-induced
osteogenesis is always bone without cartilage.6,8,9,10,11,41 The presence of bone and the
absence of cartilage has been described to occur at 2 weeks for Ti-CaP and PPHAP and at 3
weeks for IBM;6,9,42,43,44 for FGM it has been reported to occur at 5 weeks.10 Again, it has to
be emphasized that the BMP concentration also influences the speed of bone formation.30
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Nevertheless, a carrier which promotes the induction of high-quality bone, in a short time
interval, is highly desirable for bone reconstructive procedures. 
In summary, we conclude that IBM, CaP-coated Ti mesh, FGM and PPHAP all
provided with rhBMP-2, can induce ectopic bone formation with a cartilaginous phase in a
rat model at short implantation periods. Considering the different nature of the carrier
materials used these findings even suggest that an endochondral ossification-like process is
always present in rhBMP-2 induced osteogenesis, although the amount of cartilage differs.
These differences are believed to be related to the vascular-inducing geometry: a greater
vascular-inducing geometry leads to early osteogenesis and the early disappearance of
cartilage, while a vascular-inhibiting geometry will lead to higher amounts of cartilage,
which remain for a longer time. Therefore, the terms “bone-directing” and “cartilage-
directing” carrier might be appropriate for the former and the latter, respectively.
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7.1 Introduction
Osteoinductive factors like Bone Morphogenetic Proteins (BMPs) or Transforming Growth
Factor-βs (TGF-βs) provided to porous carrier materials have been used to improve healing
in bone defects as well as around medical and dental implants. At present more than 14
different BMPs are known (BMP-1 to BMP-15). In mammals 3 isoforms of TGF-β have
been described: TGF-β1, TGF-β2 and TGF-β3. BMPs and TGF-βs share a sequence homo-
logy of 40 to 50%. BMPs can be isolated from bone; TGF-βs can be isolated from both bone
and platelets. Alternatively, they can be produced by transfected cells using recombinant
DNA techniques, the so-called recombinant (human) BMPs or TGF-βs. BMPs are known
to induce bone formation in both heterotopic and orthotopic sites. In addition, TGF-β1 and
TGF-β2 have also been shown to stimulate osteogenesis in orthotopic sites.1,2 However,
TGF-β does not induce bone formation in a rodent ectopic assay model as shown by
Sampath et al.,3 although, Ripamonti et al.4 did report the induction of heterotopic ossi-
fication by TGF-β1 in babboons. Considering the final application of dental and medical
implants we decided to focus on the effect of TGF-β on implant related bone healing. 
A prerequisite to the use of osteoinductive growth factors is a suitable carrier or scaf-
fold material. Carrier materials currently used to support bone healing are polymers or co-
polymers, mainly poly(α-hydroxyl) acids) and collagen. For TGF-β1, mainly demineralized
bone matrix (DBM), or Guanidine-treated DBM (GuDBM) has been used as a carrier
material. Another candidate material for bone stimulating-factors is sintered titanium (Ti)
fiber mesh material. The advantages of this material are that it can be applied directly on,
for example titanium implants. This allows its use even in load-bearing situations. Tita-
nium is currently being applied in surgical practice because of its excellent mechanical
characteristics in terms of stiffness and elasticity, bone compatibility and ease of use during
surgery.
Ti-mesh has been shown to be an effective carrier for both osteogenic cells and BMPs
in ectopic bone formation in vivo.5,6 In addition, the osteogenic and osteoinductive proper-
ties of a titanium fiber mesh scaffold can be further enhanced by the application of an
additional thin calcium phosphate (Ca-P) coating.5,6 Thin RF magnetron sputtered calcium
phosphate coatings have also been shown to enhance the osteoconductive properties of
titanium implants.7-9
The objective of the study reported here was to investigate: (1) whether Ti-fiber mesh
loaded with rhTGF-β1 can induce bone formation in an orthotopic site; (2) the osteocon-
ductive properties of Ti-fiber mesh; (3) the influence of a Ca-P coating on the osteocon-
ductive properties of Ti-fiber mesh.
7.2 Materials and Methods
7.2.1 Implant preparation, carrier material
Bekaert N.V. (Zwevegem, Belgium) provided the Ti-fiber mesh implants. The mesh im-
plants were fabricated by interengaging and intertwining a multiplicity of commercially
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pure titanium fibers with a fiber diameter of 50 µm. After compression against a solid
Al2O3 rod, the fiber structures were sintered to bond the fibers at their points of contact. In
this way, a hollow, cylindrically shaped structure was obtained. The volumetric porosity of
the titanium mesh was 86%. One-cm-long tubes, with an outer diameter of 8 mm and an
inner diameter of 4 mm, were cut to 2-mm-high discs. The implants had a weight of
approximately 40 mg. The central space in each implant was filled with a solid titanium rod
with a diameter of 4 mm and a height of 2 mm. 
All implants were ultrasonically cleaned with 70% ethanol for 15 min. The mesh was
applied as-received (Ti) or provided with a thin (2 µm) Ca-P coating (Ti-CaP) at the outer
surface. The coating procedure was performed using a commercially available RF magne-
tron sputter unit (Edwards ESM 100).10 The target material used in the deposition process
was a copper disc provided with a plasma-sprayed hydroxyapatite coating (CAMCERAM®).
The process pressure was 5 x 10-3 mbar and the sputter power was 400 W. The deposition
rate of the films was 100–150 nm/min sputtering. 
After deposition, all coated specimens were subjected to an additional heat treatment
for 2 h at 500ºC. X-ray diffraction (XRD), Fourier Transform Infrared spectroscopy (FTIR)
and Energy Dispersive Spectroscopical (EDS) analysis showed that this resulted in the
coatings having a crystalline apatite structure with a Ca/P ratio of 1.8–2.0. Before use, im-
plants were sterilized by autoclaving for 15 min at 121°C. A total of 28 implants were
prepared: 19 Ti and 9 Ti-CaP.
7.2.2 Implant preparation, Transforming Growth Factor beta-1
The growth factor used in the present study was recombinant human Transforming
Growth Factor beta-1 (rhTGF-β1) (R&D Systems Inc. Minneapolis, Minn., USA). RhTGF-
β1 was produced by Chinese hamster ovary (CHO) cells.
Before being loaded with rhTGF-β1, all materials were treated for 5 min with RF glow-
discharge (Harrick PDC-3XG, Argon, 0.15 Torr) to enhance wettability. Ten of the non-
coated meshes were loaded with rhTGF-β1. The rhTGF-β1 was dissolved in sterile 4 mM
HCl containing 1 mg/ml bovine serum albumin (BSA). A dose of 2 µg rhTGF-β1 was
applied to each of the 10 Ti-fiber mesh implants. Prior to implantation, 40-µl-aliquots of the
rhTGF-β1 solution were added to each Ti-fiber mesh implant, which was placed in an
Eppendorf® tube. The constructs were then lyophilized and kept at 4°C until implantation. 
7.2.3 In vitro rhTGF-β1 release
In vitro rhTGF-β1 release of the loaded implants was measured using an Enzyme-Linked
Immunosorbent Assay (ELISA) using a commercially available test kit (Promega® Benelux
b.v., Leiden, the Netherlands). One implant was used loaded with 2 µg rhTGF-β1. The
implant was placed in 1 well of a 24-well plate, and 2 ml minimal essential medium (α-
MEM, Gibco BRL, Life Technologies B.V., Breda, The Netherlands) containing 10% FCS
and gentamycin was added to the well. After that, the 24-well plate was placed in an incu-
bator (humidified atmosphere of 95% air, 5% CO2 at 37°C). At 15 min, 30 min, 1 h, 2 h, 4 h,
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24 h and 1 week, two 50 µl-samples were taken out of the well. Subsequently, 100 µl α-MEM
solution was added to the well. Samples were kept at 4°C until the time of meas-urement.
Duplicate samples were prepared and diluted, and the ELISA test was performed according
to the Promega® protocol. Finally, the absorption was read using a microplate reader set at a
wavelength of 450 nm. All measurements were corrected for the dilution that had occurred
during sampling.
7.2.4 Experimental animal study
For implantation, 18 healthy skeletally mature male New Zealand White rabbits with a
weight between 2.5 and 3.4 kg were used . The animals were housed separately in cages.
Surgery was performed under general inhalation anaesthesia. The anaesthesia was induced
by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl citrate and 10 mg/ml
fluanisone) and atropine, and maintained by a mixture of nitrous oxide, isoflurane and
oxygen through a constant volume ventilator. The peri-operative infection risk was reduced
by giving the rabbits antibiotical prophylaxis [Baytril® 2.5% (Enrofloxacin), 5–10 mg/kg]. 
For the insertion of the implants, the animals were placed in a ventral position. The
skull was shaved, washed and disinfected with povidone-iodine. A longitudinal incision
was placed through the skin in the midline over the parietal skull. The skin and subcuta-
neous tissue were separated from the periosteum using blunt dissection. After that, a
longitudinal incision was made through the periosteum. Subsequently, the periosteum was
elevated from the underlying skull bone. After exposure of the parietal calvarial bone, one
full-thickness skull defect was drilled on each side using a 7.3 mm-trephine (Merck®) drill
at low rotational speed with continuous cooling with saline (Figure 1A, B). A cylindrical
guide, which was used to avoid damage to the underlying dura, surrounded the trephine.
The implants were inserted (Figure 1C), and the periosteum was closed over the implant
using 3-0 Vicryl® sutures. Subsequently, the skin was closed using a subcuticular Vicryl®
3-0 suture. 
In this way, a total of 27 implants were placed: 9 non-coated titanium fiber mesh
implants (Ti), 9 Ca-P-coated titanium fiber mesh implants (Ti-CaP), and 9 non-coated
titanium fiber mesh implants loaded with rhTGF-β1 (Ti-TGF-β1). In addition, 9 defects
were left empty and used as controls. Nine rabbits received one Ti and one Ti-CaP implant
and 9 rabbits recieved one Ti-TGF-β1-implant with an unfilled defect at the contralateral
side. The rhTGF-β1-loaded implants were not combined with other implants in the same
animal in order to avoid crossover effects from the growth factor.
In addition, in 8 rabbits quadruple fluorochrome labeling was performed. Fluoro-
chrome labels, i.e. tetracycline (yellow), alizarin-complexone (red), calcein (green), and
tetracycline (yellow) were subcutaneously administered at 1, 3, 5, and 7 weeks postopera-
tively, respectively. The treatment dose was 25 mg/kg body weight for all labels.
At 8 weeks post-implantation, euthanasia was performed with an overdose of Nem-
butal® (pentobarbital). Subsequently, the implants with the surrounding tissues were re-
trieved en bloc and prepared for light-microscopical evaluation. In this study, national
guidelines for the care and use of laboratory animals were observed.
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7.2.5 Light microscopy (subjective and histomorphometry)
Implants for histology were fixed in 4% phosphate-buffered formaldehyde solution (pH =
7.4), dehydrated in a graded series of alcohol and embedded in methylmethacrylate. After
polymerization, 10-µm-thick longitudinal sections were made using a modified microtome
technique.11 Light-microscopical sections were stained with basic fuchsin and methylene
blue. These sections were evaluated with a light microscope (Leica®). 
Two slightly thicker sections (30 µm) were made per implant for fluorochrome label-
ing analysis. These sections were left unstained and examined with a fluorescence micro-
scope (Leica®) equipped with an excitation filter of 470-490 nm. 
Light and fluorescence microscopical analysis consisted of a full morphological
description of the tissue response to the different implants. In addition, image analysis was
performed on all sections to evaluate the ingrowth of and to quantify the amount of newly
formed bone. For this purpose a Leica® Qwin Pro-image analysis system was used. 
Therefore, at least 3 histological sections per implant were digitalized at low magni-
fication. For this purpose one digital image was made at both the left and the right side of
the solid titanium core (Figure 2A,B). In these digital images, the computer detected the
bone tissue and titanium. The computer then measured the thickness of the Ti-fiber mesh
– i.e. the distance from the most peripheral titanium fiber up to the solid titanium core
(Figure 2C). Subsequently, the absolute bone ingrowth, the distance from the most
peripheral titanium fiber up to the front of the newly formed bone in the fiber mesh, and
the bone surface area were measured by the computer (Figure 2D). In addition, the com-
puter calculated the area of this region of interest (ROI) (Figure 2D). From these values the
bone ingrowth percentage (the index of the absolute bone ingrowth and Ti-fiber mesh
125
Bone formation in Transforming Growth Factor beta-1-loaded titanium fiber mesh implants
Figure 1. 
Figure showing (A,B) the drilling of the defect and (C) insertion of the Ti-fiber mesh implant. 
thickness) and bone fill percentage (the index of the bone surface area and the area of ROI)
were calculated. Per section, the average was taken of the values from each side. 
7.2.6 Statistical methods
A paired t-test was applied to evaluate the differences between the Ti-CaP and Ti implants
since the implants were always combined in the same animal. An unpaired t-test was used
to evaluate differences between Ti-TGF-β1, and Ti-CaP and Ti implants since the Ti-TGF-
β1 implants were not combined with the other two implant types in the same animal.
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Figure 2.
Figure showing the method of the histomorphometrical analysis. (A, B) One digital image was made at both the left and
the right side of the solid titanium core. The bone and Ti-fiber mesh were detected. (C) The thickness of the Ti-fiber
mesh was measured. (D) The absolute bone ingrowth and the bone surface area were measured by the computer. In
addition, the computer calculated the bone ingrowth percentage and bone fill percentage (see text). 
7.3 Results
7.3.1 In vitro rhTGF-β1 release
The results of the rhTGF-β1 release are depicted in Figure 3. A rapid release was observed
during the first 2 h in which more than 70% of the total dose of rhTGF-β1 was released.
Following this first peak, a decline in the level of rhTGF-β1 occurred at 4 h. After 1 week
almost 80 % of the theoretical initial 2-µg dose has been released in the medium.
7.3.2 Experimental animal study
During the experiment one rabbit died due to a broken spine. Hence, one Ti-TGF-β1 im-
plant and one control were lost. The other rabbits remained in good health and did not
show any wound complications. At the end, a total of 26 implants (9 Ti, 9 Ti-CaP and 8 Ti-
TGF-β1 implants), and 8 controls were retrieved. At explantation, no inflammatory signs or
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Figure 3. 
Graph showing the in vitro
rhTGF-β1 release.
(A) A burst release can be seen
in which the majority of the
rhTGF-β1 was released by 2 h,
(B) followed by a slow release
up to 1 week. 
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Figure 4. 
adverse tissue reaction could be seen. For the Ti-TGF-β1 implants, bone formation could
already be observed macroscopically.
7.3.3 Light microscopy, subjective
Light microscopical analysis of the sections revealed that all implants showed various levels
of bone formation at 8 weeks post-implantation. The former defect edge was still visible. In
and around all specimens, hardly any inflammatory cells were seen.
In two out of the eight control defects complete closure occurred (Figure 4A). The
newly formed bone had a trabecular appearance with bone marrow lined by periosteum.
On the other hand, the newly formed bone was very thin. In the non-closure defects
(Figure 4B) the center of the defect area was filled with fibrous tissue and capillaries.
In the Ti and Ti-CaP implants bone had grown into the fiber mesh from the edge of
the former defect and from the overlying periosteum (Figure 4C). However, penetration
inside the mesh porosity was limited. Only a part of the porosity was filled with bone. Bone
was present in close contact to the titanium fibers. Inside the mesh material, the newly
formed bone had a trabecular appearance (Figure 4D). Some areas with bone marrow
could be observed. The remaining non-bony part of the porosity was filled with fibrous
tissue and capillaries. In some specimens bone guidance had occurred from the periosteum
and dura over the top and/or bottom part of the solid titanium rod. Hardly any inflamma-
129
Bone formation in Transforming Growth Factor beta-1-loaded titanium fiber mesh implants
Figure 4. 
(A) Undecalcified section of a control defect left empty. In 2 defects closure occurred (orig. magn. 1.6x). 
(B) Undecalcified section of a control defect left empty. In 6 defects no closure occurred (orig. magn. 1.6x). 
(C) Undecalcified section of a non-coated Ti-mesh implant at 8 weeks post-implantation. Only partial penetration
of bone can be observed (Ti = solid titanium rod). Ca-P-coated Ti-mesh implants show the same histological image
(orig. magn. 2.5x). 
(D) Undecalcified section of a non-coated Ti-mesh implant at higher magnification. The Ti-CaP implants have the
same morphological appearance. Only a part of the porosity is filled with bone. Bone is present in close contact to the
titanium fibers. Inside the mesh material, the newly formed bone has a trabecular appearance; some areas with bone
marrow can be observed. The other part of the porosity is filled with fibrous tissue and capillaries without an
intervening fibrous capsule around the titanium fibers. Hardly any inflammatory cells could be seen (orig. magn. 20x). 
(E) Undecalcified section of a non-coated Ti-mesh loaded with TGF-β1. Bone has grown into the entire mesh up to
the solid titanium core (orig. magn. 2.5x). 
(F) Undecalcified section of a non-coated Ti-mesh loaded with TGF-β1. The bone has a trabecular appearance and
is present in close contact with the Ti-fibers without an intervening fibrous tissue layer. In addition hemopoietic bone
marrow-like tissue (BM) can be observed (orig. magn. 20x). 
Figure 5. 
(A) Non-stained undecalcified section of a non-coated Ti-mesh. This section is viewed with a fluorescence
microscope. This section shows that bone formation started from the former defect edge (orig. magn. 10x). 
(B) Non-stained undecalcified section of a non-coated Ti-mesh. This section is viewed with a fluorescence
microscope. In both the Ti-CaP and Ti-implants, the accumulation sequence of the various labels, T = tetracylin (1 week),
A = alizarin-complexon (3 weeks), C = calcein (5 weeks) and T’ = tetracylin (7 weeks) label, indicates that bone guidance
has occurred, starting from the former defect edge (orig. magn. 20x). 
(C) Non-stained undecalcified section of a non-coated Ti-mesh loaded with rhTGF-β1. This section is viewed with
a fluorescence microscope. Bone formation started in the porosity of the mesh (orig. magn. 10x). 
(D) Non-stained undecalcified section of a non-coated Ti-mesh loaded with rhTGF-β1. This section is viewed with
a fluorescence microscope. The accumulation sequence of the labels T = tetracylin (1 week), A = alizarin-complexon
(3 weeks), C = calcein (5 weeks) and T’ = tetracylin (7 weeks) label, (see Figure 5B) indicates that bone formation has
started in the center of a pore growing towards the Ti-fibers (orig. magn. 20x).
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tory cells could be seen. Subjective light microscopical analysis revealed no differences in
histological appearance and bone ingrowth between Ti and Ti-CaP implants.
In the Ti-TGF-β1 implants bone had grown into the fiber mesh up to the solid
titanium core (Figure 4E) without an intervening fibrous tissue layer (Figure 4F). Exten-
sive trabecular bone and hemopoietic bone marrow-like tissue formation was observed.
Bone was present throughout and surrounding the implant in close contact with the
titanium fibers. At the upper part, the newly formed bone was lined by the periosteum. In
the majority of the specimens the bone also covered the top and bottom part of the solid
titanium rod. The bone appeared to be more dense than in the Ti-CaP and Ti implants.
7.3.4 Fluorochrome labeling
In all specimens fluorochrome labels were clearly visible. In the Ti-CaP and Ti implants
bone formation had mainly started from the wound edges (Figure 5A). In these implants,
the accumulation sequence of the labels revealed that bone guidance had occurred from the
wound edges (Figure 5B). In the Ti-TGF-β1 implants bone formation had mainly started in
the in the porosity of the mesh (Figure 5C). Fluorochrome labeling also revealed that in
these implants bone formation started in the center of a pore and proceeded in a centrifugal
manner towards the titanium fibers (Figure 5D). In addition, some bone had been formed
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Figure 6.
Figure showing the results of the bone ingrowth (A), bone surface area (B) and bone fill (C). In addition, the results of
the paired t-test comparing Ti with Ti-CaP and the t-tests comparing Ti with Ti-TGF-β1 and Ti-CaP with Ti-TGF-β1 are
shown. Significant differences between Ti and Ti-TGF-β1 (•) and Ti-CaP and Ti-TGF-β1 (*) are marked. No significant
difference was found between Ti and Ti-Cap implants for any parameter (P>0.05).
starting from the periosteum and dura. This bone was predominantly observed over the
central solid titanium core.
7.3.5 Light microscopy, image analysis
The results of the histomorphometrical measurements are depicted in Figure 6. In the
TGF-β1-treated implants average bone ingrowth was 97%, whereas in the non-TGF-β1-
treated implants the average ingrowth was 57% for the Ca-P-coated implants and 54% for
the non-coated Ti ones (Figure 6A). Total bone surface area was 1.37 mm2 in the TGF-β1-
treated implants and 0.57 mm2 in both the Ti-CaP and Ti implants (Figure 6B). Bone fill
percentage was 36% in the rhTGF-β1-treated implants and 26% in both the non-TGF-β1-
treated Ti-CaP and Ti implants (Figure 6C). 
Results of the statistical evaluation are also depicted in Figure 6. Statistical evaluation
revealed significant differences between the Ti-TGF-β1 implants and the non-loaded (Ti
and Ti-CaP, respectively) implants for bone ingrowth percentage, bone surface area and
bone fill percentage. No differences were observed between the Ti and Ti-CaP groups for
these parameters.
7.4 Discussion and conclusion
In our in vitro release study we found a burst release during the first 2 h in which more
than 70% of the TGF-β1 was released. Other investigators, using different carrier ma-
terials, have also observed this kind of burst release for rhTGF-β1.12-14 The initial burst
release was followed by a slow release, which led to a total release of almost 80% of the
rhTGF-β1 by 1 week. This indicates that approximately 20% of the total rhTGF-β1 was still
present on the titanium fiber mesh by that time. 
Our histological findings corroborate with our earlier findings6 and confirm again that
Ti-fiber mesh is highly bone compatible as demonstrated by the ingrowth of bone and
absence of inflammatory cells in all implants. 
With respect to the study design, our purpose was not to create a critical size defect as
illustrated by the two control defects that did show complete healing within 8 weeks. Our
intent was just to show how titanium fiber mesh can be applied to support bone healing. In
addition, in this study we chose not to combine the use of TGF-β1 with a thin Ca-P-coating.
From an earlier study we know that the use of an additional Ca-P-coating enhances BMP-
induced bone formation.6 Similarly, we assume that bone formation in rhTGF-β1-loaded
Ti-mesh implants might be enhanced by the use of an additional Ca-P-coating. 
The histological findings also showed that both Ca-P-coated and non-coated implants
allowed bone ingrowth of more than 50% into the mesh porosity. Apparently the ad-
ditional deposition of a thin calcium phosphate coating on the Ti-mesh did not have a
stimulatory effect on its bone conductive properties at 8 weeks. This finding appears to
contradict earlier results by our group where a favorable effect of RF magnetron sputtered
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Ca-P-coatings on the implant-bone response was observed.7-9 However, in the previous
studies the coatings were deposited on solid titanium implants, whereas in the study
presented here the coating was applied on a porous structure. We know that the RF magne-
tron sputter process does not allow complete coverage of the titanium fibers inside the
porous “disc-shaped” mesh. Therefore, the resulting surface coating can be insufficient to
improve bone conduction into the implant porosity. 
Although the composition and design of our fiber mesh implants differs, the observed
beneficial effect of rhTGF-β1 is in agreement with the results of many other studies.12,13,15-30
In vivo within a certain range, a dose-responsive effect exists for TGF-β1 with respect
to bone induction. However, higher doses do not necessarily generate more bone formation
as there is an optimum dose. For example, Beck et al.15,16 found that 2 µg of TGF-β1 applied
in a 3% methyl cellulose gel is able to regenerate a critical size defect in a rabbit skull in 28
days; 0.1- and 0.4-µg dose showed less bone formation. In the same model no difference
was found between a 1-µg and 5-µg rhTGF-β1 dose. In contrast, very low doses, 10 and 25
ng, mixed through a calcium phosphate cement and implanted into rat cranial defects,
resulted in minimal bone growth.31 Similarly, in a dog radial defect model a 10-ng dose
combined with a poly(lactic-co-glycolic acid) carrier did not show any response.32 Consider-
ing the available literature and selected experimental animal we decided to apply 2 µg of
rhTGF-β1 in our fiber mesh implants. Future studies have to demonstrate whether a de-
crease in concentration will result in the same bone response. 
Another striking observation was that the Ti and Ti-CaP implants still supported a
bone ingrowth of more than 50% (about 1 mm) at 8 weeks post-implantation. In the study
presented here, the thickness of the fiber mesh surrounding the solid central titanium core
was 2 mm. Consequently, it can be supposed that in implants provided with a fiber mesh
thickness of 1 mm or less, 100 % ingrowth can be obtained. On the other hand, bone fill
was higher in the rhTGF-β1-loaded implants than in the non-rhTGF-β1-loaded implants.
These results can be explained by a more homogenous distribution of bone in the Ti-TGF-
β1 implants. In these implants the entire mesh porosity was filled with bone. This is also
illustrated by the more than twofold increase in bone surface area compared to the non-
rhTGF-β1-loaded implants. 
Further, the fluorescent labeling study revealed that the process of bone formation was
different between TGF-β1-loaded and non-loaded implants. In TGF-β1-loaded implants the
newly formed bone was deposited in a centrifugal manner, starting in the porosity and
growing towards the surface of the carrier. This observation was similar to the one made in
previous studies in which we loaded the Ti-fiber mesh with BMPs or osteogenic cells. For
bioactive materials, like hydroxyapatite loaded with BMP, so-called bonding osteogenesis,
i.e. bone formation starting at the surface area and proceeding away from the surface, has
been reported.33 Since titanium is not a bioactive material this explains the absence of
bonding osteogenesis. 
Despite the favorable effect of TGF-β on bone healing, we have to emphasize that
some concern exists about the safety of this growth factor in human administration. Several
conditions indicative of fibrosis a.o., renal and hepatic diseases, are associated with in-
creased TGF-β1 expression.34,35,36 Studies have shown that transgenic animals with in-
creased plasma levels of TGF-β1 develop renal37,38 and liver disease.38 In animals, systemic
injection with high doses of TGF-β2 can also lead to renal fibrosis and a decline renal
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function.39,40 In humans, one clinical trial has demonstrated that systemic administration
of TGF-β2 can lead to a reversible decline in renal function.41 However, these observations
do not prove a causal connection between local administration of low doses of TGF-β1 and
adverse renal and hepatic effects. Nevertheless, it is important that a therapeutic index is
established for TGF-β, allowing a rational approach for safe delivery and dosage of this
growth factor in local therapeutic use. 
In summary, we conclude that Ti-fiber mesh loaded with TGF-β1 can indeed stimulate
orthotopic bone formation in a rabbit cranial defect model. Titanium fiber mesh has good
osteoconductive properties. A thin Ca-P coating, as applied in this study, does not seem to
further enhance the bone-conducting properties of a titanium scaffold material at pro-
longed implantation periods. Although these results hold some promise for clinical ap-
plication, care has to be taken. More knowledge has to be obtained about the safety of
rhTGF-β1 since systemic as well as crossover effects can occur. 
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Bone formation in
Transforming Growth Factor beta-1-coated
porous poly(propylene fumarate) scaffolds
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8.1 Introduction
A prerequisite for the use of osteoinductive growth factors or osteogenic cells to regenerate
bone tissue is a suitable scaffold. Scaffold materials currently under investigation are
polymers or co-polymers, mainly poly(α-hydroxyl acids), ceramic materials (e.g. hydroxy-
apatite and tricalcium phosphate), collagen, and titanium. 
A recently developed scaffold material is the polyester poly(propylene fumarate)
(PPF). This material has been shown to be biodegradable.1-3 The degradation products are
the non-toxic molecules fumaric acid and propylene glycol as well as excretable molecules
related to the crosslinking of the polymer.4 Another advantage of this viscous polymer is
that it can be crosslinked into a solid with relatively low levels of heat release.5 This allows
PPF to be injected into a defect or fabricated into a scaffold prior to implantation.6 In
previous research, a chemical crosslinking method has been used. This crosslinking method
uses the monomer N-vinyl pyrrolidone (NVP), the radical initiator benzoyl peroxide (BP),
and the accelerator N,N dimethyl-p-toluidine (DMT).5,7 A drawback of this method is that
NVP and DMT may be potentially toxic. A photoinitiated crosslinking method has also
been developed. In this method, only the photoinitiator bis(2,4,6-trimethylbenzoyl) phenyl-
phosphine oxide (BAPO) and long wavelength ultraviolet (UV) light are used to cross-link
the viscous polymer into a solid. This method eliminates the potential toxicity associated
with the use of a crosslinking monomer and accelerator as well as proceeds with low levels
of heat release.8,9
Porous PPF scaffolds are prepared by photocrosslinking the PPF polymer around a
water soluble porogen (NaCl). Afterwards, the composites are placed in water, allowing the
soluble NaCl to dissolve and revealing a porous scaffold. Photocrosslinked PPF scaffolds
have been shown to generally possess an interconnected pore structure when NaCl porogen
content weight exceeds 80 wt% at synthesis. Scanning electron microscopy has shown that
pore morphology mostly is related to the porogen shape and content, not the photoinitiated
crosslinking process.9
Currently, prewetting is the standard treatment of scaffolds before their in vitro or in
vivo use.10 Physico-chemical techniques, like RF glow-discharge treatment, are also
frequently used to enhance biomaterial absorption of moisture. Since PPF is hydrophobic, it
is difficult to coat prewetted PPF scaffolds with proteins in a controlled manner. Therefore,
RF glow discharge appears to be a more appropriate technique for the coating process for
PPF scaffolds. 
An approach to improve the tissue response to biomaterials involves the use of organic
coatings of proteins (e.g., collagen, laminin, or fibronectin), glycoproteins, and peptides (e.g.,
RGD peptides). These organic coatings are known for their beneficial effect on cell
attachment but have also been applied to modify the in vivo biological response.11-20
The objectives of the study reported here were to investigate (1) whether PPF coated
with rhTGF-β1 can induce bone formation in an orthotopic site and (2) the effect of a
fibronectin coating on the bone response to porous PPF. 
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8.2 Materials and Methods
8.2.1 Preparation of porous poly(propylene fumarate) scaffolds
PPF with a number average molecular weight (Mn) of 1700 Da and a polydispersity index
(PI) of 1.6 (as determined by gel permeation chromatography) was synthesized for this
study.9 Poly(propylene fumarate) scaffolds were photocrosslinked using long wavelength
ultraviolet light and the photoinitiator bis(2,4,6-trimethylbensoyl) phenylphosphine oxide
(BAPO, Ciba Specialty Chemicals, Tarrytown, NY) in the following manner. One gram of
BAPO was dissolved in 10 ml methylene chloride to form the initiator solution. The PPF
was first warmed in an oven at 60°C to soften the viscous polymer and then mixed with
the initiator solution (0.05 ml/g PPF). The leachable porogen, 80 wt% of 300–500 µm
NaCl crystals, was subsequently added to the PPF/BAPO mixture, forming a stiff paste.
This paste was packed into a cylindrical polystyrene mold (6.3 mm diameter and 2.0 mm
height). The samples were then exposed to ultraviolet light for 30 min at a distance of
approximately 15 cm. The UV light source was an Ultralum (Paramount, CA) ultraviolet
light box outfitted with four 15W long wavelength UV bulbs. The total light emission
covers a range of long UV wavelengths (320–405 nm), with a peak at 365 nm and an in-
tensity of 4 mW/cm2 at 15 cm. BAPO absorbs wavelengths below 400 nm, with a general
increase in absorption as the wavelength decreases to 200 nm (Ciba Specialty Chemicals). 
Crosslinked samples were removed from the mold and then soaked in water for three
days to remove the NaCl porogen. These samples were dried, first with an absorbent cloth
and then with 24 h of vacuum drying. The samples were stored under nitrogen at 4°C until
sterilization by ethylene oxide gas exposure (Anprolene Automatic Ventilated Sterilizer,
Anderson Products, Chapel Hill, NC). A total of 37 disc shaped implants were prepared,
each approximately 6.3 mm in diameter, 2.0 mm in height, 20 mg in weight, and approxi-
mately 70% porous with a pore size of 300–500 µm.9
8.2.2 Implant preparation
A day before implantation, nine implants were removed from their sterile bags and pre-
wetted with 70% ethanol in 2 ml vials under sterile conditions.10 To remove air from the
pores of the samples, a vacuum was pulled above the ethanol using a 50 ml syringe. After
20 min, the ethanol was removed and the samples were washed twice with sterilized
distilled, deionized water. These samples were stored in distilled, deionized water and
under sterile conditions at 4°C until implantation. 
An additional twenty eight PPF scaffolds were removed from their sterile bags and
treated for 5 minutes with radio frequency glow discharge (Gd) (Harrick PDC-3XG, Argon,
0.15 Torr) to enhance wettability. Nine of these samples, undergoing no further treatment,
were stored in vials under sterile conditions at 4°C until implantation. 
Ten of these glow-discharged porous PPF implants were coated with human Trans-
forming Growth Factor beta-1, rhTGF-β1 (R&D Systems Inc. Minneapolis, Minn., USA),
which was produced by Chinese hamster ovary (CHO) cells. The rhTGF-β1 was dissolved
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in sterile 4 mM HCl containing 1 mg/ml bovine serum albumin (BSA). A dose of 30 µl of
the HCl solution, containing 2 µg of rhTGF-β1, was applied to each of the 10 PPF implants.
The constructs were subsequently lyophilized and then stored under sterile conditions at
4°C until implantation. 
Finally, the last nine glow discharged porous PPF scaffolds were coated with human
plasma fibronectin. Lyophilized human plasma fibronectin (Sigma Aldrich Chemie b.v.,
Zwijndrecht, the Netherlands) was dissolved in PBS at a concentration of 100 µg/ml. A
dose of 40 µl of the PBS solution, containing 4 µg of fibronectin, was added to each PPF
implant. The constructs were subsequently lyophilized and then stored under sterile
conditions at 4°C until implantation. 
8.2.3 In vitro rhTGF-β1 release
The in vitro release of rhTGF-β1 from a coated PPF scaffold was measured with a
commercially available enzyme-linked, immunosorbent assay (ELISA) kit (Promega® Bene-
lux b.v., Leiden, the Netherlands). One of the rhTGF-β1 coated implants was placed in a 24-
well-plate with 2 ml of minimal essential medium (α-MEM, Gibco BRL, Life Technologies
b.v., Breda, the Netherlands) containing 10% FCS and gentamycin. The 24-well-plate was
placed in an incubator (humidified atmosphere of 95% air and 5% CO2 at 37°C). Two 50
µl samples were extracted at 15 min, 30 min, 1 h, 2 h, 4 h, 24 h, and 1 week. Subsequent to
each of these extractions, 100 µl α-MEM solution was added to replace the lost volume.
Samples were kept at 4°C until the time of measurement. The duplicate samples were
prepared and diluted. The ELISA test was then performed according to the Promega®
protocol. The absorption was read using a microplate reader set at a wavelength of 450 nm.
All measurements were corrected for the dilution that had occurred during sampling. 
8.2.4 Experimental animal study
For implantation, nine healthy, skeletally mature, male New Zealand white rabbits with a
weight between 2.0 and 2.9 kg were used. The animals were housed separately in cages.
Surgery was performed under general inhalation anesthesia. The anesthesia was induced
by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl citrate and 10 mg/ml
fluanisone) and atropine, while maintained by a mixture of nitrous oxide, isoflurane, and
oxygen through a constant volume ventilator. To reduce the peri-operative infection risk,
the rabbits received antibiotic prophylaxis (penicillin). 
The animals were placed in a ventral position for the insertion of the implants. The
dorsum of the skull was shaved, washed, and disinfected with povidone-iodine. A mid-
sagital incision was made through the skin. The skin and subcutaneous tissue were separat-
ed from the periosteum using blunt dissection. A second longitudinal incision was made
through the periosteum, which was then elevated and carefully dissected from the under-
lying skull bone (Figure 1A) before retraction. After exposure of the parietal calvarial
bone, four full thickness skull defects were drilled (two on each side) using a 6.3 mm
trephine (Merck®) drill at low rotational speed with continuous saline cooling (Figure 1B).
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A cylindrical guide surrounding the trephine was used to avoid damage to the underlying
dura. Subsequently, one of each of the four scaffold types was inserted (Figure 1C), the
periosteum was closed over the implant using 3-0 Vicryl® sutures, and the skin was closed
using a subcuticular Vicryl® suture. 
A total of 36 scaffolds were implanted: 9 prewetted PPF scaffolds (PPF-Pw), 9 glow
discharge only treated PPF scaffolds (PPF-Gd), 9 glow discharge treated PPF scaffolds
coated with rhTGF-β1 (PPF-TGF-β1), and 9 glow discharge treated PPF scaffolds coated
with fibronectin (PPF-Fn). The PPF-Pw scaffolds were used as a general control since in
our group pre-wetting is the standard treatment of PPF scaffolds before experimental use. 39
The PPF-Gd scaffolds were used as a control for the TGF-β1-coated specimens. All rabbits
received one implant of each scaffold type. A statistical randomization scheme was used to
locate the scaffolds so that the cranial anatomy would not affect the outcome. 
Additionally, six rabbits received quadruple fluorochrome labeling. The fluorochrome
labels tetracycline (yellow), alizarin-complexone (red), calcein (green), and tetracycline
(yellow) were subcutaneously administered at 1, 3, 5, and 7 weeks postoperatively, respec-
tively. The treatment dose was 25 mg/kg body weight for all labels. 
At 8 weeks postimplantation, euthanasia was performed with an overdose of Nem-
butal® (pentobarbital). The implants with surrounding cranial tissue were retrieved en bloc
and prepared for light microscopy. In this study, the Dutch and the U. S. National Institutes
of Health guidelines for the care and use of laboratory animals were observed. 
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Figure 1.
Figure showing (A) the exposure of the skull bone, (B) the four cranial defects and (C) the inserted porous PPF scaffolds. 
Figure 2.
Image analysis procedure. (A) Three histological sections per implant were digitalyzed at low magnification, allowing
coverage of the entire PPF implant. (B) The computer detected and measured the area of the PPF. (C) The outline of the
PPF area was then designated as the region of interest (ROI). (D) The computer detected and measured the area of bone
within the ROI (bone surface area). From these areas, the analysis program calculated the pore area percentage, the
bone area percentage and pore fill percentage. 
8.2.5 Light microscopy (subjective and histomorphometry)
Implants for histology were fixed in 4% phosphate-buffered formaldehyde solution (pH =
7.4), dehydrated in a graded series of alcohol, and embedded in methylmethacrylate. After
polymerization, 10 µm transverse sections were made using a modified microtome tech-
nique.21 These sections were stained with basic fuchsin and methylene blue for evaluation
by light microscopy (Leica®). 
In appropriate implants, two additional sections of 30 µm were made for fluorochrome
labeling analysis. These sections were left unstained and examined with a fluorescence
microscope (Leica®) equipped with an excitation filter of 470 –490 nm. 
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Figure 3.
Graph showing the in vitro
rhTGF-β1 release.
(A) A burst release can be seen
in which the majority of the
rhTGF-β1 was released by 2 h,
(B) followed by a slow release
up to 1 week [data shown are
mean +/- standard deviation
(SD)]. 
Table 1.
The percent of bone formed in each of nine PPF scaffolds coated with TGF-β1. 
Implant number
1
Bone area %
0.9
2 16.6
3 5.7
4 4.2
5 6.3
6 12.9
7 24.3
8 10.8
9 19.5
With the help of light- and fluorescence microscopy, the tissue response to the differ-
ent implants was fully described. In addition, image analysis was performed on all sections
to evaluate the quantity of newly formed bone. Specifically, three histological sections per
implant were digitized at low magnification, allowing coverage of the entire PPF implant
(Figure 2A). Using a Leica® Qwin Pro image analysis system, the computer detected the
areas of the PPF implant and bone. The outline of the implant area was then designated as
the region of interest (ROI). The image analysis program then measured the surface area of
PPF (FSA) (Figure 2B), area of the ROI (Figure 2C), and surface area of bone (BSA)
(Figure 2D). The analysis program then calculated the percent of pore area ([ROI - FSA]/
ROI), the percent of bone area (BSA/ROI), and percent of pore fill (BSA/ [ROI - FSA]). 
Statistical Analysis
Statistical analysis was performed using a paired t-test. Nine repetitions were performed for
all in vivo studied and all data are reported as means and standard deviations. 
8.3 Results
8.3.1 In vitro TGF-β1 release
The results of the TGF-β1 release are depicted in Figure 3. A rapid release was observed
during the first 2 h, during which almost 55% of the total dose of TGF-β1 was released.
Following this initial peak, a decline in the level of TGF-β1 occurred at 4 h. After 1 wk, the
entire theoretical initial 2 µg dose was observed to have been released. 
8.3.3 Experimental animal study
During the experiment all rabbits remained in good health and did not show any wound
complications. At the end of the 8 wk study, all 36 implants were retrieved. At explan-
tation, no inflammatory signs or adverse tissue reaction could be seen. For some of the
PPF-TGF-β1 implants, bone formation could already be observed macroscopically on the
internal (dural) surface. 
8.3.4 Light microscopy, subjective
Analysis of the sections via light microscopy revealed various levels of bone formation at 8
weeks post-implantation. For all implants, the defect edge was still visible. In all specimens,
some inflammatory cells were seen. 
In all non-TGF-β1 coated implants (PPF-Pw, PPF-Gd, PPF-Fn), very limited bone
growth inside the pores of the PPF scaffold could be observed (Figure 4A,B). Bone had
grown from the edge of the former defect up to the PPF scaffold. An intervening fibrous
capsule was present in between the newly formed bone and PPF scaffold. In addition, an
organized fibrous capsule was present covering the top and bottom of the PPF. Inside the
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PPF, some inflammatory cells, fibroblasts and small blood vessels were seen. Also, no signs
of microfragmentation could be observed histologically. Subjective light microscopical
analysis revealed no differences in histological appearance and bone in-growth between
PPF-Gd, PPF-Fn and PPF-Pw implants. 
On the other hand, in all PPF-TGF-β1 implants bone formation had occurred. In five
PPF-TGF-β1 implants extensive bone formation had occurred (10%–25% of the original
graft volume) (Table 1, Figure 4E). In these implants the bone had a trabecular appearance
together with hemopoietic bone marrow-like tissue (Figure 4F). Bone was present
throughout and surrounding the implant in close contact with the PPF pore surface with-
out an intervening fibrous tissue layer. In some areas active bone formation could be
observed with osteoblast-like cells and osteoid. Almost no PPF degradation was seen histo-
logically. Occasionally multinucleated giant cells in contact with the PPF were observed. In
the other four PPF-TGF-β1 implants bone formation was limited (1%–6%) (Table 1,
Figure 4C). The bone also had a trabecular appearance. Less hemopoietic bone marrow-like
tissue was present (Figure 4D). In addition, some inflammatory cells were present. Where
bone formation was not present within the scaffold, fibrous tissue ingrowth could be
observed. 
8.3.5 Fluorochrome labeling
The fluorochrome labels were clearly visible. In the non-TGF-β1-coated implants, the
accumulation sequence of the labels revealed that some initial bone formation had occurred
starting at the wound edges up to the PPF scaffold (Figure 5A, 5B). In the PPF-TGF-β1
implants, bone formation was observed throughout the porous foam interior. Indeed, bone
formation appeared to proceed from the interior of the pore towards the PPF scaffold
(Figure 5C, 5D). 
8.3.6 Light microscopy, image analysis
The results of the histomorphometrical measurements show that the TGF-β1-treated
implants present an average bone surface area of 1.72 mm2, whereas in the non-TGF-β1-
treated implants the average was 0.06–0.07 mm2 (Figure 6A). Furthermore, bone filled
approximately 11% of the defect area for the TGF-β1-treated implants but less than 0.5%
of the defect area for the non-TGF-β1-treated implants (Figure 6B). Average pore fill
percentage was approximately 16% for the TGF-β1-treated implants and below 1% for the
non-TGF-β1-treated implants (Figure 6C). The pore area percentage of total scaffold
volume was approximately 66% for the TGF-β1-treated implants and 53 - 56% for the non-
TGF-β1-treated implants (Figure 6D). 
Statistical evaluation, using a paired t-test, revealed significant differences between
PPF-Gd and PPF-TGF-β1 implants for bone surface area (P<0.005), bone area percentage
(P<0.005), pore fill percentage (P<0.005) and pore area percentage (P<0.005) (Figure
6). No significant differences were observed between the PPF-Gd and PPF-Fn, and PPF-Gd
and PPF-Pw implants for any parameter (Figure 6). 
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8.4 Discussion and conclusion
In our in vitro release study we found a burst effect during the first 2 h in which almost
55% of the TGF-β1 had been released. This initial burst release was followed by a slow
completion of TGF-β1 release by the end of week 1. Although this experiment does not
provide data about the activity of the released TGF-β1, our results suggest that the same
release profile will occur in situ. The observed burst release of TGF-β1 also corroborates
previous work studying the growth factor release from titanium fiber mesh implants.22 The
initial phase of rapid protein loss is thought to be related to protein properties, especially
solubility, rather than scaffold properties.23,24 Furthermore, in the present study total
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Figure 4.
release was higher after 1 week than in our titanium mesh experiment. This may be at-
tributable to the lower affinity of the PPF implants for TGF-β1.23 We also note that Figure
3 shows a total release of approximately 112 +/- 5% (mean +/- SD), which is indicative of
the error involved with the measurement. 
We have previously demonstrated that the experimental design used is not a critical
size defect model.22 However, the purpose of this study was to evaluate the tissue response
to TGF-β1 adsorbed onto PPF scaffolds and non-TGF-β1-treated PPF scaffolds. In view of
this, our histological findings show again that, PPF is biocompatible with host bone.25
There were slightly more inflammatory cells than are observed in the earlier titanium fiber
mesh study.22 but this is to be expected for a biodegradable material. However, histological
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Figure 4.
(A) Undecalcified section of a non-coated porous PPF scaffold at 8 weeks post-implantation. Bone has grown up to
the external edge of the PPF scaffold. Only very limited penetration of bone can be observed inside the PPF scaffold.
PPF-Fn, PPF-Gd and PPF-Pw show a similar histological image (orig. magn. 2.5x).
(B) Undecalcified section of a non-coated porous PPF scaffold at higher magnification. Bone ingrowth is very limited.
The porous spaces of the scaffold are filled with fibrous tissue and capillaries. The outside the PPF is surrounded by a
small fibrous capsule. Some inflammatory cells (multi nucleated giant cells) are seen (orig. magn. 20x). 
(C) Undecalcified section of a porous PPF scaffold coated with TGF-β1. Only some bone is present throughout the
porous PPF space (orig. magn. 2.5x). 
(D) Undecalcified section of a porous PPF scaffold coated with TGF-β1. Some bone formation is present. The formed
bone has a trabecular appearance and is present in close contact with the PPF surface. Only some bone marrow-like
tissue can be observed (orig. magn. 2.5x). 
(E) Undecalcified section of a porous PPF scaffold coated with TGF-β1. Bone is present throughout the porous PPF
space. The bone has a trabecular appearance and is present in close contact with the PPF surface without an intervening
fibrous tissue layer. In addition, hemopoietic bone marrow-like tissue (BM) appears to be present (orig. magn. 20x). 
(F) Undecalcified section of a porous PPF scaffold coated with TGF-β1. Again, the formed bone has a trabecular
appearance and is present in close contact with the PPF surface without an intervening fibrous tissue layer. However,
more bone marrow-like tissue (BM) can be observed compared with Figure 4D (orig. magn. 20x). 
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Figure 5.
(A) Non-stained undecalcified section of a non-coated porous PPF scaffold viewed with a fluorescence microscope.
Some initial bone bone guidance has occurred from the former defect edge up to the edge of the PPF scaffold. A similar
result was observed in the PPF-Gd, PPF-Pw and PPF-Fn implants (orig. magn. 10x). 
(B) Non-stained undecalcified section of a of a non-coated porous PPF scaffold. In PPF-Gd, PPF-Pw and PPF-Fn
implants, the accumulation sequence of the various labels, T = tetracylin (1 week), A = alizarin-complexon (3 weeks),
C = calcein (5 weeks) and T’ = tetracylin (7 weeks) label, indicates that some initial bone guidance has occurred, starting
from the former defect edge up to the PPF scaffold edge (orig. magn. 20x).
(C) Non-stained undecalcified section of a porous PPF scaffold coated with rhTGF-β1. This section is viewed with a
fluorescence microscope. We observe bone formation starting within the porous space (orig. magn. 10x). 
(D) Non-stained undecalcified section of a porous PPF scaffold coated with rhTGF-β1. The accumulation sequence
of the labels T = tetracylin (yellow, 1 week), A = alizarin-complexon (3 weeks), C = calcein (5 weeks) and T’ = tetracylin
( 7 weeks) label (see Figure 5 B) indicates that bone formation has started in the center of the porous space and has
grown towards the scaffold (orig. magn. 20x). 
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Figure 6.
Figure showing (A) the bone surface area, (B) bone area %, (C) pore fill % and (D) pore area %. In addition, the results
of the paired t-test comparing PPF-Gd with the other implant types are shown. Significant differences between PPF-Gd
and PPF-TGF-β1 (*) are marked. No significant difference was found between PPF-Gd and the other non-coated implants
for any parameter (p > 0. 05) (data shown are mean +/- SD). 
observations found only a minimal sign of degradation. The polymer maintained its porous
structure throughout the 8 week study. Chemically crosslinked PPF has been shown to
degrade within days in vivo in a rat intramuscular site.3 Furthermore, in a proximal tibial
rat model, progressive replacement by bone had occurred by 5 weeks.25 Both of these
works, however, studied a PPF composite containing both a NaCl porogen and β-tricalcium
phosphate. Consequently, full degradation characteristics of photocrosslinked PPF remain
to be investigated over a longer time span. 
The application of a fibronectin coating did not modify the tissue response to a PPF
scaffold by 8 weeks. Though fibronectin has been proven to enhance osteoblast-like cell
adhesion and in vivo bone formation by osteogenic cell-loaded scaffolds,15 it does not
further enhance the biological response in a porous PPF scaffold material. On the other
hand, no adverse effects were observed. Therefore, in future experiments, we plan to
investigate the osteogenic properties of fibronectin coated porous PPF scaffolds loaded with
osteogenic cells.26
The bone stimulative effect of rhTGF-β1 in combination with a porous carrier is in
agreement with the results of many other studies.22,27-44 The amount of bone formation
within the scaffolds was variable. Five scaffolds with adsorbed TGF-β1 showed significant
amounts of bone, while four implants showed less. Comparison of the findings with our
similarly designed titanium fiber mesh study22 reveals that more bone occurred in the
titanium fiber mesh with less inter-implant variation. In the present study average total
bone surface area was 1.72 mm2 per implant. In the titanium study the total bone surface
area was approximately 2.74 mm2 per implant. Two explanations can be given for these
findings. First, coating difficulties caused by a relatively low affinity of TGF-β1 for PPF
could have resulted in a suboptimal amount of TGF-β1 at the time of implantation. Al-
though, the implants were treated with Gd to enhance adsorption, we know that a shadow
effect exists, which prevents the Gd treatment to reach the surface of the inner pores.
Second, a low affinity of TGF-β1 for PPF can lead to insufficient retention of the TGF-β1
after implantation. Unfortunately, no exact information is currently available about this
phenomenon. For other osteoinductive growth factors, like BMPs, carrier-protein affinity
has been more thoroughly studied.23,24,45 The in vivo osteoinductive activity was found to
be positively correlated with the amount of protein retained at the site. Higher retention
yields a higher osteoinductive activity. Supposedly, if less growth factor is retained, a higher
dose is needed for the same osteoinductive response. In view of this, due to coating
difficulties or protein retention, the remaining dose on some of our implants might have
been below the optimal osteoinductive level.28,29,46,47
Image analysis revealed a higher pore area percentage for the TGF-β1 coated scaffolds
(66%) than for non-coated specimens (53–56%). Several possible explanations can be
given for this observation. A possible explanation is the reduced compression of the im-
planted PPF-TGF-β1 foams (and thus reduced porosity decrease) because of the mechanical
reinforcement of the foams due to increased bone formation. Another explanation is the
reduced contraction of the implanted PPF-TGF-β1 foams due to decreased fibrovascular
tissue growth.48 Alternatively, it may have occured due to the image analysis measuring
technique which is based on color differences between the various structures. In general,
the color difference between PPF and fibrous tissue is smaller than the difference between
bone tissue and PPF. This may have resulted in a measurement error. 
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Further, fluorescent labeling revealed that in the TGF-β1-coated scaffolds the process
of bone formation had proceeded in a centrifugal manner, starting in the middle of the
pores and growing towards the surface of the scaffold. We have also observed this type of
bone formation in titanium scaffolds loaded with TGF-β1, BMPs, or osteogenic cells.22,49,50
Only for bioactive scaffold materials, so-called bonding osteogenesis, i.e. bone formation
starting at the surface area and proceeding away from the surface, can occur.51
Despite the favorable effect of TGF-β1 on bone healing, there is currently concern
about the safety of this growth factor for use in humans.52-58 One clinical trial has demon-
strated that systemic administration of TGF-β2 can lead to a reversible decline in renal
function.59 However, these observations do not prove a causal connection between local
administration of low doses of TGF-β1 and adverse effects. Nevertheless, it is important
that a therapeutic index is established for TGF-β1, allowing a rational approach for safe
delivery and dosage of this growth factor in local therapeutic use. 
Photocrosslinked PPF is biocompatible with host bone and shows minimal histological
evidence of degradation during an 8 week experimental period. On the other hand, the
osteoconductive properties of porous PPF are limited in the model used. Additionally, a
fibronectin coating as applied in this study does not modify the bone response to these PPF
scaffolds in vivo. TGF-β1 did induce significant bone formation in these porous PPF
scaffolds. These results indicate that porous PPF combined with an appropriate growth
factor carrier is a good candidate for the creation of osteoinductive bone graft substitutes. 
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Chapter 9
Summary, address to the aims,
closing remarks and future perspectives
9.1 Summary and address to the aims
As a means to overcome the current clinical problems associated with the regeneration of
bone defects, so-called tissue engineering techniques have been developed to create bone
graft substitutes (BGSs). The current experimental approach consists of the use of a mostly
synthetic porous scaffold or carrier to which osteogenic cells and/or growth factors are
added. While extensive research has focussed on the ideal scaffold or carrier material, none
of the carrier or scaffold materials that have been used so far meet all of the required de-
mands with respect to clinical application. In view of this, we propose the use of titanium
(Ti) fiber mesh as a candidate scaffold or carrier material. Titanium fiber mesh is biocom-
patible, easy to use during surgery and has excellent mechanical characteristics. An ad-
ditional advantage is that the titanium mesh can be provided with a thin bioactive calcium
phosphate (Ca-P) coating. Therefore, in this thesis, all of the investigations revolve around
the potential use of titanium fiber mesh with or without a Ca-P coating as a carrier or scaf-
fold material in the creation of BGSs. Consequently, a general introduction to the current
knowledge on bone formation and the use of tissue engineering strategies is presented in
Chapter 1. In the subsequent chapters, the aims as described in the scope of the thesis are
addressed in a step-wise manner. Each subsequent chapter comprises a separate investi-
gation. 
Aims
1. What is the osteogenic expression in porous titanium fiber mesh loaded with rat bone
marrow cells in vitro, and how is it influenced by cell seeding density and rhBMP-2
concentration?
In chapter 2 titanium fiber mesh discs were seeded with two densities of cultured rat
bone marrow (RBM) cells, i. e. a low density [3. 54 x 104 cells/cm2 = 10,000 cells per mesh]
and a high density [3. 54 x 105 cells/ cm2 = 100,000 cells per mesh]. Cells were cultured for up
to sixteen days, seven days of which the cells were in the presence of various concentrations of
recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) (0, 10, 100, and 1,000 ng/ml)
in order to evaluate osteogenic expression. Scanning electron microscopy (SEM), light
microscopy (LM), energy dispersive spectroscopy (EDS), DNA and calcium (Ca) content
measurements, and X-ray diffraction (XRD) analysis were performed. SEM and EDS
evaluation showed that a confluent layer of cells was present on top of the meshes together
with collagen bundles and calcified globular accretions. Light microscopical evaluation showed
a densely stained layer in the upper part of the mesh. SEM and Ca content measurement
showed that calcification starts at eight days. In addition, it was demonstrated that DNA
content peaked at eight days. LM, SEM, and Ca content evaluation revealed positive effects of
increasing the cell seeding density, the rhBMP-2 concentration and the culture time on
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mineralization. Increasing the cell seeding density also resulted in a positive effect on DNA
content. No effects of rhBMP-2 concentration were seen on DNA content. Finally, XRD
revealed that the deposited matrix contained a precipitate of a stable calcium phosphate phase.
Therefore, we concluded that titanium fiber mesh sustains excellent osteogenic expression
in vitro, increasing the cell seeding density has a positive effect on osteogenic expression in
titanium mesh in vitro, and in high density specimens, rhBMP-2 concentrations of 100
ng/ml and 1,000 ng/ml, stimulate extracellular matrix calcification in a dose-responsive
manner.
2. What is the efficacy of a titanium fiber mesh loaded with cultured osteogenic cells on
bone formation in an ectopic location, and what is the additional influence of the
application of a thin Ca-P coating?
Chapter 3 describes the investigation on the osteogenic activity of porous titanium
fiber mesh and Ca-P-coated titanium fiber mesh loaded with cultured syngeneic osteogenic
cells in a syngeneic rat ectopic assay model. In thirty syngeneic rats, Ca-P-coated and non-
coated porous titanium implants were subcutaneously placed either without or loaded with
cultured RBM cells. The rats were sacrificed at two, four, and eight weeks post-operative,
and the implants were retrieved. Further, in the eight-week-group fluorochrome bone
markers were injected at two, four, and six weeks. Histological analysis demonstrated that
none of the Ca-P-coated and non-coated meshes alone supported bone formation at any
time period. In RBM-loaded implants, bone formation started at two weeks. At four weeks,
bone formation increased. However, at eight weeks bone formation was absent in the non-
coated titanium implants, while it had remained in the Ca-P-coated titanium implants.
Also, in Ca-P-coated implants more bone was formed than in non-coated samples. In
general, osteogenesis was charac-terized by the occurrence of multiple spheres in the
porosity of the mesh. The accumulation sequence of the fluorochrome markers showed
that the newly formed bone was deposited in a centrifugal manner starting at the center of
a pore. On the basis of our results, we concluded that the combination of Ti-mesh with rat
bone marrow cells can indeed generate bone formation. In addition, a thin Ca-P coating can
have a beneficial effect on the bone-generating properties of a scaffold material. Never-
theless, the occurrence as well as the amount of new bone were very limited using the
procedures described in this study. 
3. What is the effect of the cell seeding method in combination with prolonged in situ
culturing on bone formation in titanium fiber mesh scaffolds in an ectopic location?
In the investigation described in chapter 3 we found that the occurrence as well as the
amount of bone formation were very limited when osteogenic cells were seeded in Ti-fiber
mesh scaffolds. We assumed that this was related to our culture and cell-loading technique
that consisted of the use of the so-called droplet loading technique without prolonged
culturing in vitro. Therefore, in the experiment described in chapter 4 we examined the
osteogenic activity of Ca-P-coated and non-coated porous Ti-fiber mesh loaded with cul-
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tured syngeneic osteogenic cells after prolonged in situ culturing in a syngeneic rat ectopic
assay model. RBM cells were loaded onto the CaP-coated and non-coated Ti-scaffolds using
either a droplet or a suspension loading method. After loading, the RBM cells were cul-
tured for eight days in vitro. Thereafter, implants were subcutaneously placed in thirty-nine
syngeneic rats. The rats were sacrificed and the implants retrieved at two, four, and eight
weeks post-operatively. Further, in the eight-week-group fluorochrome bone markers were
injected at two, four, and six weeks. Histological analysis demonstrated that only the Ca-P-
coated meshes supported bone formation. The amount of newly formed bone varied
between single or multiple spheres to filling a significant part of the mesh porosity. In the
newly formed bone, osteocytes embedded in a mineralized matrix could clearly be ob-
served. On the other hand, in the non-coated Ti-implants abundant mineralization was
present without a bone-like tissue organization. Calcium content analysis revealed that the
cell-loading method did not influence the final amount of bone formation. In Ca-P-coated
implants the accumulation sequence of the fluorochrome markers showed bonding osteo-
genesis. We conclude that the combination of Ti-mesh with RBM cells can indeed generate
ectopic bone formation after prolonged in vitro culturing. The effect of prolonged culturing
in vitro was different for the Ti-CaP and Ti implants: only Ca-P-coated implants supported
bone formation. No effect of the loading method was observed on the final amount of bone.
Finally, our results confirmed once again that a thin Ca-P coating can have an additional
positive effect on the bone-generating properties of a scaffold material. 
4. Can titanium fiber mesh loaded with Bone Morphogenetic Proteins (BMPs) induce
bone formation in an ectopic location, and can the osteoinductive effect of recombinant
human BMP synergistically be enhanced by native bovine BMPs?
In chapter 5 we evaluated the osteoinductive properties of porous Ti-fiber mesh with
or without a calcium phosphate (Ca-P)-coating and loaded with rhBMP-2 or rhBMP-2 and
native bovine BMP [S-300 BMP cocktail (S-300)] in a rat ectopic assay model. One hundred
and twelve Ca-P-coated and one hundred and twelve non-coated porous Ti-implants, either
loaded with rhBMP-2 and S-300 or loaded with rhBMP-2 alone, were subcutaneously
placed in fifty-six Wistar King rats. The rats were sacrificed at five, ten, twenty, and forty
days post-operative and the implants retrieved. Histological analysis demonstrated that all
growth factor and carrier combinations had induced ectopic cartilage and then bone
formation at five and ten days, respectively. At twenty days, bone formation increased and
was characterized by trabecular bone and bone marrow-like tissue. At forty days, more
lamellar bone and hemopoietic bone marrow-like tissue were present. At both times more
bone had been formed in the Ca-P-coated implants than in the non-coated samples. In
addition, bone formation was higher in the rhBMP-2 and S-300-loaded specimens than in
the rhBMP-2-only-loaded specimens. In rhBMP-2-only-loaded specimens bone formation
was mainly localized inside the mesh material, while in specimens loaded with both
rhBMP-2 and S-300 the bone was localized inside as well as surrounding the Ti-mesh. The
histological findings were confirmed by calcium content and alkaline phospha-tase activity
measurements. In addition, all specimens showed osteocalcin expression as early as five
days. From these findings we deduced that the combination of Ti-mesh with BMPs can
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indeed induce ectopic bone formation and that this bone formation seems to be similar to
“enchondral” ossification, a thin Ca-P coating can have a beneficial ef-fect on the bone-
inducing properties of a scaffold material, and rhBMP-2 and native BMP act synergistically
in ectopic bone induction. 
5. What is the nature of the bone induction process in various BMP-loaded carrier
materials?
In chapter 6 we studied the osteoinductive properties of porous Ti-fiber mesh with a
calcium phosphate (Ca-P)-coating (Ti-CaP), insoluble bone matrix (IBM), fibrous glass
membrane (FGM) and porous particles of hydroxyapatite (PPHAP), all loaded with
rhBMP-2, using a rat ectopic assay model and short implantation periods. Twelve Ti-CaP,
twelve IBM, twelve FGM and twelve PPHAP implants, all loaded with rhBMP-2 were
subcutaneously placed in sixteen Wistar King rats. The rats were sacrificed at three, five,
seven, and nine days post-operative, and the implants were retrieved. Histological analysis
demonstrated that both IBM and Ti-CaP had induced ectopic cartilage and bone formation
by five and seven days, respectively, while in PPHAP bone and cartilage formation were
seen concurrently at seven days. At nine days, cartilage was seen together with trabecular
bone in Ti-CaP, IBM, and PPHAP, while in FGM only cartilage was observed. We con-
cluded that IBM, Ti-CaP, FGM, and PPHAP, when loaded with rhBMP-2, can indeed in-
duce ectopic bone formation with a cartilaginous phase in a rat model at short implantation
periods. Given the different nature of the carrier materials used these findings even suggest
that an endochondral ossification-like process is always present in rhBMP-2 induced
osteogenesis, even though the amount of cartilage may differ. We believe these differences
are related to the vascular-inducing geometry. 
6. What is the bone formation-supporting efficacy of titanium fiber mesh as-received,
provided with a thin calcium phosphate coating, or loaded with rhTGF-β1 in an
orthotopic site? 
In Chapter 7 we evaluated the bone formation-supporting properties of porous tita-
nium (Ti) fiber mesh with or without a calcium phosphate (Ca-P)-coating or loaded with
recombinant human Transforming Growth Factor beta-1 (rhTGF-β1) in a rabbit noncritical
size cranial defect model. Nine Ca-P-coated and eighteen non-coated porous titanium
implants, half of the latter loaded with rhTGF-β1, were bilaterally placed in the cranium of
eighteen New Zealand white rabbits. At eight weeks post-operative, the rabbits were eu-
thanized and the skulls with the implants retrieved. Histological analysis demonstrated that
in the TGF-β1-loaded implants bone had been formed throughout the implant up to its
center, whereas in the non-loaded implants only partial ingrowth of bone was observed.
Bone formation had a trabecular appearance together with bone marrow-like tissue. No
difference in ingrowth could be observed between the non-TGF-β1-loaded, non-coated im-
plants and the CaP-coated ones. All histological findings were confirmed by image analysis:
97% ingrowth was observed in the rhTGF-β1-loaded implants, while only 57% and 54%
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ingrowth was observed in the non-loaded Ca-P-coated and non-coated implants, respec-
tively. Bone surface area and bone fill were significantly higher in the rhTGF-β1-loaded im-
plants (1.37 mm2 and 36%, respectively) than in the non-loaded implants (0.57 mm2 and
26%). No statistical difference was found for any parameter between the CaP-coated and
non-coated implants. Quadruple fluorochrome labeling showed that in the Ti and Ti-CaP
implants mainly bone guidance had occurred from the former defect edge, while in the Ti-
TGF-β1 implants bone formation had mainly started in the center of a pore and proceeded
in a centrifugal manner. Based on these observations we concluded that the combination of
Ti-mesh with TGF-β1 can induce orthotopic bone formation, that Ti-fiber mesh has good
osteoconductive properties, and that a thin Ca-P coating, as applied in this study, does not
seem to further enhance the bone-conducting properties of a Ti-scaffold material. 
7. What is the efficacy of porous PPF provided with rhTGF-β1 on bone induction in an
orthotopic site, and what is the effect of a fibronectin coating on the bone response to
porous PPF?
In Chapter 8 we determined bone growth into pretreated poly(propylene fumarate)
(PPF) scaffolds implanted into a sub-critical size, rabbit cranial defect. PPF scaffolds were
first constructed using a photo-crosslinking/porogen leaching technique. These scaffolds
were then either prewetted (PPF-Pw), treated with radio frequent (RF) glow-discharge
(PPF-Gd), coated with fibronectin (PPF-Fn), or coated with rhTGF-β1 (PPF-TGF-β1). One
of each scaffold type was subsequently placed into the cranium of nine New Zealand white
rabbits. The rabbits were euthanized after eight weeks and the scaffolds were retrieved for
histological analysis. Little or no bone formation was observed in implants without rhTGF-
β1 or in those with a fibronectin coating. No differences in bone formation were observed
between the PPF scaffolds without rhTGF-β1. The most bone formation was present in the
PPF-TGF-β1 implants; the newly formed bone had a trabecular appearance together with
bone marrow-like tissue. However, bone formation showed a high inter-implant variation,
from filling almost the entire porosity up to some bone formation because of the variable
TGF-β1 retention on the implants. These histological findings were confirmed by image
analysis. Bone surface area, bone area percentage, pore fill percentage, and pore area per-
centage were significantly higher in the rhTGF-β1-coated implants than in the non-coated
implants. No statistical difference was seen between the PPF-Fn, PPF-Pw, or PPF-Gd
scaffolds for these parameters. Quadruple fluorochrome labelling showed that in PPF-TGF-
β1 implants bone formation mainly started in the interior of a pore and proceeded towards
the scaffold. In PPF-Gd, PPF-Pw and PPF-Fn implants, limited bone guidance had occurred
from the former defect edge up to the PPF scaffold. We concluded that a PPF scaffold is
bone biocompatible and, in the configuration utilized, shows minimal signs of degradation
during the experimental period. TGF-β1 can indeed adequately induce bone formation in
porous PPF. These results indicate that PPF-TGF-β1 scaffolds prepared by the photo-cross-
linking/porogen leaching technique are good candidates for the creation of bone graft
substitutes. 
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9.2 Closing remarks and future perspectives
The research conducted in this thesis provides evidence that the combination of Ti-mesh
with osteogenic cells or osteoinductive factors like BMP and TGF-β can be used in the crea-
tion of bone graft substitutes.
This was demonstrated by the osteogenic expression in vitro and the deposition of
bone-like tissue in vivo. In vitro we found that increasing the cell seeding density and
rhBMP-2 concentration enhanced osteogenic expression. On the other hand, in vivo use of
cell-based strategies in the creation of BGS, resulted in a limited amount of newly formed
bone. Therefore, we investigated the efficacy of prolonged culturing in vitro. This effect
appeared to be different for the Ca-P-coated and non-coated implants in which only the
Ca-P-coated implants supported bone formation. Also, for these implants the amount of
bone seemed to be slightly enhanced compared with the earlier study. Further experiments
showed that the combination of Ti-mesh with BMPs can also effectively induce bone
formation in ectopic locations. In addition, we showed that the combination of recombi-
nant and partially purified native BMP act synergistically in ectopic bone induction. A
comparison of the results of rhBMP-2 loaded and cell-loaded scaffolds, revealed that the
rhBMP-2-loaded carrier yielded not only a greater quantity but also more reproducible bone
formation in the rat ectopic assay model. The BMP-induced bone for-mation process also
occurred with a cartilaginous phase present and therefore seemed similar to “enchondral”
ossification. In addition, a comparative study between Ti-fiber mesh and various other
carriers, some of which are known from previous studies to form bone through an
endochondral ossification-like process (FGM, IBM) and one of which is known to induce
direct ossification (PPHAP), showed the presence of a cartilaginous phase for all carriers.
Considering the different nature of the carrier materials used, these findings even suggest
that an endochondral ossification-like process is always present in rhBMP-2-induced osteo-
genesis, although the amount of cartilage does differ. The difference is believed to be related
to the vascular-inducing geometry of the carriers. Carriers which show a higher vascular-
inducing geometry lead to early osteogenesis and a early disappearance of cartilage, while a
vascular-inhibiting geometry will lead to greater amounts of cartilage that remain for a
longer time. Therefore, the terms “bone-directing” and “cartilage-directing” carrier might
be appropriate for the former and the latter, respectively. This information, together with
an increasing knowledge of the growth factor release profiles from different carriers, should
allow a more rational approach towards carrier design and will also be beneficial in the fi-
nal clinical application, where a carrier that yields high-quality bone within a short time
period is highly desirable. 
Further investigations showed that Ti-mesh loaded with TGF-β can stimulate bone
defect healing. Our investigation of non-TGF-β-loaded titanium scaffolds revealed that the
titanium fiber mesh itself has good osteoconductive properties. In addition to its application
for the creation of bone graft substitutes, these investigations hold some promise for the use
of titanium fiber mesh with or without growth factors in implant fixational use. Additional
experiments with a newly developed porous poly(propylene fumarate) (PPF) scaffold de-
monstrated that this material was also bone-biocompatible and could adequately induce
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bone formation when loaded with rhTGF-β1. Nevertheless, when loaded with the same
dose of rhTGF-β1 as the Ti-carrier, PPF yielded less bone formation with a higher inter-
implant variability. This was thought to be related to a lower retention of TGF-β on the
PPF implants. In view of this, we have to notice that the choice of an appropriate material
depends on the final application: degradation might be desirable in some situations while
mechanical and structural properties are mandatory in others. 
Despite the favorable effect of TGF-β on bone healing, it has to be emphasized that
some concern exists with respect to the safety of this growth factor in human admini-
stration. However, no causal connection between local administration of low doses of TGF-
β and adverse renal and hepatic effects have been proven. Still, it is important that a
therapeutic index will be established for TGF-β, thereby allowing a rational approach for
the safe delivery and dosage of this growth factor in local therapeutic use. 
The application of a thin calcium phosphate coating has been shown to further
stimulate the bone formation process for osteogenic cell- and BMP-2-loaded scaffolds.
However, the coating technique-used might not be the optimal one for a porous scaffold,
since it does not provide a bioactive surface throughout the scaffold. This was illustrated by
the absence of bonding osteogenesis inside the CaP-coated scaffolds in cell-loaded and
BMP- loaded scaffolds and the non-stimulative effect on the osteoconductive properties of
the Ti-fiber mesh. 
Consequently, future efforts should be directed towards approaches which provide a
standardized and reproducible surface and improve the (biocompatibility and) functionality
of the carrier material. Examples of such methodologies are sol-gel and biomimetic routes.
Our in vitro studies showed that the use of static culture methods resulted in the
occurrence of osteogenic cells together with mineralized matrix in only the upper part of
the mesh. After prolonged culturing in vitro and subsequent implantation, bone deposition
was also observed in the upper mesh area. As a means of overcoming this problem, in vitro
BGS culturing techniques should be directed towards dynamic seeding and culture methods
like perfusion flow and rotating wall vessels (RWVs). Other investigators have proven that
these methods are more beneficial in the generation of tissue-engineered bone-like tissue in
vitro. In our group a perfusion system has also been used, which indeed did show an en-
hancement of osteogenic expression in titanium fiber mesh in vitro. Nevertheless the
advantage of dynamic culture methods on in vivo bone formation remains to be investi-
gated. 
Moreover, we have to stress that the differentiation pathway of cells within the osteo-
genic lineage is still poorly understood. Increased knowledge in this area should enable a
more rational approach towards tissue engineering of bone tissue. Cell selection that would
enable the isolation of true osteo-progenitor cells or mesenchymal stem cells, for example
through the development of specific cell markers or antibodies, would allow such an
approach. 
Although some of the intracellular signaling for BMPs through the Smad pathway, and
the subsequent gene activation resulting in osteoblast differentiation, has now been elu-
cidated the pathway used by BMPs in the activation of particular osteoblast genes remains
to be investigated. Increased knowledge in this field will result in a rational basis in the
development of clinical therapeutical strategies. 
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The favorable results that we obtained in rodents should be repeated in higher animals
prior to a reliable transfer to the clinical situation. For example, in recent research, BMPs
have been proven to be effective in clinical trials when used with a collagen carrier. How-
ever, the the response varies strongly between individuals. It has also to be emphasized that
the BMP doses used are still unphysiologically high and that long-term efficacy and safety
have to be awaited. Consequently, the combination of cells and growth factors and or the
combination of different growth factors in an appropriate combination holds promise for
the future. It might enable a decrease in the concentration of growth factors used and
enhance the biological activity. 
Another solution for the “concentration” problem of growth factors can perhaps be
found by using a gene therapeutical approach in which cells within or outside the osteo-
genic lineage are genetically transfected in vivo or in vitro by different vectors such as retro-
viruses in order to overexpress growth factors. The safety of these methods concerning the
fate of the transfected cells still needs further investigation. 
Finally, the ultimate goal for large reconstructive surgical procedures will be the
creation of a vascularized BGS using prefabrication techniques in which a vascular pedicle,
for example muscle flap, is combined with an osteoinductive scaffold to form a preshaped-
vascularized bone graft. Other researchers have proven that ceramic scaffolds loaded with
BMPs placed in a muscle flap can be used to create a vascularized bone graft substitute and
to regenerate a mandibular defect in minipigs. Again, the effectiveness of the combination
of cell-based scaffolds and prefabrication remains to be proven in higher animals and
humans. 
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Samenvatting, evaluatie van de doelstellingen,
afsluitende opmerkingen en toekomstperspectief
9.3 Samenvatting en evaluatie van de doelstellingen
Om de huidige klinische problemen die optreden bij de behandeling van grote botdefecten
te overwinnen, worden momenteel zogenaamde tissue engineering technieken ontwikkeld
met als doel het vervaardigen van bone graft substitutes (BGSs) of bottransplantaat-
vervangers. Hierbij wordt gebruik gemaakt van (meestal synthetische) poreuze drager-
materialen, waaraan botvormende cellen en/of groeifactoren worden toegevoegd. De
onderzoeksinspanningen hebben zich vooral toegespitst op het ontwikkelen van een ideaal
dragermateriaal. Desondanks voldoet nog steeds geen van de nu beschikbare materialen
aan alle gestelde klinische eisen. In dit verband stellen wij dan ook voor om het potentieel
van titanium vezelgaas dragermateriaal te onderzoeken. Titanium vezelgaas is biocompati-
bel, gemakkelijk te gebruiken bij operaties en bezit een zekere stevigheid, waardoor het met
name veel geschikter lijkt voor toepassing bij de regeneratie van botweefsel dan alle tot nu
toe geteste materialen. Een ander voordeel is dat titanium vezelgaas kan worden voorzien
van een dunne bioactieve calciumfosfaat (Ca-P) coating. Het onderwerp van alle in dit
proefschrift beschreven experimenten is dan ook het mogelijke gebruik van titanium
vezelgaas met of zonder dunne Ca-P coating als dragermateriaal ter vervaardiging van
BGSs. In hoofdstuk 1 wordt een algemene inleiding gegeven over de huidige kennis op het
gebied van botvorming en het gebruik van de diverse tissue engineering methoden. In de
daarop volgende hoofdstukken worden de doelstellingen van dit proefschrift stapsgewijs
uiteengezet. Elk hoofdstuk bevat een opzichzelfstaand onderzoek.
Doelstellingen 
1. Wat is de in vitro osteogene expressie van ratten beenmergcellen aangebracht in poreus
titanium vezelgaas? Wat is verder de invloed van celdichtheid en rhBMP-2-concentra-
tie op deze osteogene expressie? 
In hoofdstuk 2 worden een zogenaamde lage dichtheid (3.54x104 cellen/cm2=10.000
cellen per vezelgaas) en hoge dichtheid (3.54x105 cellen/cm2=100.000 cellen per vezel-
gaas) ratten beenmergcellen (RBM) aangebracht in titanium vezelgaas. Om de osteogene
expressie te bepalen werden de cellen gedurende zestien dagen gekweekt, waarvan zeven
dagen in aanwezigheid van diverse concentraties rhBMP-2 (0, 10, 100 en 1000 ng/ml).
Scanning electronen microscopie (SEM) en energie dispersieve spectrometrie (EDS)
liet zien dat aan de bovenkant van het vezelgaas een confluente cellaag aanwezig was met
verder collageen vezels en een neerslag van zogenaamde gecalcificeerde globuli. Licht
microscopie (LM) bevestigde het osteogene karakter van deze laag. SEM en calcium-
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bepalingen toonden aan dat het calcificatieproces van de cellen begon op dag acht. Verder
bleek het DNA gehalte op die dag het hoogst te zijn. SEM, LM en calciumbepalingen lieten
voorts een positief effect zien van het verhogen van de celdichtheid, de rhBMP-2 concen-
tratie en de tijdsduur van de celkweek op de verkalking van de cellen in het vezelgaas. Het
verhogen van de celdichtheid resulteerde tevens in een toename van het DNA-gehalte. Het
variëren van de rhBMP-2 concentratie bleek geen effect op het DNA-gehalte te hebben. Ten
slotte liet de XRD zien dat de gevormde matrix een neerslag bevatte van een stabiele
calcium fosfaat fase. Hieruit concluderen we dat (1) titanium vezelgaas uitstekend de in
vitro osteogene expressie van beenmerg cellen ondersteunt, (2) het verhogen van de
celdichtheid een positief effect heeft op de in vitro osteogene expressie in titanium vezelgaas
en (3) bij hoge celdichtheden rhBMP-2 concentraties van 100 ng/ml en 1000 ng/ml de
calcificatie van de extracellulaire matrix stimuleren op een dosis afhankelijke wijze. 
2. Kan titanium vezelgaas geladen met gekweekte osteogene cellen, aanleiding geven tot
botvorming in een ectopische locatie en wat is hierbij de additionele invloed van de
toepassing van een dunne Ca-P coating? 
In hoofdstuk 3 is de osteogene activiteit van poreus titanium vezelgaas, eventueel
voorzien van een dunne Ca-P coating en geladen met ratten beenmergcellen onderzocht. Bij
dertig genetisch identieke ratten werd poreus titanium vezelgaas met en zonder Ca-P
coating en al dan niet geladen met gekweekte RBM-cellen, subcutaan geïmplanteerd. De
ratten werden twee, vier of acht weken na het implanteren van de titaniumimplantaten op-
geofferd, waarna histologisch onderzoek plaats vond van deze implantaten. Tevens dient
hierbij opgemerkt te worden dat in de acht weken-groep na twee, vier en zes weken im-
plantatie fluorochrome merkers geïnjecteerd werden in de ratten. Het histologisch onder-
zoek liet zien dat op geen enkel implantatietijdstip in geen enkel poreus titanium vezelgaas
zonder RBM-cellen botvorming had plaatsgevonden. In titanium vezelgaas geladen met
RBM-cellen vond wel botvorming plaats. De botvorming begon op twee weken en was na
vier weken verder toegenomen. Echter na acht weken werd geen botvorming meer gezien
in het niet Ca-P gecoate vezelgaas, terwijl nog wel botvorming aanwezig was in het tita-
nium vezelgaas met een Ca-P coating. Ook was in het vezelgaas met een Ca-P coating meer
bot gevormd dan in het vezelgaas zonder Ca-P coating. Over het algemeen werd de bot-
vorming gekenmerkt door het optreden van meerdere bolvormige lokalisaties in de poriën
van het titanium vezelgaas. De neerslagvolgorde van de fluorochrome merkers liet zien dat
het bot was gevormd op centrifugale wijze en dat de botvorming was begonnen in het
midden van een porie. Gebaseerd op deze resultaten concludeerden wij dat de combinatie
van titanium vezelgaas met gekweekte RBM-cellen aanleiding kan geven tot botvorming op
een ectopische lokatie. Daarnaast worden de botvormende eigenschappen van het titanium
dragermateriaal verder bevorderd door het aanbrengen van een dunne Ca-P coating. Niet-
temin dient benadrukt te worden dat de hoeveelheid bot zeer beperkt was met de in deze
studie gebruikte methoden.
166
Samenvatting, evaluatie van de doelstellingen, afsluitende opmerkingen en toekomstperspectief
3. Wat is het effect van de celzaai-techniek in combinatie met doorkweken in situ op
ectopische botvorming in titanium vezelgaasdragers?
In het onderzoek dat is beschreven in hoofdstuk 3 bleek de hoeveelheid nieuw bot
zeer beperkt te zijn in titanium vezelgaas geladen met osteogene cellen. We veronderstelden
dat dit was gerelateerd aan onze kweek- en celzaai-techniek, die bestond uit een zogenaam-
de druppellaadtechniek zonder doorkweken in vitro. Daarom werden in het experiment
zoals beschreven in hoofdstuk 4 genetisch identieke osteogene cellen met behulp van een
druppel- of een suspensiezaai-methode aangebracht in poreus titanium vezelgaas. Het ve-
zelgaas was wederom al of niet van een Ca-P coating voorzien. Het titanium vezelgaas werd
acht dagen in kweek gehouden na het aanbrengen van de beenmergcellen. Vervolgens
werden de implantaten op dezelfde wijze en voor dezelfde implantatietijden, als beschreven
in hoofdstuk 3, subcutaan aangebracht bij 39 genetisch identieke ratten. Wederom werden
in de acht weken-groep fluorochrome merkers geïnjecteerd op twee, vier en zes weken.
Histologisch onderzoek liet zien dat uitsluitend nieuw bot was gevormd in het titanium
vezelgaas dat voorzien was van een Ca-P coating. De hoeveelheid gevormd bot varieerde
van één of enkele bolvormige lokalisaties tot een hoeveelheid waarbij de porositeit voor een
belangrijk deel werd gevuld. In het nieuw gevormde bot waren duidelijk osteocyten zicht-
baar. Deze waren, ingebed in een gemineraliseerde matrix. In het titanium vezelgaas
zonder Ca-P coating werd alleen een ruime hoeveelheid gemineraliseerde substantie waar-
genomen. Deze substantie vertoonde geen enkel teken van botweefsel organisatie. De
calciumbepaling liet zien dat de celzaai-techniek niet van invloed was op de uiteindelijke
hoeveelheid botvorming. In titanium vezelgaas met een Ca-P coating liet de neerslag volg-
orde van de fluorochrome merkers zien dat de botvorming begonnen was op het titanium
vezelgaas oppervlak. Derhalve kan geconcludeerd worden dat de combinatie van titanium
vezelgaas met RBM-cellen ectopische botvorming kan genereren na doorkweken in vitro.
Het effect van het doorkweken in vitro verschilde voor titanium vezelgaas met en zonder
Ca-P coating: botvorming was alleen aanwezig in dragers met een Ca-P coating. De celzaai-
methode had geen enkele invloed op de uiteindelijke hoeveelheid bot. Tenslotte bevestigden
onze resultaten dat een dunne Ca-P coating een additioneel positief effect kan hebben op de
botvormende eigenschappen van een dragermateriaal.
4. Kan titanium vezelgaas dat voorzien is van botvorming stimulerende eiwitten, zoge-
naamde BMPs, botvorming induceren in een ectopische locatie en kan het osteo-induc-
tieve effect van recombinant humane BMP synergistisch worden versterkt door bovine
BMP? 
In hoofdstuk 5 onderzochten wij de osteo-inductive eigenschappen van poreus
titanium vezelgaas met of zonder dunne Ca-P coating en geladen met recombinant humane
BMP-2 (rhBMP-2) of bovine BMP [S-300 BMP cocktail (S-300)]. Hiervoor werden 112
titanium vezelgaas dragers met een Ca-P coating en 112 zonder Ca-P coating, geladen met
rhBMP-2 of rhBMP-2 + S-300. Deze implantaten werden vervolgens subcutaan aan-
gebracht in 56 Wistar King ratten. De ratten werden na vijf, tien, twintig of veertig dagen
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opgeofferd, waarbij de titanium implantaten werden verwijderd. Histologisch onderzoek
liet zien dat alle groeifactor en drager combinaties na 5 en 10 dagen respectievelijk ecto-
pische kraakbeen- en botvorming hadden geïnduceerd. Na 20 dagen nam de botvorming
toe. De botvorming werd gekenmerkt door de aanwezigheid van trabeculair bot en been-
mergachtig weefsel. Na 40 dagen was het bot meer lamellair van opbouw en was er meer
beenmergachtig weefsel aanwezig. Na 20 en 40 dagen implantatie werd er ook duidelijk
meer bot gezien in titanium vezelgaas met een Ca-P coating dan in titanium vezelgaas
zonder Ca-P coating. Eveneens was er meer bot aanwezig in het vezelgaas geladen met de
combinatie rhBMP-2 + S-300 dan in vezelgaas met alleen rhBMP-2. Verder was in
titanium vezelgaas met rhBMP-2 de botvorming hoofdzakelijk gelokaliseerd binnen in het
vezelgaas terwijl in het titanium vezelgaas met rhBMP-2 + S-300 botvorming zowel
binnenin als aan de buitenkant van het titanium plaats vond. De histologische resultaten
werden bevestigd door de calciumbepaling en alkalisch fosfatase-activiteit meting. Hieruit
concludeerden we dat (1) de combinatie van titanium vezelgaas met BMPs ectopische
botvorming kan induceren, (2) deze botvorming gekenmerkt lijkt te zijn door “enchondrale
ossificatie”, (3) een dunne Ca-P coating een positief effect heeft op de botinducerende
eigenschappen van een dragermateriaal en (4) rhBMP-2 en S-300 hierbij synergistisch
werken.
5. Hoe verloopt het botvormingsproces onder invloed van BMP in verschillende drager-
materialen?
In hoofdstuk 6 werden de osteo-inductieve eigenschappen van poreus titanium
vezelgaas met een Ca-P coating (Ti-CaP), geïnactiveerde gedemineraliseerde bot matrix
(IBM), glasvezel membraan (FGM) en poreuze hydroxyapatiet partikels (PPHAP) vergele-
ken. Al deze materialen werden geladen met rhBMP-2 en vervolgens voor 3, 5, 7 of 9 dagen
subcutaan geïmplanteerd bij ratten. Histologisch onderzoek liet zien dat zowel IBM als Ti-
CaP ectopische kraakbeen- en botvorming induceerden na respectievelijk 5 en 7 dagen. In
PPHAP werd bot- en kraakbeenvorming waargenomen na 7 dagen implantatie. Na 9 dagen
was er in Ti-CaP, IBM en PPHAP zowel kraakbeen als trabeculair bot aanwezig. In FGM
daarentegen was op dit tijdsstip alleen kraakbeen te zien. Hieruit concludeerden wij dat in
een rattenmodel zowel Ti-CaP, IBM, FGM als PPHAP geladen met rhBMP-2 reeds na korte
tijd ectopische botvorming kunnen induceren. De botvorming ging altijd gepaard met
kraakbeenvorming. De hoeveelheid kraakbeen kan hierbij echter verschillen. Wij ver-
onderstellen dat deze verschillen samenhangen met de mate waarin bloedvatingroei in het
dragermateriaal kan plaats vinden.
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6. Wat is de botvormingondersteunende activiteit van recombinant humane Trans-
forming Growth Factor beta-1 (rhTGF-β1) aangebracht in titanium vezelgaas, in een
orthotopische locatie? 
In hoofdstuk 7 evalueerden we de botvormingondersteunende eigenschappen van
poreus titanium (Ti) vezelgaas al of niet voorzien van een Ca-P coating (Ti-CaP) en geladen
met rhTGF-β1 (Ti-TGF-β1) in een schedeldakdefect bij konijnen. Negen Ti-CaP, negen Ti
en negen Ti-TGF-β1 implantaten werden aangebracht in de schedels van achttien konijnen.
Na acht weken werden de konijnen opgeofferd en werden de schedels met de implantaten
verwijderd. Histologisch onderzoek liet zien dat in het vezelgaas met rhTGF-β1 bot was ge-
vormd door de gehele porositeit van het implantaat tot aan de kern. In de implantaten
zonder rhTGF-β1 vond slechts gedeeltelijke botingroei plaats. Het nieuw gevormde bot
werd gekenmerkt door trabeculair bot met beenmergachtig weefsel. In de implantaten
zonder rhTGF-β1 werd geen verschil in botingroei gevonden tussen implantaten met en
zonder Ca-P coating. Alle histologische bevindingen werden bevestigd door beeldanalyse;
97% ingroei werd gezien in de met rhTGF-β1 geladen implantaten, terwijl de niet-geladen
implantaten met of zonder Ca-P coating respectievelijk 57% en 54% ingroei lieten zien.
Het totale botoppervlak in het vezelgaas (1,37 mm2) en de hoeveelheid bot als percentage
van het totale vezelgaas oppervlak (36%) waren significant groter in de met rhTGF-β1
geladen implantaten vergeleken met de niet-geladen implantaten (0,57 mm2 en 26%). Er
werden geen statistische verschillen gevonden tussen implantaten met of zonder Ca-P
coating voor de bestudeerde parameters. Fluorochrome merkers lieten zien dat in de Ti en
de Ti-CaP implantaten met name botgeleiding had plaatsgevonden vanuit de oorspronke-
lijke rand van het botdefect. In de Ti-TGF-β1 implantaten startte de botvorming in het mid-
den van een porie en breidde zich vervolgens uit op centrifugale wijze. Op basis van deze
bevindingen concluderen wij dat (1) de combinatie van titanium vezelgaas geladen met
rhTGF-β1 orthotopische botvorming kan induceren, (2) titanium vezelgaas goede osteo-
conductieve eigenschappen bezit, en (3) een dunne Ca-P coating, zoals in deze studie werd
toegepast, de botgeleidende eigenschappen van het Ti-dragermateriaal niet verder stimu-
leert. 
7. Wat is het osteo-inductief vermogen van poreus poly(propyleen fumaraat) (PPF) voor-
zien van rhTGF-β1 in een orthotopische locatie en wat is tevens het effect van het aan-
brengen van een fibronectinecoating op het poreuze PPF op de uiteindelijke botrespons? 
In hoofdstuk 8 bestudeerden we de botvormingondersteunende eigenschappen van
voorbehandelde PPF-dragers aangebracht in een schedeldakdefect bij koijnen. Het poreuze
PPF-dragermateriaal werd op vier verschillende manieren voorbehandeld: (1) voorbevoch-
tigd met alcohol en water (PPF-Pw), (2) radiofrequent gloeien (PPF-Gd), (3) aanbrengen
van een fibronectine coating (PPF-Fn) en (4) aanbrengen van een rhTGF-β1 coating (PPF-
TGF-β1). Bij negen konijnen werd één specimen van elk type drager in de schedel aange-
bracht. Na acht weken werden de konijnen opgeofferd en werden de implantaten histo-
logisch bewerkt. Licht microscopisch onderzoek liet vervolgens zien dat in de implantaten
zonder rhTGF-β1 bijna geen bot was gevormd. Daarentegen werd wel bot gevormd in de
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porositeit van de PPF-TGF-β1 implantaten. Het nieuw gevormde bot had een trabeculaire
structuur . Tussen de trabekels werd beenmergachtig weefsel gezien. Echter de botvorming
in de PPF-TGF-β1 implantaten vertoonde grote inter-individuele verschillen. De hoeveel-
heid botvorming varieerde van vrijwel volledige opvulling van de PPF-porositeit tot een
zeer beperkte opvulling. Deze histologische bevindingen werden bevestigd door beeld-
analyse, waarbij er kwantitatief telkens meer bot in de PPF-TGF-β1 implantaten werd
waargenomen in vergelijking met de andere voorbehandelingen. Fluorochrome merkers
lieten zien dat in de PPF-TGF-β1-implantaten de botvorming startte in het midden van een
porie en zich vervolgens uitbreidde op centrifugale wijze in de richting van het oppervlak
van de PPF. In PPF-Gd-, PPF-Pw- en PPF-Fn-implantaten was zichtbaar dat beperkte bot-
geleiding had plaatsgevonden vanuit de oorspronkelijke rand van het botdefect tot aan de
PPF-drager. Op basis van deze bevindingen concludeerden we dat een PPF-dragermateriaal
biocompatibel is met bot tijdens de experimentele periode. Daarnaast kan rhTGF-β1 op
adequate wijze botvorming induceren in poreus PPF. Deze resultaten geven aan dat een
PPF-drager voorzien van rhTGF-β1 zeer geschikt is voor het vervaardigen van BGSs. 
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9.4 Afsluitende opmerkingen en toekomstperspectief
Het onderzoek dat werd uitgevoerd in dit proefschrift, toont aan dat de combinatie van tita-
nium vezelgaas met osteogene cellen of osteo-inductieve groeifactoren zoals BMP en TGF-
β, gebruikt kan worden ter vervaardiging van bottransplantaten. Dit werd geïllustreerd
door de ostegene expressie in vitro en de vorming van botachtig weefsel in vivo. In vitro
vonden we dat het verhogen van de celdichtheid en de rhBMP-2 concentratie een positieve
invloed had op de osteogene expressie. Het in vivo gebruik van tissue engineering strategieën
waarbij cellen gebruikt worden voor het vervaardigen van BGSs, resulteerde in de vorming
van een beperkte hoeveelheid nieuw bot. Daarom onderzochten we de werkzaamheid van
doorkweken in vitro. Het effect van doorkweken bleek verschillend te zijn voor implan-
taten met en zonder Ca-P coating: alleen de eerstgenoemde groep bleek botvorming te
ondersteunen. Voor de implantaten met een Ca-P coating leek de hoeveelheid nieuw bot
enigszins te zijn toegenomen in vergelijking met de eerdere studie. Andere experimenten
lieten daarnaast zien dat ook de combinatie van titanium vezelgaas met BMPs ectopische
botvorming kan induceren. Bovendien hebben we laten zien dat de combinatie van
recombinante humane BMP en (deels) gezuiverde bovine BMP hierbij synergistisch werkt.
Wanneer de resultaten van het onderzoek –waarin titanium met rhBMP-2 werd geladen–
worden vergeleken met het onderzoek –waarin deze drager met cellen werd geladen–, blijkt
dat in de eerstgenoemde groep niet alleen meer bot gevormd wordt maar dat de botvorming
eveneens op meer reproduceerbare wijze plaatsvindt. In het botvormingsproces dat door
BMP wordt geïnduceerd is altijd een kraakbeenfase aanwezig. Een vergelijkende studie
tussen titanium vezelgaas en andere dragers, twee waarvan eerder werd gevonden dat zij
enchondrale botvorming induceerden (FGM, IBM) en één waarvan eerder was gevonden
dat het directe botvorming induceerde (PPHAP), liet zien dat toch voor alle dragers een
kraakbeenfase aanwezig was. Bovendien suggereren deze bevindingen dat bij rhBMP-2-
geïnduceerde botvorming altijd een enchondrale botvormingachtig proces plaatsvindt
ongeacht het gebruikte dragermateriaal. De hoeveelheid kraakbeen kan hierbij echter
verschillen. Wij veronderstellen dat deze verschillen samenhangen met de mate waarin het
dragermateriaal de ingroei van bloedvaten stimuleert. In dragers die vaatingroei stimuleren
vindt vroege osteogenese plaats en verdwijnt het gevormde kraakbeen eerder. In dragers die
de vaatingroei remmen wordt een grotere hoeveelheid kraakbeen gevormd die ook langer
aanwezig blijft. Daarom zouden op deze twee groepen respectievelijk de termen “bone-
directing” en “cartilage directing” van toepassing kunnen zijn. Deze informatie in
combinatie met de toenemende kennis op het gebied van het afgiftepatroon van groei-
factoren van verschillende dragers, zou een meer rationele benadering van het ontwikkelen
van dragers mogelijk maken. Deze benadering is eveneens van belang bij de uiteindelijke
klinische toepassing, waarbij een drager die bot induceert van een hoge kwaliteit binnen
een korte tijdsperiode zeer wenselijk is.
Verder onderzoek liet zien dat titanium vezelgaas voorzien van rhTGF-β1 eveneens de
genezing van botdefecten kan stimuleren. Ons onderzoek van titanium vezelgaas zonder
rhTGF-β1 liet zien dat titanium vezelgaas zelf al over goede osteoconductieve eigenschap-
pen bezit. In aanvulling op het gebruik van het titanium vezelgaas ter vervaardiging van
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BGSs zijn deze resultaten veelbelovend voor de toepassing (met of zonder groeifactoren)
van dit materiaal bij de fixatie van implantaten. Aanvullende experimenten met een nieuw
ontwikkelde polymeer, poreus poly(propyleen fumaraat) (PPF) drager toonde aan dat dit
materiaal biocompatibel was met bot en botvorming kon induceren wanneer het was
voorzien van rhTGF-β1. Echter wanneer dit materiaal werd voorzien van dezelfde hoe-
veelheid rhTGF-β1 als de titanium drager resulteerde dit in minder botvorming waarbij ook
nog eens een grotere variatie tussen de implantaten aanwezig was. Dit is mogelijk ge-
relateerd aan een lagere rhTGF-β1 retentie in de PPF. Daarom is de keuze van een passend
dragermateriaal afhankelijk van de uiteindelijke toepassing: afbreekbaarheid kan immers
wenselijk zijn in bepaalde situaties, terwijl mechanische en structurele eigenschappen
vereist zijn in andere situaties.
Ondanks het gunstige effect van TGF-β op botgenezing moet worden benadrukt dat
enige bezorgdheid bestaat omtrent de veiligheid van deze groeifactor bij toediening aan
mensen. Echter tot op heden is geen causaal verband aangetoond tussen lokale toediening
van lage doses TGF-β en nadelige effecten op de nier of lever. Niettemin is het belangrijk
dat een therapeutische index wordt bepaald voor TGF-β die een meer rationele benadering
mogelijk maakt voor de veilige afgifte en dosering van deze groeifactor in lokale thera-
peutische toepassingen.
De toepassing van een dunne Ca-P coating op titanium vezelgaas heeft aangetoond dat
dit de botvorming verder stimuleert, zowel voor dragers met osteogene cellen als dragers
met BMP-2. Echter de gebruikte hoog vacuüm coating techniek zou wel eens niet de meest
optimale kunnen zijn voor deze toepassing, omdat wij weten dat de coating niet door het
hele materiaal heen dringt en het bioactieve oppervlak derhalve niet aanwezig is door het
gehele dragermateriaal. Dit werd geïllustreerd door de wijze waarop de botvorming plaats
vond in de dragers met een Ca-P coating. Tevens blijkt deze beperking van de gebruikte
coating techniek uit het feit dat de osteoconductieve eigenschappen van titanium vezelgaas
niet gestimuleerd werden.
Gelet op het voorgaande dient toekomstig onderzoek te zijn gericht op een aanpak die
voorziet in het ontwikkelen van een gestandaardiseerde en reproduceerbare oppervlakte
voorbehandelingstechniek, die de functionaliteit van een dragermateriaal kan verbeteren.
Mogelijkheden zijn wellicht het gebruik van sol-gel en biometische coatings. 
Onze in vitro studies lieten zien dat bij het gebruik van statische kweekmethoden
cellen en gemineraliseerde matrix alleen gevonden worden bovenin het vezelgaas. Om dit
probleem op te lossen moet meer gebruik gemaakt worden van dynamische zaai- en kweek-
methoden zoals “perfusion flow” en “rotating wall vessels” (RVWs). Andere onderzoekers
hebben reeds bewezen dat deze methoden nuttig kunnen zijn bij het vervaardigen van
botachtig weefsel in vitro. In onze onderzoeksgroep hebben we reeds gebruik gemaakt van
een “perfusion flow” systeem. Het gebruik van dit systeem liet inderdaad een toename zien
van de osteogene expressie in titanium vezelgaas in vitro. Het voordeel van dynamische
methoden op de botvorming in vivo moet echter nog worden onderzocht. 
Daarnaast moeten we benadrukken dat het differentiatie proces van osteoblasten
slechts voor een deel is opgehelderd. Een toename van de kennis op dit gebied zou een meer
gerichte benadering mogelijk maken met betrekking tot tissue engineering van botweefsel.
Celselectie van osteoprogenitor cellen of mesenchymale stamcellen door specifieke cel-
markers of antilichamen zou in dit verband bijvoorbeeld een oplossing kunnen bieden.
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Hoewel een deel van het intracellulaire communicatieproces voor BMPs via de zoge-
naamde Smad route en de daaropvolgende gen-activatie, die resulteert in osteoblast diffe-
rentiatie, momenteel is opgehelderd, is de precieze route die BMPs gebruiken bij de
activatie van specifieke osteoblastgenen nog niet onderzocht. Vergroting van de kennis op
dit terrein is essentieel voor de uiteindelijke klinische therapeutische toepassing van BMP.
De positieve resultaten die werden gevonden in knaagdieren, dienen herhaald te
worden in hogere dieren alvorens een betrouwbare extrapolatie mogelijk is naar de kli-
nische situatie. In recent klinisch onderzoek bijvoorbeeld, is de werkzaamheid van BMPs
met een collageen drager aangetoond bij het genezen van botdefecten. Echter de bot-
vormingsrespons varieert sterk tussen individuen. Ook dient te worden benadrukt dat de
gebruikte doses van BMP nog steeds onfysiologisch hoog zijn en dat de lange termijn
effecten en veiligheid nog moeten worden afgewacht. Reden waarom de combinatie van
cellen met groeifactoren of de combinatie van verschillende groeifactoren in de juiste
verhouding veelbelovend voor de toekomst is. Dit zou een afname in de gebruikte concen-
tratie van de groeifactor mogelijk maken en de biologische activiteit wellicht vergroten.
Een andere oplossing voor het “concentratie” probleem van groeifactoren is misschien
gelegen in de toepassing van een gentherapeutische benadering. In deze benadering worden
cellen, uit de osteoblasten reeks of daarbuiten, genetisch getransfecteerd in vivo of in vitro.
Hierbij wordt gebruik gemaakt van verschillende vectoren zoals retro-virussen om groei-
factoren tot (over)expressie te brengen. De veiligheid van deze methoden en de uiteinde-
lijke afloop van de getransfecteerde cellen dient nader te worden onderzocht.
Tot slot is het ultieme doel voor grote reconstructieve chirurgische ingrepen het
creëren van een gevasculariseerde BGS door gebruik te maken van préfabricage technieken.
Hierbij wordt de aanwezigheid van een vaatvoorziening gecombineerd met een osteo-
inductieve drager (door de drager bijvoorbeeld in een spierlap te plaatsen), zodat op deze wijze
een voorgevormd gevasculariseerd bottransplantaat kan worden vervaardigd. Andere on-
derzoekers hebben bij varkens (minipigs) reeds aangetoond dat wanneer keramische
dragermaterialen voorzien van BMPs, in een spierlap worden geplaatst, dit resulteert in de
vorming van een gevasculariseerd botransplantaat. Met deze transplantaten kunnen de-
fecten in de mandibula worden genezen. Opnieuw dient de effectiviteit van préfabricage
technieken in combinatie met dragers voorzien van botvormende cellen nog te worden
bewezen in hogere diersoorten en mensen.
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(prof.dr. P.H.M. Spauwen) van het UMC Nijmegen en werd
tevens aangenomen voor de opleiding plastische chirurgie
(opleider: prof.dr. P.H.M. Spauwen). 
Tijdens het onderzoek bracht hij in 1998 en 2000 een werkbezoek
aan de afdeling biochemie van de Hokkaido universiteit in Sapporo,
Japan (hoofd: prof.dr. Y. Kuboki). Dit resulteerde in twee publicaties
(zie hoofdstuk 5 en 6). Eveneens werd nauw samengewerkt met
de afdeling bioengineering van Rice University in Houston, Texas,
de Verenigde Staten (hoofd: prof.dr. A.G. Mikos). Dit resulteerde
eveneens in een publicatie (zie hoofdstuk 8).
In mei 2001 begon hij in het kader van de opleiding tot plastisch
chirurg met de chirurgische vooropleiding in het Canisius-
Wilhelmina Ziekenhuis te Nijmegen (opleider: dr. E.D.M. Bruggink).
